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The hepatitis C virus (HCV) is estimated to infect about 3% of the world 
population with chronic infections resulting in liver fibrosis, cirrhosis, and 
hepatocellular carcinoma. Current treatment regimens are not universally 
effective across all genotypes and there is no vaccine against HCV infection.  
Cell-death modulation is an important survival determinant in virus-host 
interactions, hence most viruses encode proteins that interfere with cell-death 
signaling, skewing it to their advantage. For HCV infection, apoptosis and other 
forms of cell-death have been observed, with numerous reports indicating that 
HCV-induced liver injury resulting from chronic infection is linked to hepatocyte 
apoptosis. While apoptosis of HCV-infected cells is believed to be an antiviral 
defense mechanism, which interferes with HCV replication and assist in the 
elimination of virus-infected cells, it may as well be a virus strategy to promote 
dissemination of progeny viruses, especially at later stages during an infection. 
However, the detailed understanding of this intricate viral-host interaction as well 
as its regulation by both viral and host factors, is still unclear. In this thesis, we 
screened for the viral and host factors involved in cell death modulation so as to 
gain some insight into how these factors perpetuate and regulate the cell death 
process. 
Identified as an important viral factor in our screening, HCV p7 protein was 
shown to induce caspase-dependent apoptosis via the intrinsic and extrinsic 
! "!xiv!"!
pathways, independent of its ion channel activity. As a viroporin, p7 is similar to 
the well-characterized M2 protein of the influenza A virus in terms of ion channel 
activity and induction of caspase-dependent cell death. We however observed 
that p7 and M2 differed in their activation of autophagic cell death, although both 
were shown to interact with the essential autophagy protein, Beclin-1.  
When pathway-specific gene profiling was used to screen for host genes 
involved in HCV-induced apoptosis, 9 apoptosis-related genes, implicated in the 
intrinsic and extrinsic apoptosis pathways, were identified. Subsequent analysis 
confirmed the differential expression of 6 of these genes at the mRNA and 
protein levels, while 3 genes were only confirmed at the mRNA level due to 
unavailability of suitable reagents. The differential expression BIK was 
demonstrated at all three time points (day 2, 4, and 6) post infection, hence it was 
chosen for detailed study.  
In examining the functional significance of BIK expression in HCV infection 
using siRNA-mediated knockdown, we observed that the proliferation of HCV-
infected BIK-depleted Huh7.5 cells were not protected against the inhibitory 
effects of HCV infection, although, it did protect them against apoptosis insults 
from HCV. Similarly, there was a significant reduction in HCV replication in BIK-
depleted cells, but this had minimal effect on viral release.  
Taken together, these results provide evidence that p7 protein is an 
important viral factor involved in apoptosis induction via the intrinsic and extrinsic 
pathways, independent of its ion channel function. It also revealed that, HCV 
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infection induces apoptosis via the intrinsic and extrinsic pathways by 
dysregulating genes implicated therein. Furthermore, HCV-infected cells depleted 
of BIK expression using RNAi revealed that BIK is probably an important host 
apoptosis-related factor that has some effects on the host cells’ response to 
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LITERATURE REVIEW AND INTRODUCTION 
 
1.1 Historical Perspective and Discovery of Hepatitis C Virus 
The history of hepatitis (inflammation of the liver) dates back to antiquity. It 
is reported that Hippocrates mentioned hepatitis as early as 400 BC and in 752 
Pope Zacharias wrote a letter to St. Boniface, Bishop of Mainz (Germany), about 
“Jaundice of a contagious nature” where those affected would have to be 
segregated (Kuntz E, 2006). However, the attention of scientists and the public 
health community was drawn to the seriousness of hepatitis in the 1940’s after 
World War II when blood banking had just begun in earnest and when alarming 
rates of post-transfusion hepatitis (PTH) infections among recipients of blood 
transfusion was noted (Alter et al., 1975). It was however not until the mid 1970s 
that researchers using specific serological assays demonstrated that the cause 
of PTH was not due to hepatitis A or hepatitis B viruses (Alter et al., 1975; 
Feinstone et al., 1975). However, at that time, the cause and name of the virus 
had not yet been discovered. Thus, this unknown virus was temporarily named 
non-A, non-B hepatitis (NANBH)(Alter et al., 1975). It was not until 1989 that the 
putative agent that caused NANBH was isolated and identified by Michael 
Houghton and coworkers at Chiron Corporation in Emeryville, CA, in 
collaboration with Daniel Bradley of the Centers for Disease Control in Atlanta, 
GA; employing exclusively molecular biology techniques using the blood of an 
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experimentally infected chimpanzee (Choo et al., 1989; Houghton, 2009). In 
announcing their discovery in a landmark publication on April 21, 1989, Michael 
Houghton said (Farci, 2002): 
 
“Thus, our data indicate that clones 5-1-1 and 81 are derived from the genome of 
a blood-borne NANBH virus that we now term hepatitis C virus (HCV). The cDNA 
clones reported here were obtained in the absence of prior knowledge 
concerning the virus, the viral genome, and the presence of circulating 
antibodies. As such, this represents cloning without characterization of the 
infectious agent. This approach should be relevant to studies of other diseases in 
which an unknown infectious agent (viral or otherwise) might be involved” 
 
Following the discovery of HCV, research on the molecular biology of the 
virus progressed rapidly such that within one year of its cloning, the nucleotide 
sequence of the entire viral genome was determined, and the agent was 
characterized as a single-stranded positive-sense RNA virus of about 9600 
nucleotides in length (Choo et al., 1991; Farci, 2002). 
 
1.2 Classification and Genotypes of HCV 
After the genome of HCV was determined as a single-stranded positive-
sense RNA virus (Choo et al., 1991), it was then classified as the sole member 
within the Hepacivirus genus and the Flaviviridae family together with the genera 
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Pestivirus and Flavivirus; although some studies suggest that HCV is more 
closely related to the pestiviruses than to the flaviviruses (Lindenbach, 2007).  
Due to the error-prone nature of the viral RNA-dependent RNA 
polymerase, an infected individual could be found with a mixture of genetically 
different but related quasispecies, which differ by 1–5% in nucleotide sequence 
(Pawlotsky, 2003). Thus, HCV is classified into 7 phylogenetic clades which are 
designated as genotypes numbered 1 to 7, with more than 30% nucleotide 
sequence divergence, and over 70 variants or subtypes (1a, 1b, 2a, etc.) within 
each genotype (Simmonds, 2013; Simmonds et al., 2005).  
The HCV genotypes generally show differences in worldwide distribution 
(refer to Figure 1.1 for the global distribution of HCV genotypes), transmission, 
disease progression, and response to treatment (Chakravarti et al., 2011; Dias et 
al., 2011; Lee et al., 2008a). In fact, HCV genotypes are important predictors of 
treatment outcome (Zein, 2000). While genotype 1, 2, and 3 viruses are prevalent 
almost worldwide, HCV genotypes 4 – 6 are to a large extent restricted to distinct 
geographical regions, including Africa and Middle East (genotype 4), South Africa 
(genotype 5), and Southeast Asia (genotype 6).  
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The boundaries and names shown and the designations used on this map do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization 
concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries.  Dotted lines on maps represent 
approximate border lines for which there may not yet be full agreement. 













Figure 1.1. Global distribution of HCV genotypes. Adapted from (WHO, 2009) 
 
1.3 Epidemiology and Natural history of HCV infection 
Chronic hepatitis C virus (HCV) infection is a major and growing public 
health problem throughout the world. However, the global scale of the infection is 
not well known, due to the asymptomatic nature of the acute phase of infection. 
The World Health Organization (WHO) estimates that approximately 130 –170 
million individuals representing 2.2 - 3% of the world population are chronically 
infected with HCV (Lavanchy, 2009). In addition, 3 – 4 million people are newly 
infected with HCV each year and 350,000 patients die from HCV-related disease 
(Shepard et al., 2005; WHO, 2012). There are also geographic and regional 
differences in the epidemiology and burden of HCV infection (Averhoff et al., 
2012) with high rates of chronic infection in places such as Egypt (15%), 
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Pakistan (4.8%), and China (3.2%)(WHO, 2012) (Refer to Figure 1.2 for the 
geographic distribution and prevalence of HCV). 
HCV infection has been referred to as the ‘silent epidemic’ as majority (75 
- 80%) of the infected individuals are hardly diagnosed because most of the 
acutely infected individuals are asymptomatic (Hnatyszyn, 2005; Zoulim et al., 
2003). Moreover, most infected persons are unaware of their exposure to HCV, 
and do not get diagnosed until many years later (de Oliveria Andrade et al., 2009; 
Zoulim et al., 2003). Thus, the rate of chronic HCV infection is affected by the 
person’s age at the time of infection, gender, race, and viral immune response 
(Chen and Morgan, 2006). A large proportion (about 75%) of HCV-infected 
persons will go on to develop chronic HCV infection, and are at risk for advanced 
liver complications including cirrhosis, liver failure, and hepatocellular carcinoma 
(Mauss, 2012; Seeff, 2002), a fact attributed to the genetic diversity of the virus 
and its tendency towards rapid mutation, thus allowing it to escape immune 
recognition. However, a good proportion of the infected patients (about 20 - 40%) 
will spontaneously clear the virus, becoming HCV RNA negative (Chen and 
Morgan, 2006; Kamal, 2008; Micallef et al., 2006). Similarly, an estimated 10 - 
20% of chronic HCV infections advance to end-stage liver disease over one or 





Figure 1.2. Geographic distribution of prevalence of HCV infection. Adapted from 
Centers for Disease Control and Prevention(CDC, 2012).  
 
1.4 Therapy 
There is currently no prophylactic or therapeutic vaccine to prevent HCV 
infection. Prior to 2011, the standard of care (SOC) for chronic HCV infection was 
based on a combination therapy of pegylated interferon-α (PEG-IFN) plus 
ribavirin (RBV) administered over about 48 weeks (Ghany et al., 2009). With this 
treatment regimen, a sustained virological response (SVR), i.e., undetectable 
serum HCV RNA after cessation of treatment is achievable only in about 50% of 
patients with HCV genotype 1 and about 80% of those with genotype 2 (EASL, 
2011; Hayashi and Takehara, 2006). Moreover, therapy is expensive and is 
associated with numerous side effects (Hadziyannis et al., 2004; Manns et al., 
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2001; Manns et al., 2006), which reduces its effectiveness in many cases. In 
addition to its limited efficacy, response to therapy is also variable and depends 
on both viral and host specific factors (Ge et al., 2009; Hayashi and Takehara, 
2006; Huang et al., 2007b; Hwang et al., 2006; Romero-Gomez et al., 2005; 
Suppiah et al., 2009; Thomas et al., 2009).  
In 2011, the FDA approved the first direct-acting antivirals (DAAs) 
Boceprevir (Victrelis) and Telaprevir (Incivek), which target the HCV protease 
(see recent review by (Shah et al., 2013)). A combination of these DAAs-
protease inhibitors (PIs) with PEG-INF-α and ribavirin (RBV) in triple combination 
therapy has been shown to substantially increase the SVR rate in difficult to treat, 
treatment-naïve, and treatment-experienced patients (Bacon et al., 2011; EASL, 
2011; Hezode, 2011; Jacobson et al., 2011; Poordad et al., 2011; Zeuzem et al., 
2011). For instance, SVR rates for patients with genotype 1 HCV infection have 
increased to 70 – 80%, and one-half to two-thirds of patients are eligible for a 
shortened duration of therapy (Jacobson et al., 2011; Poordad et al., 2011; 
Welsch et al., 2012). However, the efficacy of these new drugs is not genotype-
wide, and several infected individuals respond poorly. Apart from the adverse 
effects and complicated treatment schedules which may lead to poor adherence, 
some clinical data show that these drugs might not be suitable for monotherapy 
because the selective pressure imposed by the drugs can lead to the rapid 
emergence of resistant mutants (Chatel-Chaix et al., 2012). 
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As a result of the intrinsic limitations of the current treatment regimens, 
including the new DAAs, as well as the potential resistance development and 
mutational escape by the virus, there is still need to develop additional 
therapeutics for HCV. Future therapeutics should ideally act on distinct 
mechanisms and be applicable in patients who are non-responders or not eligible 
for current antiviral therapies (Pan and van der Laan, 2012). So far, a number of 
studies have demonstrated the feasibilities of targeting HCV receptors by either 
using neutralizing antibodies (Giang et al., 2012; Keck et al., 2012; Meuleman et 
al., 2012) or small molecule inhibitors (Coburn et al., 2012; Haid et al., 2012; 
Syder et al., 2011). These approaches are said to be attractive for both treatment 
and prevention of HCV infection, especially for the prevention of HCV recurrence 
after liver transplantation, since there is still no specific treatment available for 
HCV recurrence (Pan and van der Laan, 2012). Similarly, studies on the use of 
RNAi technology in HCV therapy has attracted a lot of interest, although studies 
using this innovative technology has still not gone pass the preclinical stages 
(Pan et al., 2009a; Pan et al., 2009b). In addition, studies on targeting cellular 
factors, including cyclophilins and miR-122, are far advanced, with some already 
at the clinical stages (Flisiak et al., 2009; Flisiak et al., 2008; Lanford et al., 2010; 





1.5 HCV Structure and Genome Organization 
1.5.1 Viral Structure 
For a long time, the structural analyses of HCV virions has been limited 
due to the difficulty in cultivating the virus in cell culture systems, a prerequisite 
for yielding sufficient viral particles for electron microscopy (Mauss, 2012). 
Moreover, the composition of the HCV virion tends to vary depending on where it 
is produced, i.e., in patients, animals, or the infectious tissue culture system 
(Joyce and Tyrrell, 2010). Despite these challenges, a couple of studies have 
shown that HCV virions isolated from cell culture have a spherical envelope 
containing tetramers (or dimer of heterodimers) of the HCV E1 and E2 
glycoproteins (Heller et al., 2005; Wakita et al., 2005; Yu et al., 2007). Similarly, 
inside the virions a spherical structure has been observed (Wakita et al., 2005) 
representing the nucleocapsid (core) that harbours the viral genome (see Figure 
1.3). Thus, the virion is believed to adopt a classical icosahedral scaffold in which 
glycoproteins E1 and E2 are anchored to the host cell-derived double-layer lipid 




Figure 1.3. A cartoon of a Hepatitis C virion (not drawn to scale). The HCV virion 
comprised of a capsid, an internal complex of core protein and an RNA genome, 
surrounded by a phospholipid bilayer envelope. 
 
1.5.2 HCV Genome Organization 
The HCV genome of 9.6 kb is made up of a single stranded RNA molecule 
of positive polarity that encodes a unique open reading frame (ORF) that is 
translated into a precursor polyprotein of about 3000 residues. The ORF is 
flanked by two regulatory untranslated regions (UTR) (Figure 1.4), 5’UTR and 
3’UTR respectively (Bostan and Mahmood, 2010). Both UTR bear highly 
conserved RNA structures essential for polyprotein translation and genome 
replication. The 5’UTR contain an internal ribosomal entry site (IRES) that binds 
the 40S ribosomal subunit and initiates polyprotein translation in a cap-





Figure 1.4: A schematic representation of HCV genome, structural and 
nonstructural proteins: The viral RNA consists of a 5' untranslated region (5’UTR) 
containing the internal ribosome entry site (IRES), followed by the genomic 
region for structural and nonstructural genes and the 3' UTR. HCV is translated 
as a polyprotein that is proteolytically processed by host and viral proteases. The 
structural proteins (C, core; E1, envelope protein 1; E2, envelope protein 1) are 
located at the amino-terminal end while the nonstructural proteins (NS2, NS3, 
NS4A, NS4B, NS5A, and NS5B) are located at the carboxyl-terminal end. The p7 
protein (ion channel or viroporin) is located at the junction of structural and 
nonstructural proteins. Adapted from (Poordad and Dieterich, 2012) 
 
The HCV polyprotein precursor is co-translationally and post-
translationally processed by both cellular and viral proteases to yield at least 
three structural (core, E1, and E2), six non-structural (NS2, NS3, NS4A, NS4B, 
NS5A, and NS5B) viral proteins (Lindenbach, 2007), and a small ion channel 
protein, p7, located between the structural and nonstructural proteins(Lin et al., 
1994) (see Figure 1.4). These proteins have important roles at different steps of 
the virus life cycle and are involved in viral-viral as well as viral-host interactions. 
A summary of the characteristics as well as the viral and cellular functions of the 
various HCV proteins are given below (see Table 1.1), while a comprehensive 
review of the p7 protein is given in section 1.5.3 below as it pertains to the work 
in chapter 3.   
!
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Table 1.1: Hepatitis C Viral Proteins: Properties, Role in the Viral Lifecycle and Cellular Functions 
 Protein 
Properties and role in viral life cycle 
Cellular and other functions 
Core  
HCV core is the first structural protein encoded by 
the ORF. It is located at the N-term









oradpour and Penin, 2013). 
 Initially translated as a 23kDa protein, Core is 
released from
 the viral polyprotein by the host signal 
peptidase via cleavage at the C-term




 of the protein. Subsequent cleavage 
by signal peptide peptidase releases the m
ature 
form
 (21kDa) of the protein (M
cLauchlan, 2009; 
Oehler et al., 2012; Okam
oto et al., 2008). 
 It is suggested that at least 177 residues of core 
protein are needed for infectious particle production 
(Kopp et al., 2010). 
 Core is com
posed of two dom
ains (Boulant et al., 
2005), i.e., N-term
inal hydrophilic dom
ain 1 (D1) with 
high proportion of basic am




























association with LDs (Boulant et al., 2006). 














apoptosis (Lai and W
are, 2000; M
cLauchlan, 2000; Ray 
and Ray, 2001). 
 In term
s of cell death m
odulation, core is reported to 
exhibit both pro-apoptotic and anti-apoptotic properties 
(Benali-Furet et al., 2005; Berg et al., 2009; Chou et al., 





an et al., 2003; Sacco et al., 2003).   
 The ability of core to interact with several cellular 
pathways m
ay be the m
ain contributory factor towards 
its ability to m
odulate different pathways of apoptosis 
(Aweya and Tan, 2011). 




Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
















brane glycoproteins with an N-term
inal 
ectodom
ain (~160 aa for E1 and ~360 aa for E2) 






D) of ~30 aa (M
oradpour and Penin, 2013). 
 E1 and E2 associate into non-covalently attached 
heterodim
ers and play pivotal roles at different 
steps of the HCV life cycle, including assem
bly of 




brane (reviewed in (Helle and 
Dubuisson, 2008) and (M
oradpour and Penin, 
2013)). 
 The TM
Ds of E1 and E2 contribute im
portantly to 
their functions, including m
em
brane anchoring, ER 
retention, and E1–E2 noncovalent heterodim
er 
form
ation; believed to represent the building block 









variable, and several HVRs have been identified in 
E2, differing by up to 80 %
 am
ong HCV genotypes 
(M
oradpour and Penin, 2013). 
E1 and E2 are required for binding of the HCV particle to 
the target cell. E1 and E2 are involved in m
odulating 
cellular functions when they are expressed intracellularly. 









(Ciccaglione et al., 2004). Apoptosis induced by E1 is 
dependent on the TM
D at the C-term
inal of E1, which m
ay 
be due to the alteration of ER m
em
branes by E1 
(Ciccaglione et al., 2003). E1 seem
s to function as a 
scaffold for the proper orientation and stability of E2 
(Cocquerel et al., 2001). 
 Unlike E1, E2 is able to m
odulate apoptosis via several 
pathways. E2 m
odulates extrinsic and intrinsic apoptotic 
pathways differently, and therefore induces both pro-
apoptotic and anti-apoptotic effects in host cells(Chiou et 
al., 2006; Lee et al., 2007). 
 Binding of recom
binant E2 to the surface of Huh7.5 or 
Daudi cells is shown to be sufficient to cause a decrease 
in cell viability, suggesting that E2 m
ight also be able to 
induce apoptosis via an “innocent bystander” m
echanism
 




, E2 has been shown to 




unodeficiency virus type 1 (HIV-1) gp20 to induce 
apoptosis in HepG2 cells (M
unshi et al., 2003). 
!
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Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
Cellular and other functions 
P7 
P7 is a sm
all (7kDa) highly hydrophobic protein 
m
ade of two transm
em
brane (TM
) alpha helices 
joined by an interhelical loop (Cook and Opella, 
2011). It is located at the junction between the 
structural and nonstructural proteins in the HCV 
polyprotein 
 P7 form
s ion-channels in the ER (Brohm
 et al., 2009; 
Steinm
ann and Pietschm
ann, 2010) and is classified 
as a viroporin; sm

















et al., 2010). 
 Precise function of p7 is unknown, but is believed to 











ozniak et al., 
2010). P7 m
ight be critical for other functions in virus 
assem




 P7 is believed to act in concert with core, E1, and E2, 
as well as NS2, to exert its function(s) (Boson et al., 
2011; Jirasko et al., 2010; M
a et al., 2011; Popescu 
et al., 2011a; Stapleford and Lindenbach, 2011). 
HCV p7 has been shown to act as a proton channel 
within infected cells, which is directly required for the 
production of infectious virions (W












panzees (Sakai et al., 2003). It is therefore thought 
to be crucial for viral assem
bly and viral release in vitro 
and essential in the form
ation of infectious virions in vivo 
(Boson et al., 2011). 










inhibitors block virion release in cell culture, strongly 
im
plicating a functional requirem










ann et al., 2007b).  
 Deletion of p7 or specific point m
utations abrogate HCV 
particle release in culture (Jones et al., 2007; Steinm
ann 
et al., 2007a), yet the specificity of these m
utations 
regarding ion channel activity or an as-yet undefined 
alternative role for p7 has not been established. 
 P7 induces caspase-dependent cell death independent 
of its ion channel activity (Aweya et al., 2013; M
adan et 




Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
Cellular and other functions 
NS2 
NS2 is part of the NS2/3 protease, responsible for 
the intram
olecular cleavage of NS2 from
 NS3 
(Grakoui et al., 1993; Hijikata et al., 1993). It is the 
first of two virally encoded proteases required for 
HCV polyprotein processing (W
elbourn and Pause, 
2007). NS2 is a polytopic transm
em
brane protein 




(Jirasko et al., 2008). 
 NS2 plays a role in the late stages of the virus life 
cycle (M
a et al., 2011). Exam
ple, NS2 is suggested 

















interactions with structural and other nonstructural 
viral proteins (Boson et al., 2011; Jirasko et al., 
2010; M
a et al., 2011; Popescu et al., 2011a; 







yields have been m
apped to NS2 (Gottwein et al., 
2009; Jensen et al., 2008; Kato et al., 2008; Scheel 
et al., 2008; Yi et al., 2007), and m
utagenesis of 
NS2 identified several residues that are im
portant 
for infectious virus production (Dentzer et al., 2009; 
Jirasko et al., 2008; Phan et al., 2009; W
elbourn et 
al., 2009; Yi et al., 2009) 
NS2 is targeted to the ER (Santolini et al., 1995; Yam
aga 
and Ou, 2002). 
 NS2 m
ay also play a role in m
odulating cellular gene 
expression in infected cells. It is reported that NS2 exerted 
a general inhibitory effect on the expression of a reporter 
gene expressed from










elbourn and Pause, 2007). 
 NS2 and other HCV proteins (i.e., core, E2, and NS5A) 
have been im
plicated in the m
odulation of cell signaling 
and apoptosis (Gale et al., 1997; Honda et al., 2000; 
M










inhibited in transgenic m
ice expressing HCV core, E1, E2, 
and NS2 proteins (M
achida et al., 2001).  










ore, expression of the NS2 protein has been 
shown to inhibit cell proliferation in both transient (Huh-7) 
and stable (Vero, HeLa) cell assays (Yang et al., 2006). 
!
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Table 1.1, continued 
Protein 
Properties and role in viral life cycle 





















Preugschat et al., 1996). The protease activity of 
NS3 and its cofactor NS4A is responsible for 





junction sites, while the helicase/NTPase plays an 
essential but unknown role in viral RNA replication 
(M
a et al., 2011). 
 The NS3 helicase is essential for HCV RNA 




urray et al., 2008). However, its 
precise function(s) in the viral life cycle rem
ain(s) 
elusive. 
 NS4A (6 kDa) is a sm
all protein with m
ultiple 
functions in the virus life cycle. It binds NS3, 
functions as a cofactor for NS3 and anchors the 
NS3-4A enzym
e com
plex to cellular m
em
branes 
(Beran et al., 2009; Failla et al., 1994; Kuang et al., 
2004; W
olk et al., 2000). NS4A can physically 
interact with NS4B and NS5A and uncleaved 
NS4B-5A to prom
ote NS5A hyperphosphorylation 
(Lindenbach, 2007). 
NS3 protein is reported to have oncogenic potential (He et 
al., 2003; Sakam
uro et al., 1995; Zem
el et al., 2001; 
Zem
el et al., 2000), e.g., NS3 protein can prom
ote cell 
growth and contribute to hepatocarcinogenesis by the 
activation of ERK/AP-1 and NF-κB/cyclin D1 cascades (Li 
et al., 2010). 
 NS3 is im
portant for m
odulating innate anti-viral defenses 
(Li et al., 2005; Lin et al., 2006; Loo et al., 2006; M
eylan et 
al., 2005), and has been im
plicated in virus particle 
assem
bly (M
a et al., 2008; Phan et al., 2009). NS3 can 
induce both pro-apoptotic and anti-apoptotic effects in the 
cell (M
eylan et al., 2005; Prikhod'ko et al., 2004). 
 NS4A is localized to the m
itochondria and ER and have 
been shown to induce m
itochondria redistribution in the 




ura-Takigawa et al., 
2006). 
 The NS3-4A protease plays essential roles not only in the 
replication but also in the persistence and pathogenesis of 
HCV (M
orikawa et al., 2011). Two first-generation NS3-4A 
protease inhibitors, telaprevir and boceprevir, have been 
approved recently for the treatm
ent of chronic hepatitis C 
(M
oradpour and Penin, 2013). 
!
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Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
Cellular and other functions 
NS4B 
NS4B (27kDa) is a relatively poorly characterized, 





















brane-bound viral RNA replication m
achinery 











(Elazar et al., 2004). 
 NS4B not only plays an im
portant role in RNA 
replication but also contributes to virus assem
bly 







proteins and has been reported to bind viral RNA 
(Einav et al., 2008).  
 NS4B has been reported to harbor NTPase activity 
(Einav et al., 2004; Thom
pson et al., 2009). 
Although NS4B is poorly characterized, evidence from
 
biochem
ical, structural and genetic studies as well as 
electron m











oradpour and Penin, 2013). It is no surprise, therefore, 
that NS4B is also actively being pursued as antiviral target 
(Rai and Deval, 2011). 
 Until recently, little was known about the effects of NS4B 
on cell death. It has recently been reported that NS4B is 
pro-apoptotic and induces apoptosis via the m
itochondrial 
death pathway (Zhao et al., 2012b).  
  
     
!
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Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
Cellular and other functions 
NS5A 
NS5A is a large (56–58 kDa) hydrophilic m
em
brane-
associated phosphoprotein that plays an im
portant 
role in m
odulating HCV RNA replication and particle 
form
ation (M
oradpour and Penin, 2013). It can be 
found in basally phosphorylated (56 kDa) and hyper-
phosphorylated (58 kDa) form
s. 
 NS5A is localized m
ostly to the ER m
em
brane and 
believed to be a com
ponent of the HCV replication 
com
plex(Huang et al., 2007a), although nuclear 
localization has also been reported (Ide et al., 1996). 









(LCS)(Tellinghuisen et al., 2004). Dom
ains 1 (D1) 
and 2 (D2) are prim











bly (Appel et al., 2008; Kim
 et al., 2011c; 
Tellinghuisen et al., 2008). In addition, D1 is involved 
in LD binding (M
iyanari et al., 2007) whereas D3 is 
involved in interaction with the core protein (M
asaki 







region (ISDR) that plays a significant role in the 
response to IFN-α-based therapy (Enom
oto et al., 
1996).  
NS5A is im
plicated in the m
odulation of host cell cycle, 
apoptosis, and stress-responsive pathways(Huang et 
al., 2007a). It is reported to be anti-apoptotic (Chung et 
al., 2003; Gong et al., 2001; Lan et al., 2002; Lin et al., 
2003; Street et al., 2004; Zhou and Gong, 2006). 
 HCV NS5A has attracted considerable interest because 
of its potential role in m
odulating the response to IFN-α 
therapy. Although controversial, som
e studies have 
reported a correlation between m









oradpour and Penin, 2013). 
 NS5A interacts with and stim
ulates phosphatidylinositol 
4-kinase IIIα (PI4KIIIα) activity and phosphatidylinositol 
4-phosphate (PI4P) production that appears to be 
essential for HCV replication com
plex form
ation (Berger 
et al., 2011; Lim
 and Hwang, 2011; Reiss et al., 2011). 
 Cyclophilin A (CypA) was recently found to play an 
essential role in HCV RNA replication and assem
bly, 
through interactions with NS5A (Ciesek et al., 2009; 
Kaul et al., 2009; Liu et al., 2009). 
!
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Table 1.1, continued 
Protein 
Properties and role in viral life cycle 
Cellular and other functions 
NS5B 
NS5B is a large (68kDa), hydrophilic protein that is 
associated with ER derived m
em
branes (Ivashkina 
et al., 2002; M
oradpour et al., 2004; Schm
idt-
M








ashita et al., 1998). NS5B 
is an error-prone enzym










isincorporation and genetic diversity. 
 The NS5B catalytic dom
ain, form
ed by the N-
term
inal, contains m
otifs that are shared by all 
RdRps, including the hallm
ark GDD sequence 
within m




ain organization of a right hand 
(M
oradpour and Penin, 2013). 
 NS5B is a so-called tail-anchored protein. The 
m
em
brane anchor of NS5B is dispensable for 
polym
erase activity in vitro but indispensable for 
RNA replication in cells (M
oradpour et al., 2004).  
NS5B has been and rem
ains a m
ajor target for the 
developm
ent of HCV-specific drugs. Drug research and 
developm
ent is focusing on cellular cofactors of NS5B, 
the cyclophilins (IARC, 2012).  
 In addition to its m
odulation by other viral factors, 










erase activity of NS5B has been 
shown to be enhanced by cyclophilin B interaction 
(Piccininni et al., 2002; Shirota et al., 2002; W
atashi et al., 
2005). 









ediated JNK activity was observed to 
be synergistically enhanced by NS5B (Choi et al., 2006).  
 It was reported that NS5B interacts with retinoblastom
a 
tum
our suppressor protein and targets it for degradation, 
resulting in activation of E2F-responsive prom
oters and 
cell proliferation (M
unakata et al., 2005). 
 A pro-apoptotic effect of NS5B has been dem
onstrated in 
dendritic cells (Siavoshian et al., 2005). 
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1.5.3 The HCV p7 Protein 
The p7 protein was first identified by expression of a series of C-terminally 
truncated HCV polyproteins fused to a human c-myc epitope tag, which mapped 
it between E2 and NS2 (Lin et al., 1994). Since then, p7 has been shown to be a 
small (63 amino acid) hydrophobic protein located between the structural and 
nonstructural region of the HCV polyprotein, although it is not clearly identified as 
structural or nonstructural protein (reviewed in (Khaliq et al., 2011)). A number of 
studies have reported that p7 localizes to the endoplasmic reticulum (ER) when it 
is encoded by the viral genome or expressed transiently (Carrere-Kremer et al., 
2002; Griffin et al., 2005; Haqshenas et al., 2007). The structural topology of p7 
as revealed by nuclear magnetic resonance (NMR) analysis and by different 
secondary structure prediction algorithms have shown that monomeric p7 is 
comprised of one N-terminal helix, two amphipathic transmembrane alpha-
helices (TM1 and TM2), and a cytoplasmic loop rich in basic amino acid 
residues, with both the N- and C-termini oriented toward the lumen (Carrere-
Kremer et al., 2002; Montserret et al., 2010; Patargias et al., 2006). 
HCV p7 is believed to be an unstable protein, as a recent overexpression 
study reported that p7 is a labile protein and is degraded via the proteasome-
dependent pathway in a cell type-dependent but a phosphorylation-independent 
manner (Haqshenas, 2013). Other HCV proteins, including core (Shirakura et al., 
2007), F protein (Yuksek et al., 2009), NS2 (Franck et al., 2005), NS5A, and 
NS5B (Gao et al., 2003), have previously be shown to be degraded via the 
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proteasomal degradation route, but with only NS2 undergoing phosphorylation-
dependent degradation (Franck et al., 2005). 
A number of studies have indicated that p7 homo-oligomerizes to form ion 
channels in artificial lipid bilayers in vitro (Griffin et al., 2003; Griffin et al., 2004; 
Luik et al., 2009; Pavlovic et al., 2003; Premkumar et al., 2004). In addition, 
increasing evidence suggest that p7 forms proton channels that translocate 
protons across different cellular compartments (Meshkat et al., 2009; Wozniak et 
al., 2010). Based on this property, p7 is classified in the viroporin protein family, a 
group of small hydrophobic proteins encoded by a variety of RNA viruses, such 
as M2 of influenza virus and Vpu of HIV-1, which are capable of modulating 
membrane permeability in order to assist in viral entry, assembly or release 
(Wang et al., 2011). Although the role of p7’s ion channel activity in the viral life 
cycle remains uncertain, a number of in vitro studies have shown that it can be 
blocked by a variety of ion channel inhibitors, including adamantane, 
hexamethylene amiloride (HMA), and a number of iminosugar derivatives, 
although with varying efficacies (Clarke et al., 2006; Griffin et al., 2003; Pavlovic 
et al., 2003; Premkumar et al., 2004; Steinmann et al., 2007b), and in a 
genotype-dependent manner (Griffin et al., 2008). 
The detailed structure of p7 has not yet been solved, but a number of 
NMR studies have showed that the p7 monomer has three helical segments, i.e. 
two in the amino-terminal half of the sequence and one near the carboxy 
terminus (Cook and Opella, 2011; Montserret et al., 2010). A single-particle 
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electron microscopy (EM) study obtained a 16Aº resolution electron density map 
of the p7 oligomer (Luik et al., 2009), which showed that the p7 channel is a 42-
kDa hexamer and adopts a flower-like shape that has no homology with any of 
the known prokaryotic or eukaryotic ion channel proteins in the database 
(OuYang et al., 2013). Similarly, using the latest NMR technologies, OuYang and 
colleagues recently showed that the structure of p7 (genotype 5a) exhibits an 
unusual mode of hexameric assembly, where the individual p7 monomers, not 
only interact with their immediate neighbours, but also reach farther to associate 
with other monomers, forming a sophisticated, funnel-like architecture, which 
may have a cation selection mechanism. In this putative funnel structure, the 
authors reported that an asparagine/ histidine ring constricts the narrow end of 
the funnel, whereas an arginine/lysine ring defines the wide end of the funnel. 
Hence, these residues are said to be critical for p7 channel activity (OuYang et 
al., 2013). 
 
1.5.3.1 Role of p7 Protein in the Viral Lifecycle and on Cellular 
Activity 
The exact role p7 protein in the viral lifecycle is currently not well 
understood, but it is believed that its biological roles may be more numerous and 
multifaceted than simply acting as a channel (Cook et al., 2013). Thus, p7’s 
channel activity may be secondary to its principal biological activities, a notion 
reinforced by the position of its gene located between those for the nonstructural 
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and structural proteins of HCV. This might also suggest why some of its functions 
are believed to involve interactions with other proteins (Chandler et al., 2012). 
So far, a number of studies have indicated that p7 is important for 
successful HCV infection in chimpanzees as well as for infectious virus 
production in cell culture, although it is seemingly dispensable for virus entry and 
RNA replication (Brohm et al., 2009; Jones et al., 2007; Meshkat et al., 2009; 
Sakai et al., 2003; Steinmann et al., 2007a; Vieyres et al., 2013). There is 
however some debate about the precise step in the virus lifecycle that p7 acts. 
For instance, some studies employing full-length HCV chimeras have indicated 
that p7 acts at a late stage during viral assembly and release (Steinmann et al., 
2007a; Yi et al., 2007), whereas others think that p7 functions at an early stage 
during virion morphogenesis (Jones et al., 2007).  
The ion channeling function of p7 has been demonstrated by a number of 
studies to be important for infectious HCV production, since mutations that 
inhibited the ion channel function of p7 also inhibited infectious virus production 
(Shanmugam and Yi, 2013). For instance, the ectopic expression of the influenza 
virus M2 ion channel protein or the treatment with Bafilomycin was shown to 
partially rescue the virus production defect caused by some p7 mutations 
(Steinmann et al., 2007a; Wozniak et al., 2010). However, it has also been 
shown that the p7 protein or its precursors, but not M2, was capable of rescuing 
the virus production defect of the ∆p7-half deletion mutant, which seems to 
suggest that p7 is involved in HCV production in both ion channel-dependent and 
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ion channel-independent manners (Brohm et al., 2009; Steinmann and 
Pietschmann, 2010; Wozniak et al., 2010). Some recent studies however suggest 
that p7 is critical for functions in virus assembly unrelated to its ion channel 
activity (Popescu et al., 2011a). 
The cytoplasmic loop of p7, which links the two transmembrane domains 
and harbors a conserved dibasic motif, R33 and R35, have been implicated in 
p7’s ion channel activity (Griffin et al., 2004). These residues were specifically 
shown to be important for p7 ion channel activity in artificial membrane assays. 
Apart from its role in ion channel activity, the cytoplasmic loop has also been 
shown to be important in virus production. In deed, its importance had been 
shown in multiple in vitro (employing the HCVcc system), and in vivo studies after 
intrahepatic injection of chimpanzees (Jones et al., 2007; Sakai et al., 2003; 
Steinmann et al., 2007a).  
Similarly, in their quest to identify the stage in the viral lifecycle that p7 
acts, Atoom and colleagues recently performed alanine triplet mutations 
spanning p7’s TM1 and the cytoplasmic loop (Atoom et al., 2013). They observed 
that, regions of both the cytoplasmic loop and TM1 of p7 were important for virus 
production, and that p7 was not involved in virus release. They noticed that 
mutations of these regions neither altered core localization to lipid droplets nor 
affected capsid assembly. However, their main finding was that, disruption to the 
integrity of the conserved dibasic motif within the cytoplasmic loop of p7 resulted 
in diminished levels of E2 glycoprotein. The authors therefore suggested that p7 
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acts at a point in the virus lifecycle that is after nucleocapsid formation, but before 
virus release. In view of this, it is believed that p7 is important for viral 
envelopment and that it protects E2 from premature degradation through an ion 
channel-like activity. Coupled with this, p7 is able to execute its other functions by 
interacting with other proteins in order to support late stage, post-nucleocapsid 
virus assembly (Atoom et al., 2013). 
A growing number of studies have reported that HCV p7 acts in concert 
with other viral proteins in the execution of its functions (reviewed in (Chandler et 
al., 2012; Khaliq et al., 2011; Steinmann and Pietschmann, 2010), suggesting 
that its biological functions and possibly its ion channel activity are regulated by 
specific protein−protein interactions (Chandler et al., 2012). For instance, p7 is 
reported to interact with several HCV proteins including core, NS2, NS5A, and 
NS5B during virus morphogenesis, suggesting a central role for this protein in 
virus formation (Gouklani et al., 2013; Gouklani et al., 2012; Jirasko et al., 2010; 
Ma et al., 2011; Popescu et al., 2011a). Using forward genetic analysis and 
employing the JFH1 and GT1/JFH1 intergenotypic chimeric viruses, Gouklani 
and colleagues recently demonstrated that, p7 contains structural determinants 
whose functional interactions with other viral proteins are crucial for virus 
assembly. They identified specific residues within core (K74), NS2 (T23 and 
H99), NS5A (D251), and NS5B (K151), which genetically interacted with p7 to 
promote HCV morphogenesis (Gouklani et al., 2013). It is believed that the 
interaction of p7 with NS2 is not only important for efficient viral assembly but 
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also for viral release (Boson et al., 2011; Jirasko et al., 2010; Ma et al., 2011; 
Popescu et al., 2011a; Popescu et al., 2011b; Vieyres et al., 2013). Similarly, a 
strain-specific tripartite relationship between core, p7, and NS2 has been 
reported to be responsible for modulating the subcellular localization of core 
(Boson et al., 2011) and NS2 (Tedbury et al., 2011), which is believed to be 
independent of p7’s ion channel activity. Furthermore, it had been shown that 
mutations in the p7 protein, either singly or in combination with E2 glycoprotein 
enhances several-fold production of infectious virus particles in cell culture (Kim 
et al., 2011a). A more recent study has also reported that the optimal processing 
of the E2-p7 junction site is critical for efficient virus production, as impairment of 
E2-p7 processing was shown to be detrimental for infectious HCV production 
without affecting viral RNA replication (Shanmugam and Yi, 2013). Similarly, 
previous studies had shown that amino acids required for the ion channel activity 
of p7 were also important for pH modulation of intracellular vesicles in cell 
culture, and that this activity was important for maintaining infectious virus 
production (Wozniak et al., 2010).  
The influence of other HCV proteins on the functions of p7 has also been 
observed. For instance, an extensive alanine-scanning mutagenesis on the core 
protein of the J6/JFH1 chimeric virus demonstrated that, substitution of 
phenylalanine 26 for leucine (F26L) in p7 TM1 could compensate for the defect in 
virus production by viral transcripts encoding mutated amino acids at positions 
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65–72 of the core protein, thus suggesting a critical interaction between p7 and 
core (Murray et al., 2008).  
Most of the HCV proteins have been implicated in cell death, however, 
there is dearth of information on the role of p7 in cell death regulation, except that 
previously reported by Madan and colleagues (Madan et al., 2008). Recently, we 
also demonstrated that the p7 protein was pro-apoptotic and that it’s apoptotic 
activity was not linked with its ion channel activity, since ion channel mutants 
triggered a similar level of apoptosis as the wild-type p7 (Aweya et al., 2013). It 
thus appears that p7, like other viroporins, plays a crucial role in the 
morphogenesis of HCV, details of which are beginning to emerge. Furthermore, 
p7 protein must be a remarkably complex protein considering the fact that it has 
only 63 residues, yet is implicated in a plethora of biological functions, especially 
acting in concert with other HCV proteins.  
 
1.6 The HCV Lifecycle and Replication 
The specific details of how HCV enters the cell are not fully understood, 
but recent studies showed that HCV enters cells via receptor-mediated 
endocytosis involving the interaction of the viral particle with a series of cell 
surface receptors and/or factors (Sainz et al., 2012) (Figure 1.5). 
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Claudin 1 (CLDN1), Occludin (OCLN), glycosaminoglycans (GAG), the low-density 
lipoprotein receptor (LDLR), epidermal growth factor receptor (EGFR), ephrin receptor 
A2 (EphA2), and Niemann-Pick C1-like L1 (NPC1L1) are indicated. After uncoating 
process, the positive-stranded viral RNA is released, translated, and processed into 
different viral proteins. The NS viral proteins mediate the replication of positive-stranded 
viral RNA within a membranous structure, called membranous web. The infectious viral 
particles containing the newly-synthesized viral RNA and structural proteins are assembled 
and egressed via the secretory pathway. 
  
Figure 1.5. Schematic representation of the HCV viral life cycle.  Adapted from 
(Ke and Chen, 2012).  
 
Some of the factors or receptors that are involved in HCV entry into cells 
include the tetraspanin CD81, the cholesterol transporter scavenger receptor SR-
BI/Cla1, the LDL receptor (LDL-R), the components of tight junctions claudins 
(CLDN) 1, 6, and 9 and occludin (OCLN), the receptor for epidermal growth factor 
(EGFR), ephrin receptor A2 (EphA2), and the cholesterol absorption receptor 
Niemann-Pick C1-like-1 (NPC1L1). In addition, glycosaminoglycans (GAG), such 
as heparin sulfate, and the lectins DC-specific intracellular adhesion molecule-3-
grabbing non-integrin (SIGN) and liver-specific (L)-SIGN have been implicated in 
HCV cell attachment and entry (see recent review by (Ke and Chen, 2012) and 
(Sainz et al., 2012). 
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HCV infection or entry into host cells is initiated by binding of the viral envelope 
proteins to cell surface receptors via a complex multistep process, followed by 
their internalization into endosomes in a clathrin-dependent manner (reviewed in 
(Helle and Dubuisson, 2008; Zeisel et al., 2009)). Once inside the cell, the virus-
containing endosome is uncoated to release the positive-strand viral genomic 
RNA into the cytoplasm; a process thought to occur after low pH-induced fusion 
of the viral and endosomal membranes, mediated by the viral envelop 
glycoproteins (Helle and Dubuisson, 2008; Hsu et al., 2003; Tscherne et al., 
2006). The released viral genomic RNA is then translated into a polyprotein 
within the membranous web. The polyprotein is subsequently co- and post-
translationally modified into individual viral proteins, which leads to the 
establishment of replication complexes in ER-derived membranous 
compartments where viral RNA replication occurs via negative strand viral RNA 
synthesis (Moradpour et al., 2007). The progeny viral genomes are either 
translated to produce additional viral proteins or packaged to assemble progeny 
infectious virions. These then bud into the lumen of the ER and leave the host 
cell through the secretory pathway, completing the viral lifecycle (Figure 1.5) (Ke 





1.7 Model Systems used to Study HCV 
After the identification and characterization of HCV, further research on 
the molecular properties and pathogenesis of the virus was hampered due to the 
lack of a reliable cell culture system and the fact that conventional virology 
methods failed to initiate productive HCV infection (Ashfaq et al., 2011). 
Moreover, as obligate intracellular parasites, the study of viral multiplication cycle 
requires a permissive host cell. Thus, numerous attempts were made to 
propagate the virus in primary hepatocyte cultures and various established cell 
lines, but all yielded very low level of replication and poor reproducibility of results 
(Bartenschlager and Lohmann, 2000). 
 
1.7.1 HCV Replicon Systems 
A major milestone in HCV research and in the establishment of a robust 
and reliable cell culture system was achieved with the development of 
subgenomic and selectable HCV replicons. These are RNAs consisting of 
sequences encoding non-structural proteins flanked by the 5’ and 3’ UTRs, which 
self-replicate in the hepatoma cell line Huh7 (Lohmann et al., 1999). This 
experimental approach provided the first opportunity to study efficient HCV RNA 
replication in vitro (Roingeard et al., 2004).   
The first replicon was a bicistronic RNA under the translational control of 
two separate IRES elements. The first cistron consisted of a neomycin 
phosphotransferase gene under the control of the 5’ HCV IRES, while the second 
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cistron consisted of the minimal necessary HCV replicase proteins NS3-5B under 
the control of a heterologous IRES from encephylomyocarditis virus. Following 
electroporation of subgenomic RNA into human hepatoma cell lines, replication 
produces the selectable gene product, allowing transduction of G418 drug-
resistance as an indirect readout of replication efficiency (Lohmann et al., 1999). 
Some of the widely used replicons reported to date include genotype 1b 
replicons (e.g., Con1, HCV-N), the H77 clone genotype 1a replicon, and the JFH-
1 clone genotype 2a replicon (Blight et al., 2003; Guo et al., 2001a; Ikeda et al., 
2005; Ikeda et al., 2002; Kato et al., 2003; Kishine et al., 2002; Lohmann et al., 
1999; Maekawa et al., 2004).  
One major advantage of the replicon system is that, replication has been 
established in multiple liver-derived cell lines (e.g., HepG2 and Huh6) as well as 
non-liver cell lines (e.g., 293 and HeLa) and rodent cell lines (e.g., NIH3T3, 
AML12, MMHD3)(Ali et al., 2004; Date et al., 2004; Kato et al., 2005; Uprichard 
et al., 2006; Zhu et al., 2003). Despite these advantages, the most obvious 
limitation of the replicon system is that it cannot be used to study the entire HCV 
infection process, particularly the early steps of virus life cycle (e.g., viral 
attachment, entry, and un-coating) or the late steps of viral infection (e.g., virion 
assembly, maturation, and release). In addition, all replicons, except for the 
genotype 2a JFH-1 clone, contain cell culture adaptive mutations, which when 
introduced back into the viral genome, render it non-infectious in chimpanzees 
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(Bukh et al., 2002). Hence, HCV replicons may not accurately mimic which viral-
host interactions are most critical in vivo (Hussain et al., 2012). 
 
1.7.2 The HCV Pseudoparticle System (HCVpp) 
To overcome the limitations of the replicon system and to allow for the 
study of HCV entry, researchers created the infectious pseudoparticles system 
(Bartosch et al., 2003; Hsu et al., 2003). Like other viral pseudotyped particles, 
the HCVpp system is accomplished in 293 cells by co-transfecting a plasmid 
encoding an envelope deficient, packaging competent retroviral genome 
[Moloney Murine Leukemia Virus (MMLV) or HIV] engineered to express a 
reporter gene (e.g., GFP or Luciferase) along with a plasmid encoding E1/E2 
envelope glycoproteins of HCV. Entry of the recombinant viral particles into cells 
is then dictated by the envelope glycoproteins and efficiency of the entry process 
can be measured by a simple reporter gene assay. A number of studies using 
functional analysis have demonstrated that the requirements for HCVpp cell entry 
closely mimic HCV entry in terms of antibody neutralization. Therefore, the 
HCVpp system is a useful method to study the entry of various HCV genotypes, 
the cellular factors required for HCV entry, and the tropism restrictions associated 
with HCV entry (Ashfaq et al., 2011; Evans et al., 2007; McKeating et al., 2004; 
Owsianka et al., 2005; Ploss et al., 2009; Tong et al., 2011). However, one 
caveat of the HCVpp is that these pseudo-particles are not identical to the 
authentic HCV particles in terms of lipid composition and this does result in some 
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functional differences in entry factor requirements and kinetics. For example, the 
LDL receptor and the Niemann-Pick C1-Like 1 (NPC1L1) cholesterol uptake 
receptor are required for the entry of infectious HCV particles such that HCV 
infection is blocked by antibodies or other small-molecule inhibitors directed 
against these cell surface proteins; however, HCVpp entry is much faster and 
independent of these two factors (Bartosch et al., 2003; Hsu et al., 2003; Molina 
et al., 2007; Sainz et al., 2012). 
 
1.7.3 The HCV JFH-1 Cell Culture Infectious System (HCVcc) 
In spite of the great progress made in HCV research with the HCV 
replicons and pseudoparticles system, the lack of virus production was an 
obvious limitation of these systems. A breakthrough finally came to HCV 
research upon the identification of the HCV genotype 2a isolate, JFH-1, which 
was cloned from a Japanese patient with fulminant hepatitis (Kato et al., 2001). 
One unique feature of the JFH-1 clone is that, replicons derived from this 
consensus genome did not require adaptive mutations in order to replicate 
efficiently in cell culture (Kato et al., 2003).  
Based on the JFH-1 clone, Wakita and colleagues (Wakita et al., 2005) 
developed the HCV culture system (HCVcc). This HCV full-length genome 
replicates efficiently (without requiring cell culture-adaptive mutations) and 
produces virus particles (HCVcc) in Huh-7. Specifically, when the in vitro 
transcribed genomic HCV RNA of this construct was electroporated into Huh-7 
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cells, it resulted in efficient replication and rapid spread of HCV to non-
transfected cells. In addition, filtered media from the transfected cell culture was 
able to transmit infection to naïve cell cultures indicating the presence of secreted 
infectious virus particles. Similarly, the cell culture-produced virus was confirmed 
to be infectious in chimpanzee (Wakita et al., 2005) and in chimeric SCID-uPA 
mice transplanted with primary human hepatocytes (Lindenbach et al., 2006). 
The virus recovered from these infected mice was also infectious in Huh-7 cells 
in vitro (Lindenbach et al., 2006). 
Further refinements in the HCVcc system led to the development of Huh-7 
derived cell lines (e.g., Huh7.5.1), which are highly permissive to JFH-1 virus 
infection and have thus increased the viral titer several fold in culture 
supernatant.  Apart from these improvements and to address the fact that the 
HCVcc system is restricted to a single viral clone, JFH-1-based chimeric viruses 
(e.g., J6/JFH-1) have been created by substituting discrete regions of different 
HCV genotype clones into the JFH-1 backbone (Gottwein et al., 2011; Gottwein 
et al., 2009; Li et al., 2011; Pietschmann et al., 2006; Scheel et al., 2011; Zhong 
et al., 2005). These chimeric viruses have improved viral infectivity (Lindenbach 
et al., 2006) and replication in Huh-7 cells. 
The HCVcc system is therefore an ideal tool to study all aspects of HCV 
because it encompasses the complete viral life cycle and thus allows for 
production and analysis of infectious HCV particles. One major limitation of the 
HCVcc system is its restriction to a single isolate (JFH-1) that supports efficient 
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virus production. Although, production of infectious particles has also been 
described for a highly adapted H77 (genotype 1a) isolate, virus titres attained 
with this genome and infectivity of released particles appear to be very low(Yi et 
al., 2006). 
 
1.7.4 Primary Human Hepatocytes (PHH) 
Theoretically, primary human hepatocytes (PHH) should be the in vitro 
system of choice to grow and study HCV (Vieyres and Pietschmann, 2013). A 
number of studies have demonstrated successful infection of PHH with both 
serum- and cell culture-derived HCV particles (Fournier et al., 1998; Molina et al., 
2008). However, the preparation and culture conditions of PHH are stringent. 
Thus, work with PHH is time-consuming and a laborious process. Moreover, the 
quality of PHH is difficult to control and the replication of JFH-1 viruses is lower 
than in Huh-7.5 cells (Molina et al., 2008).  
 
1.7.5 Animal Models 
The pathogenesis of HCV infection remains incompletely understood and 
the use of animal models for such studies are limited by species tropism. Apart 
from humans, the only other known animal species that is naturally permissive to 
HCV infection are chimpanzees (Sandmann and Ploss, 2013). However, the use 
of the chimpanzee and other large apes in biomedical research has raised ethical 
concerns, coupled with their endangered status and exceptionally high cost 
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(Hussain et al., 2012; Roingeard et al., 2004). The use of chimpanzees in 
research has therefore been banned in many countries (Sandmann and Ploss, 
2013).  
Thus, in search of alternative and more readily accessible experimental 
animal models for HCV, numerous species have been tested for their 
susceptibility to HCV, including woodchucks, old-world monkeys, new-world 
monkeys, Cynomolgus monkeys, Rhesus macaques, Japanese macaques, 
Green monkeys, Doguera, Chacma Baboons, Cotton-top tamarins, marmosets, 
and tree shrews (Sandmann and Ploss, 2013). However, among all these animal 
species, it was only the tree shrew (Tupaia belangeri), a distant relative of the 
primates, which was shown to support HCV infection to some extent as well as 
showed some signs of liver disease, although the viral titers remain low (Amako 
et al., 2010; Sandmann and Ploss, 2013; Schmitz et al., 2000; Xie et al., 1998; 
Xu et al., 2012; Xu et al., 2007). Despite the numerous potential benefits of using 
this species as an animal model in HCV research, their use for the study HCV 
pathogenesis is challenging for the following reasons: cannot easily be 
manipulated genetically, there is limited availability of tupaia-specific reagents, 
limited access to this animal resource and as an outbred species, they are 
genetically heterogeneous (Billerbeck et al., 2013; Fan et al., 2013). Apart from 
these factors, there is lack of information on its complete genome (Bissig et al., 
2010; Fan et al., 2013). However, a Chinese research group has just published 
the complete annotated genome sequence of the Chinese tree shrew (Fan et al., 
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2013), which will soon pave the way for the use of this species in a number of 
biomedical research projects. 
Small animal models for virus infection are of great value for studying viral 
pathogenesis, testing new vaccines, and developing antiviral drugs, because 
they are easy to breed and handle and can be genetically modified. However, the 
restricted species tropism of HCV has hampered the development of a suitable 
small animal model for research. Thus, to overcome these species barriers, 
chimeric xenograph mouse models have been developed. The first and most 
commonly used model is based on severe combined immunodeficiency (SCID) 
mice carrying a lethal urokinase-type plasminogen activator (uPA) transgene 
expressed in their hepatocytes by the albumin promoter. While the endogenous 
hepatocytes in these mice are destined to die, these uPA-SCID mice can be 
rescued by transplantation with human hepatocytes that repopulate the liver. The 
human hepatocytes in these mice remain permissive to human hepatotropic 
viruses such as HBV and HCV (Dandri et al., 2001; Mercer et al., 2001). While 
the use of this model is not widespread due to technical as well as physiological 
limitations of the system, chimeric mice with humanized livers are currently the 
most relevant small animal model for testing inhibitors of HCV infection in vivo 
(Hussain et al., 2012). 
Recently, transgenic technology has also provided small animal models 
that can sustain HCV replication and show some features of human liver disease 
(Chouteau et al., 2012; Robinet and Baumert, 2011). However, transgenic 
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models have numerous caveats that lessen their utility. For instance, several 
copies of the transgene cassettes integrate randomly throughout the mouse 
genome. In addition, high transgene copy numbers along with the use of strong 
viral or cellular promoters results in HCV protein expression levels that massively 
exceed the amount of viral proteins present during normal infection (Billerbeck et 
al., 2013). 
Although the development of a small animal model that allows robust HCV 
infection has been achieved using chimeric liver immunodeficient mice, these 
chimeric mice can only be used as a challenge model for study of basic HCV 
virology or the development and evaluation of antiviral therapies, since their utility 
in the study of viral pathogenesis is hampered by their inability to mount 
functional immune responses coupled with practical aspects such as high costs, 
low throughput, and donor-to-donor variability (Dorner et al., 2013). Therefore, in 
order to overcome these limitations and to create a suitable mouse model 
permissive to HCV infection while maintaining complex immunity, a number of 
studies have attempted to establish a humanized mouse model that allows for 
the study of HCV pathogenesis and immune responses (see recent review by 
(Mailly et al., 2013) and (Billerbeck et al., 2013)).   
The first breakthrough in the development of a fully immunocompetent 
mouse model for the study of HCV infection came from the work of Washburn 
and colleagues (Washburn et al., 2011). They developed a novel mouse model 
consisting of a humanized mouse engineered by engraftment of both human 
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hepatocytes and human immune cells (so called dually engrafted humanized 
mice). This model was generated by the use of a fusion of the FK506 binding 
protein and caspase 8 under the control of the albumin promoter. This construct 
induced apoptotic elimination of host hepatocytes in Balb/C Rag2 (-/-) C-null 
mice. These humanized mice were shown to harbor both human hepatocytes 
and T cells. The mice supported HCV infection, which induced HCV-specific 
human immune response, liver infiltration, hepatitis, and fibrosis. However, there 
were low levels of HCV infection demonstrated by absence of HCV RNA in the 
serum, and a lack of a B cell immune response due to absence of an engraftment 
of a complete immune system (Washburn et al., 2011). 
Similarly, Dorner and colleagues developed a humanized mouse model 
using fully immunocompetent inbred mice that were permissive to HCV infection 
(Dorner et al., 2011). This was based on a previous study which had shown that 
CD81 and occludin (OCLN) were the minimal human factors required for HCV 
uptake by mouse cells (Ploss et al., 2009). Thus, by genetically engineering mice 
to express HCV-specific entry factors including CD81, occludin, SCARB-I, and 
CLDN1, it allowed them to use this model to study HCV entry in vivo and to 
assess the efficacy of entry inhibitors and vaccine candidates (Dorner et al., 
2011; Giang et al., 2012). However, because immunocompetent mice were used, 
viral replication and persistence of infection was limited. 
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Despite the fact that the development of immunocompetent humanized mouse 
models has come a long way, there are still several limitations that need to be 
overcome (Shultz et al., 2011). For instance, although HCV specific IFN-γ and 
TNF-α producing T cells are detectable in dually engrafted HCV-infected 
humanized mice, it remains to be determined whether these virus-specific T cells 
are able to control and eventually clear the infection. Similarly, it is generally 
accepted that the human immune system of the current humanized mouse 
models are not fully functional, due partly to limited interspecies cross-reactivity 
of important hematopoietic cytokines, such as TPO (thrombopoietin), SCF (stem 
cell factor), Flt3-L, GM-CSF, IL-3, or IL-15, which results in impaired 
development, maintenance and function of certain immune cell lineages. 
Furthermore, the development and function of human T and B cells in humanized 
mice are likely impaired due to the lack of HLA expression in the mouse thymus 
and peripheral tissue and limited secondary lymphoid organ development. These 
are significant shortcomings in the current humanized mouse models which 
require further improvement (recently reviewed in (Akkina, 2013; Billerbeck et al., 
2013). 
 
1.8 Programmed Cell Death 
Programmed cell death (PCD) plays an important role during 
development, homeostasis and immune regulation of multicellular organisms. As 
part of the immune response, PCD is generally induced against invading 
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pathogens. However, many pathogens have also developed strategies to 
suppress and/or modulate PCD of their host cells (Chen et al., 2006). Although, 
there are generally three broad categories of PCD, namely, apoptosis, necrosis 
and autophagy, cell death induced by some viruses can exhibit the classic 
morphological characteristics of apoptosis, whereas others induce a multitude of 
other morphologies including necrosis and autophagy (Chen et al., 2006).  
 
1.8.1 Apoptosis 
Apoptosis is a genetically controlled process of cell suicide involved in the 
regulation of homeostasis, tissue development, and the immune system to 
eliminate cells that are no longer useful. It also has a protective role by 
eliminating aberrant cells created by DNA damage or those infected by 
pathogens. A variety of stimuli can provoke apoptosis, including metabolic 
disturbances due to chemical insults, virus infections or developmental cues. The 
concept of apoptosis was first introduced in 1972 by Kerr, Wyllie and Currie to 
describe a form of cell death distinct from necrosis (Kerr et al., 1972). Apoptosis 
as a form of programmed cell death is characterized by chromatin condensation, 
DNA fragmentation, phosphatidylserine exposure, plasma membrane blebbing, 
cell shrinkage, formation of apoptotic bodies, and activation of caspase cascade 
(Fadok et al., 1998; Kerr et al., 1972; Wyllie et al., 1972; Wyllie et al., 1980). 
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Apoptosis is an important antiviral defense mechanism employed by the host cell 
to subvert virus infection and therefore limit viral replication and spread (Barber, 
2001). However, a number of viruses have evolved strategies to both counteract 
and induce apoptosis in order to maximize the production of viral progeny and to 
promote spreading to neighboring cells. 
There are generally two apoptosis signaling cascades, namely, the 
extrinsic (or receptor-mediated) and intrinsic (or mitochondrial) pathways, which 
ultimately activate a cascade of caspases (cysteine proteases) leading to 
apoptosis (see Figure 1.6 for a schematic representation). Thus, depending on 
the stimulus, apoptosis may be initiated extrinsically via the engagement of cell 
surface death receptors or intrinsically via the mitochondrial pathway. 
 
1.8.1.1 Caspases 
Apoptosis is generally initiated and executed by activation of intracellular 
enzymes termed caspases (cysteine-dependent aspartate specific protease) 
(Pop and Salvesen, 2009). Like other intracellular proteases, caspases are 
synthesized as zymogens that must undergo proteolytic cleavage to become 
active. Caspases have a dominant specificity for protein substrates containing 
four- or five-amino acid sequences containing an aspartate residue in the P1 
position (i.e. the amino acid on the NH2-terminal side of the scissile bond), a 
unique feature of this class of proteases. Moreover, caspases themselves must 
be cleaved at aspartate residues for activation, and thus caspases are activated 
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by other caspases (Malhi et al., 2010). Caspases may be classified as either 
initiator caspases or executioner (effector) caspases. Initiator caspases include 
caspases 2, 8, 9, and 10. The initiator caspases 8 and 10 are involved in death 
receptor-mediated apoptosis, whereas caspase 9 initiates apoptosis following 
mitochondrial dysfunction. The precise role of caspase 2 in apoptosis remains 
unclear, but it has been implicated in cell death by endoplasmic reticulum stress 
(the unfolded protein response) and following DNA damage (Kumar, 2009; 
Olsson et al., 2009; Upton et al., 2008). Executioner caspases such as caspases 
3, 6, and 7 are activated by cleavage by initiator caspases at aspartate residues 
and can be activated by either death receptor or mitochondrial pathways of 
apoptosis. These caspases may activate caspase-activated DNase (CAD) by 
cleaving ICAD, an inhibitor of this enzyme (Taylor et al., 2008). CAD activation 
results in DNA cleavage at internucleosomal linker regions of DNA resulting in 
the laddering pattern of DNA cleavage (multiples of the 180-bp nucleosomal 
regions) thought to be characteristic of apoptosis (Malhi et al., 2010). Caspase 
inhibitors can attenuate apoptosis, especially that by death receptors, providing a 
tool to dissect the role of apoptosis in pathophysiological models (Canbay et al., 
2004a). Also, caspase inhibitors are attractive agents for the treatment of human 
disease as they attenuate hepatocyte fibrosis by reducing apoptosis in preclinical 
models (Canbay et al., 2004a; Witek et al., 2009). 
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[9, 107]. The first model describes a non-specific mode
of release in which opening of the mitochondrial
permeability transition pore (MPTP) leads to the
swelling of mitochondria due to the osmotic influx of
water into the protein- and metabolite-dense mitochon-
drial matrix. The highly convoluted inner mitochondrial
membrane is able to expand while the outer mitochon-
drial membrane ruptures, releasing cytochrome c into
the cytosol. The second model describes specific modes
of release, where Bcl-2 family proteins form pores
either directly via oligomerization, regulate the pore
size of pre-existing pores, or indirectly by causing
membrane instability which gives rise to lipidic pores.
In the cytosol, cytochrome c binds to Apaf1 (apo-
ptotic protease activating factor 1) and in the presence
of dATP, procaspase 9 is recruited to the complex,
now termed the apoptosome, leading to the activation
of procaspase 9 [1, 143]. Activated caspase 9 can
activate downstream effector caspases, and thus deter-
mine the cell to death. Cytochrome c-dependent
activation of caspase 9 is supported by Smac/DIABLO
which is likewise released from the mitochondrial
intermembrane space and removes the anti-apoptotic
activity of IAPs (inhibitor of apoptosis proteins) [44,
182]. In addition, mitochondria release endonuclease
G and AIF (apoptosis-inducing factor) which translo-
Fig. 1 Scheme of signaling pathways implicated in apoptosis
(PCD type I) of cardiac myocytes. Depending on the stimuli
apoptosis may be initiated extrinsically via the engagement of
cell surface death receptors or intrinsically via the mitochondrial
pathway. The receptor-mediated death pathway is initiated by
binding of a death ligand (e.g., CD95L/FasL) to its cognate
receptor (e.g., CD95/Fas) in the plasma membrane. The cyto-
plasmic tail of the death receptor then engages death adaptor
molecules (e.g., FADD), resulting in the recruitment and
activation of procaspase 8. Caspase 8 activates downstream
effector caspases such as caspase 3, resulting in the execution of
apoptosis. Caspase 8 also activates Bid, thereby linking the two
death pathways. The mitochondrial death pathway is regulated by
the Bcl-2 family of proteins. Cellular stresses are communicated
to the mitochondria by pro-apoptotic Bcl-2 family members (e.g.,
Bid, Bax), leading to the release of pro-apoptotic molecules (e.g.,
cytochrome c, EndoG, AIF, Smac/DIABLO) from the mito-
chondrial intermembrane space into the cytosol where they
initiate the apoptotic cascade. Anti-apoptotic Bcl-2 family
members (e.g., Bcl-2 and Bcl-xL) oppose these actions
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Figure 1.6. Sch matic repres nt tio  f th  extrin ic and the intrinsic apoptosis 
pathways. Adapted from (Hamacher-Brady et al., 2006).  
 
1.8.1.2 Extrinsic Apoptosis Path ay 
The extrinsic apoptosis pathway is initiated by the binding of a death 
ligand (e.g., CD95L/FasL) to its cognat  receptor (e.g., CD95/Fas) in the plasma 
membrane. Upon this binding, the cytoplasmic tail of the death receptor then 
engages death adaptor molecules such as FADD (Fas-associated death domain) 
and TRADD (TNF recepto -associated de h d main), which assemble into the 
death-inducing signaling complex (DISC), a platform for the activation of the 
caspase cascade (see recent review in (Mocarski et al., 2012). The DISC then 
recruits and activates procaspase-8. Once activated, caspase-8 initiates the 
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apoptotic cascade via processing of downstream effector caspases such as 
caspase-3, -6 and -7 (Nicholson et al., 1995; Tewari et al., 1995), resulting in the 
execution of apoptosis. The activation of caspase-8 can also result in the cross-
talk between the extrinsic and intrinsic apoptotic pathway, as activated caspase-8 
can mediate the cleavage of the BH3-only protein, Bid, whose truncated form 
(tBid) can target mitochondria to trigger mitochondrial membrane 
permeabilization (Galluzzi et al., 2008; Li et al., 1998), which initiates the intrinsic 
pathway of apoptosis. 
 
1.8.1.3 Intrinsic Apoptosis Pathway 
The intrinsic apoptosis pathway can be stimulated by various stimuli, such 
as DNA damage or other intracellular stress signals, and is controlled by the 
mitochondria. The intrinsic pathway of apoptosis is regulated by the Bcl-2 family 
of proteins (see review by (Youle and Strasser, 2008)). The Bcl-2 family is 
divided into three groups based on the Bcl-2 homology (BH) domain. The BH3-
only proteins contain a single BH3 domain and are pro-apoptotic (e.g., Bid, Bim, 
Bik, and Bad). The other members contain multiple BH domains and are either 
pro-apoptotic (e.g., Bax, Bak and Bok) or anti-apoptotic (e.g., Bcl-2 and Bcl-XL). 
Apoptosis can be triggered by BH3-only proteins by inducing the oligomerisation 
of Bax and/or Bak or by binding to and inhibiting the anti-apoptotic Bcl- 2 family 
proteins. Apoptosis triggered by pro-apoptotic members of the Bcl-2 family 
causes permeabilization of the outer mitochondrial membrane leading to the 
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release of pro-apoptotic molecules such as cytochrome c (cyt c), EndoG, AIF, 
and Smac/DIABLO (second mitochondria-derived activator of caspases/direct 
IAP binding protein with low PI) from the intermembrane space. In the cytosol, cyt 
c interacts with both the adaptor molecule Apaf-1 and ATP forming a multimeric 
protein complex called the apoptosome (Cain et al., 2002; Cain et al., 1999). The 
apoptosome recruits and activates caspase-9 leading to activation of 
downstream executioner caspases, caspase-3, -6 and -7, and the manifestation 
of the apoptotic phenotype. In addition, other pro-apoptotic proteins released 
from the mitochondria, such as Smac/DIABLO, are involved in the apoptotic cell 
death. Smac/DIABLO induces apoptosis by blocking the effects of the inhibitor of 
apoptosis proteins (IAPs), such as XIAP (van Loo et al., 2002). IAPs can block 
apoptosis signaling either by binding to caspases and thus inhibiting the caspase 
cascade or by contributing to the NF-κB-mediated expression of anti-apoptotic 
genes (LaCasse et al., 2008). 
 
1.8.2 Necrosis and Necroptosis 
Necrosis as a form of cell death involves cell rounding and cytoplasmic 
swelling, resulting in the loss of membrane integrity and cytoplasmic leakage 
(Yuan and Kroemer, 2010). Since the integrity of the cell membrane is 
compromised causing the leakage of cytosolic components such as damage-
associated molecular patterns (DAMPs), these induce inflammation and an 
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immune response (Kono and Rock, 2008; Krysko et al., 2011). Therefore, 
necrotic cells induce inflammation in adjacent tissues.  
Necrosis was long believed to result from incidental cell death caused by 
external factors, such as severe energy shortage and physical injury 
(Vandenabeele et al., 2010). However, this long held view was dispelled when 
Laster and colleagues first reported that tumor necrosis factor (TNF) induced 
both apoptosis and necrosis, which suggested the existence of controlled 
necrosis (Laster et al., 1988). Since then, a number of studies have reported that 
caspase inhibition does not completely abolish cell death, but rather leads to 
necrotic cell death (Fiers et al., 1995; Holler et al., 2000; Vercammen et al., 
1998). For instance, it was observed that FASL, TNF-α, and TRAIL induced 
necrotic death of Jurkat cells in the presence of the pan-caspase inhibitor (zVAD-
fmk)(Holler et al., 2000). They also demonstrated that death-ligand-induced 
necrotic cell death of caspase-deficient cells required the activity of RIP1 
(receptor-interacting protein-1), a serine/threonine kinase (Holler et al., 2000). 
Chen and colleagues corroborated this observation when they also demonstrated 
that indeed RIP1 was required for TNF-induced necrotic cell death, which they 
referred to as “programmed necrosis”(Chan et al., 2003). Subsequently, the term 
“necroptosis” was used by Degterev and colleagues to refer to programmed 
necrosis (Degterev et al., 2005).  
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Currently, necroptosis have been shown to be dependent on RIP1 (also known 
as RIPK1) and/or RIP3 (also known as RIPK3) and is triggered via death 
receptors, pattern recognition receptors (PRRs), the T cell receptor (TCR) or 
genotoxic stress, as well as in settings when caspase-8 activity is compromised 
(reviewed in (Mocarski et al., 2012)). Thus, necroptosis is believed to play a role 
in host defense during infection, especially infection with intracellular pathogens 
that encode caspase-8 inhibitors. This means that programmed necrosis and 
apoptosis have complementary roles in host defense against pathogens 
(Mocarski et al., 2012)).  
 
1.8.3 Autophagy and Autophagic Cell death 
Autophagy is an evolutionarily conserved process that is responsible for 
bulk degradation of cytoplasmic molecules and organelles in healthy cells 
(Bergmann, 2007; Shen and Codogno, 2011) and is induced by various stress 
conditions such as amino acid starvation/nutrient deprivation, ER stress/unfolded 
protein response or viral infection (Eskelinen and Saftig, 2009). In autophagy, 
cytoplasmic components and organelles are engulfed by double-membrane 
vesicles called autophagosomes and fused with lysosomes 
(autophagolysosomes) (Degterev and Yuan, 2008; Kirkegaard et al., 2004). Their 
cargo is then degraded by lysosomal enzymes (Degterev and Yuan, 2008; 
Kirkegaard et al., 2004) and the degraded components are recycled for organelle 
synthesis or energy generation (Degterev and Yuan, 2008; Kirkegaard et al., 
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2004). Autophagy also eliminates damaged organelles and infectious agents 
from the cytosol (Cuervo, 2004). Autophagy is thus generally considered to be a 
pro-survival mechanism (Cuervo, 2004; Degterev and Yuan, 2008; Kirkegaard et 
al., 2004). However, some emerging evidence shows that under some 
conditions, autophagy can be pro-death (Kroemer et al., 2009; Kroemer and 
Jaattela, 2005; Kroemer and Levine, 2008; Levine and Yuan, 2005; Shimizu et 
al., 2010). 
Autophagic cell death, which was first described by Schweichel and 
colleagues, refers to a type of cell death that is accompanied by the presence of 
autophagosomes (Schweichel and Merker, 1973). Currently, autophagic cell 
death, also known as type II programmed cell death, has been redefined as a 
type of non-apoptotic cell death or necrotic programmed cell death in which 
autophagy has a role in the mechanism of death and displays distinct 
characteristics such as, cell death without involvement of apoptotic signaling, 
increased autophagic flux and suppression of autophagy by both 
pharmacological inhibitors or genetic approaches (Galluzzi et al., 2012; Shen and 
Codogno, 2011).  
Viruses are continually faced with the degradative mechanism of 
autophagy, so most viruses have developed molecular strategies to either avoid 
or exploit autophagy (Petkova et al., 2012). Some viruses have developed 
properties enabling them to inhibit the autophagy flux. For instance, herpes 
simplex virus (HSV)-1 or the cytomegalovirus (CMV) can inhibit autophagy 
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induction by targeting Beclin1 (BECN1), an essential autophagy-associated 
protein, through interactions with viral proteins (Chaumorcel et al., 2012; 
Orvedahl et al., 2007). Other viruses such as human immunodeficiency virus 
(HIV)-1 and influenza A virus avoid autophagy degradation by inhibiting 
autophagosome maturation by preventing autophagosome maturation through 
the physical interaction of viral proteins with BECN1 (Gannage et al., 2009; Kyei 
et al., 2009). In addition, viruses can induce a complete productive autophagy 
process and exploit it as a source for metabolites or as a platform for improving 
their own replication (Heaton and Randall, 2010; Jackson et al., 2005).  
One intriguing thing about autophagy is that, it is believed to have both 
pro-viral and anti-viral effects, involving multiple mechanisms. In terms of the pro-
viral effects, a number of studies have shown that autophagy machinery of the 
host can be induced by numerous positive-stranded RNA viruses, including 
poliovirus, CVB3 (coxsackievirus group B3), CVB4 (coxsackievirus group B4), 
EV71 (enterovirus 71), HRV (human rhinovirus), FMDV (foot and mouth disease 
virus), EMCV (encephalomyocarditis virus), DENV (dengue virus), HCV (hepatitis 
C virus), MHV (mouse hepatitis virus), SARS-CoV (severe acute respiratory 
syndrome-coronavirus), ChikV (chikungunya virus), and JEV (Japanese 
encephalitis virus) to support their life cycle. It has been demonstrated that 
pharmacological inhibition or gene silencing of autophagy pathway in vitro inhibits 
growth and/or spread of these viruses, whereas induction of autophagy results in 
increased viral yield (see review by (Shi and Luo, 2012)). The anti-viral effects of 
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autophagy is seen when it is used as a host defense mechanism against SIN 
(sindbis virus) infection (Liang et al., 1998; Orvedahl et al., 2010). It was shown 
that in response to SIN infection, mice with BECN1 overexpression had improved 
survival rate, reduced viral loads, and attenuated viral pathogenesis as compared 
to control mice (Liang et al., 1998). Similarly, it has been reported that autophagy 
plays a significant role in Toll-like receptors-mediated type I IFN signaling during 
CVB3 infection (Yajima and Knowlton, 2009). It was found that blockage of 
autophagy by either gene-silencing LC3-II, BECN1 or Atg5, or using 
pharmacological inhibitor 3-MA (3-methyladenine) inhibits TLR3 signaling in 
response to dsRNA (Shi and Luo, 2012). 
 
1.8.4 Cross-talk between Apoptotic, Necrotic and Autophagic Pathways 
Depending on a number of factors and cellular context, the same death 
stimulus can elicit apoptosis, autophagy or necrosis. It is believed that the 
molecular mechanisms behind these cell death pathways overlap, and can be co-
activated during some cellular functions. For example, proteins of the extrinsic or 
death receptor pathway of apoptosis can also influence autophagy or necrosis. It 
has been reported that in normal epithelial cells, autophagy and apoptosis are 
induced simultaneously by the FADD death domain, but since apoptotic cell 
death progresses faster, it is the dominant form of cell death to be observed. It is 
only when caspase inhibitors are used that the full onset of autophagy or 
necrosis emerges (Thorburn, 2008). Thus, the usage of caspase inhibitors allows 
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the observation of the alternative pathways, which function as back up if 
apoptosis is blocked (Chaabane et al., 2013). In fact, the caspase inhibitor, 
zVAD-fmk, is reported to modulate all three main cell death pathways. Although 
zVAD-fmk is used as a pan-caspase inhibitor to block apoptotic cell death, it has 
been shown that inhibition of caspase activity by zVAD-fmk may not only shift the 
balance in favor of autophagy, but in some cells, such as in L929 (rodent 
fibrosarcoma cell line) it also switches apoptosis towards necrosis (Los et al., 
2002). It is believed that under these conditions, the pro-necrotic action of the 
caspase inhibitor, may at least in part, be the result of lack of PARP-1 cleavage 
or inhibition by caspase-3/7. The reason being that, PARP-1 that is usually 
cleaved by caspases, becomes hyperactivated by apoptotic DNA-damage, and 
consumes enormous amounts of ATP (poly-ADP-ribosylaion of DNA and proteins 
of DNA-repair machinery), thereby exhausting the cellular ATP-pool and leading 
to necrosis (Los et al., 2002).  
RIPK1 and RIPK3, which are molecules associated with death receptor, 
may also connect all the three major death pathways. For instance, it has been 
reported that death receptor signaling via RIPK1 and RIPK3 involves the 
assembly of DISC in isolated membranes or pre-autophagosomal structures, 
which promotes caspase-8 activation and subsequently leads to caspase-
dependent apoptosis in a similar fashion as for the cell membrane-bound death 
receptor-DISC (Chaabane et al., 2013). However, in the absence of robust 
caspase-8 activity, a stable complex between RIPK1 and RIPK3 is formed, 
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promoting programmed necrosis and autophagy (instead of apoptosis) (Lu et al., 
2011).  
Among the cell death pathways, that between apoptosis and autophagy 
appears to be much obvious, probably due to the fact that these two pathways 
have received much more attention than necrosis, which hitherto was regarded 
as an accidental type of cell death. Autophagy proteins have been shown to be 
necessary for cell death under certain conditions, such as in apoptosis-defective 
cells (Pyo et al., 2005; Shimizu et al., 2004; Yu et al., 2004). In such situations, 
autophagy is needed for the execution of cell death. However, under other 
conditions, such as nutrient starvation, autophagy protects cells against 
apoptosis by providing nutrients (Bauvy et al., 2001; Boya et al., 2005; Gonzalez-
Polo et al., 2005). Apart from this, the regulation of apoptosis and autophagy are 
linked via the anti-apoptotic protein Bcl-2. Bcl-2 inhibits Beclin-1-dependent 
autophagy by binding to Beclin-1 and preventing its association with Vps34 
(Pattingre et al., 2005). This anti-autophagy function of Bcl-2 was proposed to 
help maintain autophagy at levels that are compatible with cell survival, rather 
than cell death (Eskelinen and Saftig, 2009). 
 
1.9 HCV Infection and Cell Death Manipulation 
HCV, like other viruses, have developed molecular strategies so as to 
either avoid or exploit the host antiviral mechanisms for its own benefit. For this 
reason, HCV is reported to manipulate a number of cellular signaling pathways 
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and proteins, including programmed cell death. Although apoptosis is the most 
well-characterized cell death pathway during viral infection, emerging evidence 
suggests that non-apoptotic cell death pathways are also highly regulated cellular 
suicide processes and contribute to pathological injury associated with infections 
(Degterev and Yuan, 2008; Duprez et al., 2009; Hotchkiss et al., 2009). 
 
1.9.1 HCV and Apoptosis 
HCV infection is associated with liver injury, but the mechanism behind 
this injury is not well understood. Whiles several studies have linked hepatocytes 
apoptosis with liver injury, some school of thought still has it that, liver injury in 
HCV infection is caused by host immune responses, not by viral cytopathic 
effects (Park et al., 2012). Nevertheless, both in vivo and in vitro studies have 
indicated the importance of apoptosis in liver cells. It is therefore not by 
coincidence that hepatocytes ubiquitously expresses death receptors and 
ligands, probably as a result of evolutionary pressure to protect the liver cells 
against hepatotropic viruses (Faubion and Gores, 1999). 
In the last couple of years, a number of studies have shown that 
hepatocyte apoptosis is an important part of the host anti-viral defense 
mechanism against HCV infection since it interferes with viral replication and 
assists in the elimination of virus-infected cells (recently reviewed by (Lim et al., 
2012)). In fact, it is believed that liver cell apoptosis is involved in the 
pathogenesis of HCV infection, with some reports suggesting that liver damage 
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might partly be responsible for fibrosis of the liver (Canbay et al., 2004b). The 
severity of liver damage in chronic HCV is said to be associated with the degree 
of hepatocyte apoptosis (Bantel and Schulze-Osthoff, 2003), whiles the degree of 
apoptosis has been demonstrated to correlate with the level of viraemia 
(Delladetsima et al., 2008). Similarly, in a study of a serum apoptosis biomarker, 
Bantel and colleagues reported observing liver cell apoptosis in HCV-infected 
patients but not in healthy controls. They also stated that, the rate of hepatocyte 
apoptosis of liver biopsy samples of HCV-positive patients post-liver transplant 
was significantly greater compared to that of non-transplant patients’ samples, 
with the severity of liver inflammation correlating with the level of hepatocyte 
apoptosis (Bantel et al., 2001). In addition, the HCV viral load has been shown to 
be higher post-liver transplantation (McCaughan and Zekry, 2002). Apart from 
these, some in vitro studies have shown that HCV infection causes direct 
cytopathic effects (Deng et al., 2008; Mateu et al., 2008; Mohd-Ismail et al., 
2009). 
Although there is overwhelming evidence implicating apoptosis in HCV-
associated liver damage, the mechanism is not well known. Some reports 
suggest that virus-specific cytotoxic T-cells may induce apoptosis of HCV-
infected hepatocytes by upregulating death receptor ligands (TNF, FasL/CD95L 
and TRAIL), via the production of antiviral cytokines (e.g., interferon-γ), and by 
direct cell killing with perforins and granzymes (Fischer et al., 2007). Moreover, 
HCV infection is associated with an upregulation of death receptors on 
! "!56!"!
hepatocytes, and the levels of Fas/CD95 and FasL/CD95L have been shown to 
increase in parallel with the severity of inflammation and disease progression 
(Zylberberg et al., 1999).  
There is also considerable evidence that HCV structural proteins can 
directly influence hepatocyte apoptosis. For instance, HCV core protein has been 
reported to sensitize hepatocytes to TNF-α (Kang et al., 2009) and FasL/CD95L 
(Ruggieri et al., 1997) mediated apoptosis, by interacting with the cytoplasmic 
domains of TNFR1 and Fas/CD95 to enhance down-stream signaling events. It 
also induces oxidative stress, enhances mitochondrial-mediated hepatocyte 
apoptosis (Okuda et al., 2002) and upregulates TGF-β1 gene expression, 
thereby promoting apoptosis and fibrogenesis. The non-structural proteins of 
HCV have also been shown to affect hepatocyte apoptosis. Using a NS3-5B 
subgenomic replicon of HCV, Huh7.5 human hepatoma cells were shown to be 
sensitized to TRAIL-induced apoptosis (Lan et al., 2008). Similarly, accumulation 
of NS4A on mitochondria has been found to promote mitochondrial-mediated 
apoptosis (Nomura-Takigawa et al., 2006), whiles the HCV protease NS3, was 
demonstrated to induce apoptosis in a caspase 8-dependent manner. On the 
other hand, NS2 was found to inhibit the mitochondrial release of cytochrome c, 
thereby inhibiting mitochondrial-mediated apoptosis (Erdtmann et al., 2003). 
Further more, NS5A was shown to inhibit interferon-α-mediated STAT1 signaling 
(Podevin et al., 2001) and to protect hepatocytes against interferon-α- and TNF-
α-mediated apoptosis. NS5A was also shown to prevent apoptosis by activating 
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NF-kB, inhibit TGF-β, and upregulate STAT3 expression to promote hepatocyte 
proliferation (Gong et al., 2001). Although there is limited information on the role 
of p7 protein in apoptosis induction, it was previously shown to induce apoptosis 
among other viroporins (Madan et al., 2008), while our group recently 
demonstrated that p7 protein was proapoptotic and that it’s apoptotic activity was 
independent of its ion channel activity (Aweya et al., 2013). 
It is therefore conceivable to say that, HCV infection and HCV encoded 
proteins are partly responsible for the liver damage in chronic HCV infection, 
although the detail mechanism is still not well understood. 
 
1.9.2 HCV and Necrosis/Necroptosis 
Necrosis has for a long time been regarded as an accidental, uncontrolled 
mode of cell death. However, accumulating evidence shows that some forms of 
necrosis actively involve defined signaling pathways that contribute to the cellular 
demise, as is the case for apoptosis (see recent review by (Vanlangenakker et 
al., 2012)). There is no report on HCV and necrotic cell death or necroptosis, but 
like other viruses, HCV has evolved strategies to counteract a number of death 
pathways.   
Several viruses including human immunodeficiency virus type-1 (HIV-1), 
herpes simplex virus type-1 (HSV-1), West Nile virus (WNV), vaccinia virus (VV) 
and murine cytomegalovirus (MCMV), have all been shown to induce necrotic-
like cell death (Kaczmarek et al., 2013; Vanlangenakker et al., 2012). For 
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instance, it has been shown that cells infected in vitro with WNV develop a 
necrotic morphology followed by HMGB1 release (Chu and Ng, 2003). HIV-1-
infected T cell lines, in the presence of the caspase inhibitor zVAD-fmk, undergo 
necrotic-like, mitochondria-dependent cell death (Petit et al., 2002). Similarly, 
HSV type 1 (HSV-1) can inhibit apoptosis and elicit necroptosis in vitro; this cell 
death could be partially blocked by the RIPK1 kinase inhibitor Nec-1 and 
cathepsin inhibitors (Peri et al., 2011). Additionally, dengue virus (DENV) induces 
either apoptotic or necrotic cell death, depending on the virus titer (Kaczmarek et 
al., 2013). 
It is therefore plausible to speculate that, HCV, like the other RNA viruses, 
might as well induce necrotic type of cell death given that RIPK3-dependent 
necroptotic cell death is reported to be crucial in the control of viral replication 
(Cho et al., 2009; Upton et al., 2010), coupled with the fact that the same 
stimulus can elicit apoptosis or necrosis, depending on the cellular context 
(Vanlangenakker et al., 2012). 
 
1.9.3 HCV and Autophagy 
Apart from its pro-survival role, autophagy has been implicated in the 
immune response to pathogens. Thus, a number of viruses have devised 
strategies to antagonize the autophagic process (reviewed in (Dreux and Chisari, 
2010; Dreux and Chisari, 2011)). The significance of autophagy in viral infection 
has also drawn a lot of attention. It is believed that viruses utilize autophagy to 
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generate cytoplasmic membrane structures (via ER stress/unfolded protein 
response) required for the replication of their genome (Mohl et al., 2012). 
Some recent publications have reported on how HCV is able to modulate 
the autophagy pathway and how a number of autophagy proteins regulate HCV 
replication and infection (Dreux et al., 2009; Guevin et al., 2010; Ke and Chen, 
2011; Shrivastava et al., 2011; Sir et al., 2008; Tanida et al., 2009). It was shown 
that HCV replication could be suppressed at the onset of infection when the 
autophagic proteins Beclin-1, Atg4B, Atg5, and Atg12 were knocked down (Dreux 
et al., 2009), whiles the knockdown of Atg7 was shown to decrease the 
production of infectious viral particles, but did not affect HCV viral protein 
expression (Tanida et al., 2009). Similarly, an interaction between Atg5 and HCV 
NS5B (the viral RNA-dependent RNA polymerase) was demonstrated by Guevin 
and colleagues (Guevin et al., 2010), which is believed to be required for the 
onset of viral replication, since Atg5 has been shown to be involved in other 
positive-strand RNA virus replications via formation of a double membrane 
vesicle (Lee et al., 2008b).  
Similarly, some recent studies have reported that HCV infection induces 
autophagy. It was observed that HCV-induced autophagy is independent of 
mTOR (Shrivastava et al., 2012; Su et al., 2011); while the contribution of the 
unfolded protein response to autophagy remains unclear (Mohl et al., 2012; Sir et 
al., 2008). However, it has been shown that autophagy is required for an optimal 
HCV replication since inhibition of autophagy affects HCV replication (Dreux et 
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al., 2009; Gregoire et al., 2011; Tanida et al., 2009). It has also been shown that 
HCV infection prevented autophagosome maturation at an early time of infection 
(Gregoire et al., 2011; Sir et al., 2008; Su et al., 2011). However at a later time 
point in infection, a complete autophagy flux was reported (Ke and Chen, 2011; 
Mohl et al., 2012). A subgenomic replicon expressing the non-structural NS3-5B 
proteins was recently reported to induce autophagy (Mohl et al., 2012).  
 
1.10 Aims and Objectives of Thesis Project 
Recent findings have shown that HCV infection activates various cellular 
responses, including ER stress/unfolded protein response, autophagy, apoptosis, 
and cell cycle arrest. Some of these cellular responses are believed to be 
involved in the pathogenesis of HCV-associated liver diseases (Ke and Chen, 
2012).  
As an anti-viral mechanism in viral-host interaction, cell death regulation is 
one of the most important determinants of survival, therefore, many viruses 
encode for proteins that interfere with this signaling pathway, mostly skewing it to 
their advantage. While apoptosis induction by the host cell is a way to prevent 
viral spread to neighboring uninfected cells, apoptosis induced by HCV 
contributes directly to the dissemination of the virus. Similarly, while inhibition of 
apoptosis prevents premature death of the infected cells, it also allows the virus 
to replicate to a high titer and/or establish persistent infection.  Thus, in order to 
regulate this intricate process, HCV and HCV-encoded proteins are believed to 
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interact with various host proteins/factors. However, the exact mechanism is 
currently not well understood. The main purpose of this study was therefore to 
identify and characterize the viral and host factors that might be involved in the 
regulation of apoptosis during HCV infection. 
 
The specific objectives of the study include: 
1. To characterize the HCV proteins in terms of their apoptotic activity, 
2. To study further the identified viral factor(s) and the role they play in cell 
death modulation, 
3. To screen for the host apoptosis-related factors that might be differentially 
expressed following HCV infection, 
4. To perform detailed functional/mechanistic study of the host apoptosis-












MATERIALS AND METHODS 
 
2.1 Cell Culture and Cell Lines 
Huh7.5 cells (subclone of the Huh-7 human hepatoma cell line; Apath, 
Brooklyn, NY) and 293FT cells (human embryonic kidney cell line with the 
temperature sensitive gene for SV40 T-antigen; Invitrogen, Karlsruhe, Germany) 
were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented 
with 10 % fetal bovine serum (HyClone, Utah, USA), 0.1 mM nonessential amino 
acids and antibiotics (10 units/ml penicillin and 10 μg/ml streptomycin) 
(Invitrogen, Carlsbad, CA). All cells were maintained in a 37 °C incubator with 5 
% CO2. 
 
2.1.1 Cell Maintenance 
Cell monolayers were cultured in 25cm2 or 75cm2 tissue culture flasks 
(Corning Incorporated Life Sciences, Corning, NY) in Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% (v/v) Fetal Bovine Serum (HyClone, Utah, 
USA) and incubated at 37°C/5% CO2. Depending on the growth rate of the cell-
line, cells were routinely passaged, trypsinised (Trypsin, 
ethylenediaminetetraacetic acid (EDTA); Becton Dickinson Ltd., UK) and passed 
every 3-5 days as appropriate. 
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2.1.2 Cell Stock Freezing and Resuscitation 
To freeze adherent cells for long term storage or as a backup for new cell 
lines, cells were trypsinised, resuspended in a small volume of normal growth 
medium, and pelleted at 1500rpm for 5mins. Cells were then resuspended in 
freezing medium, 90% FBS and 10% (v/v) dimethyl sulfoxide (DMSO), and 
aliquoted into cryovials. The cells were kept in a polystyrene box (to slow down 
temperature decrease) and frozen at -80°C before long-term storage in liquid 
nitrogen. 
To resuscitate frozen cells, cryovials were rapidly thawed at 37°C before 
centrifugation at 1500rpm. The supernatant was aspirated off, and the pellet of 
cells resuspended and grown in normal growth medium at 37°C/5% CO2 
overnight. Medium was replaced after 24h in order to remove traces of DMSO. 
 
2.2 Antibodies Used 
Primary antibodies used in the study included anti-actin monoclonal, anti-
flag monoclonal and polyclonal (Sigma, St. Louis, MO), anti-poly [ADP-ribose] 
polymerase [PARP] polyclonal, and anti-LC3B polyclonal (Cell Signaling 
Technology Inc., Beverly, MA), anti-HCV NS3 monoclonal (Abcam plc, 
Cambridge, UK), anti-BIK (NBK) polyclonal, anti-BNIP3 monoclonal, anti-Beclin-1 
polyclonal, (Santa Cruz Biotechnology, Santa Cruz, CA), anti-GADD45A 
polyclonal (Millipore Corporation, Temecula, CA), anti-CIDEB polyclonal, anti-
TRAIL polyclonal, anti-HCV core monoclonal (Pierce/Thermo scientific, Rockford, 
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IL), and anti-HRK polyclonal (AbD Serotec/Bio-Rad, Hercules, CA). Secondary 
antibodies used included horseradish peroxidase (HRP)-conjugated goat anti-
mouse, rabbit anti-goat, and goat anti-rabbit antibodies (Pierce, Rockford, IL), 
Alexa Fluor® 488 Goat Anti-Mouse IgG, Alexa Fluor® 488 Goat Anti-Human IgG, 
and Alexa Fluor® 568 Goat Anti-Human IgG (Life Technologies, Carlsbad, CA). 
 
2.3 DNA Cloning and Subcloning 
2.3.1 Construction of Plasmids 
Expression plasmids for the wild-type HCV proteins were generated by 
PCR cloning using Titanium Taq DNA polymerase (Clontech Laboratories Inc., 
Palo Alto, CA). Two plasmids containing the full-length HCV genome of the 
genotype 1b (S1) cloned in Singapore ((Soo et al., 2002) GenBank accession 
number AF356827) and genotype 2a JFH-1 strain ((Wakita et al., 2005), 
GenBank accession number AB047639) were used as templates. The PCR 
products were digested with restriction enzymes BamHI and XhoI and then 
ligated into the pXJ40flag vector, which is a flag-tagged plasmid, derived from 
pXJ40 (Xiao et al., 1991). The pXJ40flag vector was used so that a flag epitope 
is fused to the N-terminus of the p7 protein to allow the comparison of protein 
expression levels with an anti-flag antibody.  
Similarly, the p7 mutants were generated by 2 rounds of PCR: the first 
round of PCR was used to generate 5’ and 3’ fragments of p7 containing the 
appropriate alanine or glutamine substitutions; these were then amplified into full-
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length p7 using end primers for the p7 gene and cloned into pXJ40flag vector 
using BamHI and XhoI sites.  
The M2 gene of influenza A virus (A/Puerto Rico/8/34/Mount Sinai/Wi 
(H1N1), GenBank accession number AY768951.1) was produced by gene 
synthesis (GenScript USA Inc Piscataway, NJ, USA) and cloned into the 
pXJ40flag vector in a similar manner. All sequences were confirmed by 
sequencing performed by the DNA Sequencing Facility at the Department of 
Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 
Singapore. 
 
2.3.2 Agarose Gel Electrophoresis 
DNA was analyzed by gel electrophoresis using different percentages (1 – 
2.5%) of agarose (Sigma-Aldrich Co. Ltd., UK) in 1X TBE buffer (5X TBE, 45mM 
Tris-borate, 1mM EDTA). DNA samples were mixed with the appropriate volume 
of DNA loading buffer (Promega Ltd., UK), prior to electrophoresis. Samples 
were run at 100V in 1X TBE buffer (containing 1 g/ml ethidium bromide or Gel 
red), until bands were clearly resolved. Along with the samples, DNA size 
markers were also run (100bp ladder and 1kb ladder; Promega Ltd., UK). 
Resolved DNA bands of interest were excised under UV light, and DNA was 




2.3.3 Restriction Enzyme Digestion of DNA 
Individual backbone vector DNA and purified PCR products were mixed 
with 2   ul 10X enzyme buffer, 1u l (5U) each of the desired restriction enzymes 
(Fermentes), in a reaction mixture made up to 20  ul with de-ionized H2O. 
Reactions were incubated at 37°C (for the majority of enzymes) for 2 – 8 h, or 
overnight as appropriate. 
 
2.3.4 Ligation of DNA Fragments (vector/insert) 
Insert and vector DNA were prepared by enzyme digestion/gel purification 
as described above. Insert, vector, ligase buffer and T4 DNA ligase were mixed 
with de-ionized H2O. Reactions were incubated overnight at 16°C and stored at –
20°C until ready for use. Ligation reaction products were used for heat shock 
transformation of competent E. coli (e.g., DH5α, Stbl3  ) cells as described below. 
 
2.3.5 Heat Shock Transformation of Competent Cells 
10u l of ligated reaction mix (or ~1u g pre-purified plasmid) was added 
directly to 100u l of thawed, competent cells. After incubation on ice for 30 min, 
cells were heat shocked in a 42°C water bath for 30 seconds before being 
immediately transferred back to ice for 2 min. Cells were resuspended in 1ml LB 
broth or SOC and incubated at 37°C for 1 - 2h (in order to assist cell recovery). 
The suspension was then plated out onto solid LB-agar plates supplemented with 
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an appropriate antibiotic. Plates were inverted and incubated at 37ºC overnight. 
Mini-preps were prepared from selected colonies. 
 
2.3.6 Preparation of Plasmid DNA (mini and midi-preps) 
For small-scale preparations, bacterial cell cultures of 4ml (in LB broth 
containing appropriate antibiotic) were grown overnight at 37°C in a shaking 
incubator. DNA was extracted from cells and purified using commercial mini-prep 
kits, according to the manufacturer’s instructions. For large-scale preparations, 
bacterial cultures of 100- 200 ml were grown overnight at 37°C in a shaking 
incubator, and DNA was extracted from cells using commercial midi-prep kits 
(following manufacturer’s instructions).  
 
2.4 Transient Transfection of Mammalian Cells (Lipofectamine 2000 and 
CombiMag) 
Transient transfections of cells were performed using Lipofectamine 2000 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. 
When very high transfection efficiencies are required, the Magnetofection (QZ 
Biosciences) transfection was used. Approximately 24 h after transfection, the 
cells were harvested by scrapping into the media, spun down in a bench-top 
centrifuge and washed twice with cold PBS. The cell pellets were then 
resuspended in 250 ul RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5 % 
NP40, 0.5 % deoxycholic acid, 0.005 % SDS and 1 mM phenylmethylsulfonyl 
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fluoride) and subjected to freeze thawing five times before being spun down at 
13000 rpm to remove cellular debris. The cell lysate was then used for Western 
blot analysis and quantification of apoptosis (see next section below).  
 
2.5 Western Blot Analysis 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose or 
polyvinylidene difluoride (PVDF) membranes using wet transfer. Following 
transfer, membranes were blocked for at least 30 minutes in 5% (w/v) skimmed 
milk powder, 0.1% (v/v) Tween20 in Tris-Buffered Saline (TBS) (blocking buffer), 
and incubated overnight with the appropriate primary antibodies diluted (in 
blocking buffer) as directed by the supplier. After extensive washing with 0.1% 
Tween20 in TBS, the membranes were incubated for 1h at room temperature 
with HRP-conjugated antibodies diluted appropriately in blocking buffer. 
Following final washing in 0.1% Tween20 in TBS (TBST), specific protein bands 
were visualized by enhanced chemiluminescence (ECL) according to the 
manufacturer's protocol. ImageJ software (http://rsbweb.nih.gov/ij/index.html) 
was used for quantification of the intensities of specific bands on autoradiographs 
where necessary. 
 
2.6 Immunofluorescence Assay (IFA) 
For indirect immunofluorescence staining, transfected Huh 7.5 or 293FT 
cells grown on coverslips were fixed with 4 % paraformaldehyde in PBS for 15 
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min. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 15 min, 
blocked with 1 % bovine serum albumin (BSA) in PBS for 30 min and incubated 
with primary antibodies (anti-flag polyclonal (Sigma)) for 1 h. After several 
washes, cells were incubated with Alexa-Fluor-564-conjugated goat anti-rabbit 
IgG secondary antibodies (Invitrogen) for 1 h. The washed coverslips were then 
mounted on glass microscope slides using a mixture of Fluorsave mounting 
medium (Calbiochem) and Vectashield mounting medium with DAPI (Vector 
Laboratories). Images were captured with either Olympus BX60 fluorescence 
microscope (Olympus, Japan) using a 40x or 100x oil objective or with Olympus 
FluoView FV1000 (Olympus, Japan) laser scanning confocal microscope using a 
60x/1.45 oil objective, with 543 nm HeNe laser as the excitation source. 
 
2.7 Co-immunoprecipitation (Co-IP) 
For the coimmunoprecipitation experiments, each 6 cm dish of cells was 
resuspended in 400 µl of RIPA buffer and subjected to freeze-thawing five times. 
Anti-Beclin-1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) was added to the lysates containing 200 µg of total protein and allowed to 
mix for 1 h at 4 °C. Protein A agarose beads (Roche, Indianapolis, IN) were 
added, and the mixture was subjected to end-over-end mixing at 4 °C overnight.  
Beads were washed four times with cold RIPA buffer, and then 15 µl of 
Laemmli’s SDS buffer was added and the samples were boiled at 100°C for 5 
min to release the immunocomplexes. Samples were separated by SDS-
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polyacrylamide gel electrophoresis and subjected to Western blot analysis as 
described above. 
 
2.8 Treatment of Transfected Cells with Ammonium Chloride 
In order to block autophagosome formation, cells were treated with 
ammonium chloride (BDH, AnalaR).  The spent media from an overnight 
transient transfection was replaced with complete media containing 2.7 mg/ml of 
ammonium chloride and then incubated further for 2.5 h. Cells were then washed 
twice with 1X cold PBS, lysed directly in 2X Laemmli’s sodium dodecyl sulfate 
(SDS) buffer and the cell lysate subjected to SDS-polyacrylamide gel 
electrophoresis, followed by Western blot analysis to determine the conversion of 
LC3-I to LC3-II using anti-LC3 antibody. 
 
2.9 Treatment of Transfected Cells with Proteasome Inhibitor 
At about 16hrs post-transfection, cells were treated with 25 uM or 50 uM of 
MG-132 for 4hrs. Briefly, 16hrs after transfection, the media was aspirated and 
replenished with media containing either 25 uM or 50 uM of the proteasome 
inhibitor, MG-132. The cells were returned to the CO2 incubator for another 4hrs. 
After this, cells were harvested by scrapping into the media, spun down in a 
bench-top centrifuge and washed three times with 1X cold PBS to remove any 
residual inhibitor in the media. The cell pellets were then resuspended in 1X 
RIPA buffer containing a protease inhibitor and subjected to freeze-thaw five 
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times before being spun down at 13000 rpm to clarify the lysate. The samples 
were then analyzed by 12 - 15% SDS-PAGE. 
 
2.10 Treatment of Transfected Cells with Cell Permeable Caspase 
Inhibitors 
Cells were transfected (as above) followed by treatment with 2.5 μM of 
caspase-3 (Z-DEVD-fmk), caspase-8 (Z-IETD-fmk), caspase-9 (Z-LEHD-fmk) or 
a negative caspase inhibitor (Z-FA-fmk) (BD Biosciences). Briefly, 6 h post-
transfection, the transfection media was changed and replenished with fresh 
media plus 2.5 μM of the respective cell permeable caspase inhibitors which are 
reported to have a very short half-life (Ekert et al., 1999; Garcia-Calvo et al., 
1998). After about 24 h post-transfection, the cells were harvested by scrapping 
into the media, spun down in a bench-top centrifuge and washed three times with 
1X cold PBS to remove any residual inhibitor found in the media. The cell pellets 
were then resuspended in RIPA buffer and subjected to freeze thawing five times 
before being spun down at 13000 rpm to clarify the lysate. 
 
2.11 Membrane Permeabilization Assay using Hygromycin B 
Permeability of the plasma membrane of cells expressing p7 or mutants to 
hygromycin B (a protein translation inhibitor) was a modification of the method 
described by Liao et al (Liao et al., 2006). Huh7.5 or 293FT cells seeded onto 6 
cm dishes were transfected with plasmids as described above, followed by 
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treatment of the cells with different concentrations of hygromycin B (Sigma) for 
30 min at 6 h post-transfection. After 24 h post-transfection, the cells were 
harvested, lysed in RIPA buffer and subjected to freeze-thaw five times. The cell 
extracts were then spun at 13,000 rpm for 20 min at 4 °C to clarify the lysate. The 
proteins were immunoprecipitated (as described above) with anti-Flag beads 
(Sigma) overnight at 4 °C, and washed three times with RIPA buffer. The 
samples were then analyzed by 15% SDS-PAGE. 
 
2.12 Small interfering RNA (siRNA)-mediated Gene Silencing 
A 21-nucleotide RNA duplex targeting the coding region of human BIK 
gene (Hur et al., 2004) (siBIK) was ordered from Thermo Scientific Dharmacon 
(Dharmacon, Lafayette, CO). Similarly, an RNA duplex targeting the viral genome 
of SARS-CoV was chosen as a negative control (siCtrl) since it does not target 
any host protein. The siRNA sequences were as follows: 
siBIK 







The lypholized siRNA samples were reconstituted in RNase-free water to a final 
concentration of 20μM.  
The siRNA transfection was performed using Lipofectamine RNAiMAX 
reagent (Invitrogen) according to the manufacturer’s recommendations. Briefly, 
Huh7.5 cells were plated in antibiotic-free media at a density of 3 x 105 cells and 
when 50% confluence was reached, the cells were transfected with 40 nM of BIK 
siRNA or control siRNA. At 24 h post-transfection, the siRNA transfection media 
was removed and the cells were replenished with antibiotic-free media. Cells 
were harvested at 2, 4, 6 and 8 days post- transfection and the knockdown 
efficiency was examined by Western blot analysis. 
 
2.11 Cell Viability Assay  
The viability of the cells was determined using the CellTiter-Blue® Cell 
Viability Assay (Promega) which provides a homogeneous, fluorescent method 
for monitoring cell viability according to the manufacturer's instructions. Briefly, 
Huh7.5 cells were seeded in 96-well culture plates at a density of 1.0 x 104 cells 
per well. After 24 hours, the cells were infected with an appropriate MOI of HCV. 
At specific time points post-infection, the CellTitre-Blue® reagent was diluted (1: 
4) with PBS and added to each well, mixed for 2 min on an orbital shaker and 
incubated at 37°C for 2 - 4 hours. The fluorescence readings were measured at 
570 nm using a plate reader (Tecan). Relative cell number was calculated by 
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normalizing the absorbance to untreated cells. Relative cell viability was 
compared to untreated cells. 
 
2.12 TUNEL Assay 
The Terminal deoxynucleotidyl transferase dUTP nick end-labeling 
(TUNEL) assay was carried out using the DeadEnd Fluorometric TUNEL system 
(Promega, Madison, WI) according to the manufacturer’s protocol. Briefly, 
Huh7.5 cells were plated onto 4-well chamber slides (Lab-Tek™) at a density of 
1.0 x 104 cells per well, infected with HCV J6/JFH-1-P47 or transfected with 
plasmids expressing HCV proteins followed by treatment with cell permeable 
caspase inhibitors in the case of p7 protein. After 24 h (for plasmid transfection) 
or at the appropriate time point post-infection, cells were fixed in 4% 
paraformaldehyde at 4°C for 25 min. Fixed cells were then permeabilized in 0.2% 
Triton X-100 and labelled with fluorescein-12-dUTP using terminal 
deoxynucleotidyl transferase. After washing with 1X PBS, slides were mounted 
with VECTASHIELD® mounting medium with DAPI (Vector Laboratories, 
Burlingame, CA). The TUNEL-positive cells (bright green spots) corresponding to 
the nuclei location (DAPI) were captured with Olympus FluoView FV1000 
(Olympus, Japan) laser scanning confocal microscope using a 60x/1.45 oil 




2.13 Detection of Caspase Enzymatic Activities 
The activation of caspase-3/7, a hallmark of apoptosis, was measured by 
using the Apo-ONE® Homogeneous Caspase-3/7 assay system, the CaspACE 
fluorometric assay system or a Caspase-Glo 3/7 luminescent assay system 
(Promega, Madison, WI) according to the manufacturer’s instructions. These 
assays involve the addition of fluorogenic or luminogenic substrates, which 
contain the caspase-3 cleavage site tetrapeptide sequence DEVD. The amount 
of fluorescence or luminescence produced upon cleavage of these substrates is 
proportional to the amount of caspase activity present in the sample. 
The Apo-ONE Homogeneous Caspase-3/7 Assay provides a 
profluorescent substrate with an optimized bifunctional cell lysis/activity buffer for 
caspase-3/7 (DEVDase) activity assays. To perform the Apo-ONE assay, the 
Buffer and Substrate are mixed and added to the sample samples in an opaque 
96-well plate. The plates were incubated at room temperature for 2hrs. Upon 
sequential cleavage and removal of the DEVD peptides by caspase-3/7 activity 
and excitation at 499 nm, the rhodamine 110 leaving group becomes intensely 
fluorescent. Fluorescence readings were measured at 485Ex/527Em using a 
microplate reader (Tecan). 
In the CaspACE fluorometric assay, 5 μl of cell lysate were added to 
individual wells of an opaque 96-well microplate and diluted in caspase assay 
buffer before incubation at 30°C for 30 min. After addition of the substrate which 
is labelled with the fluorochrome 7-amino-4-methyl coumarin (AMC), the plate 
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was incubated at 30°C for 1 h. The yellow-green fluorescence of liberated AMC 
was measured at an excitation wavelength of 360 nm and an emission 
wavelength of 465 nm using a microplate reader (Tecan). 
The Caspase-Glo 3/7 assay employs a direct lysis method. An equal 
volume of Caspase-Glo reagent, which contains cell lysis buffer and substrate, 
was added to cells cultured in an opaque 96-well microplate. The plate was 
incubated at room temperature for 2 h. Caspase cleavage of the substrate 
releases aminoluciferin, which is utilized in the luciferase reaction to produce 
light. Luminescence was measured in relative light units (RLU) using a microplate 
reader (Tecan). 
 
2.14 Multiplexed Cell Viability and Apoptosis Assay 
To measure both cell viability and apoptosis in the same sample well, 
especially for infected samples, we multiplexed these two measurements by 
making use of two of Promega’s homogeneous cell-based assays. By this 
method we are able to determine both cell viability using the CellTiter-Blue® Cell 
Viability Assay and caspase-3/7 activation or apoptosis using the Caspase-GloTM 
3/7 Assay in the same sample well. The experimental set up is as follows: 
A cell density of 1 x 104 cells per well was plated onto opaque 96-well 
plates. Following infection with the appropriate multiplicity of infection (m.o.i) of 
the virus or control, the cells were incubated at 37°C / 5% CO2 up to the required 
time point. First, the CellTiter-Blue® reagent, diluted 1:4 in 1X PBS, was added to 
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the assay plate. After the CellTiter-Blue® addition, plates were incubated for 2 h 
at 37°C / 5% CO2. Fluorescence was recorded at excitation 540 nm and 
emission of 590 nm on a plate reader (e.g., Tecan). Next, the Caspase-Glo® 3/7 
reagent was added to the plates, and incubated for 1 - 3 h at room temperature. 
Luminescence was then recorded with a plate reader.  
 
2.15 Virus Used in the Study 
The HCV used in the study was the J6/JFH-1-P47 virus (Bungyoku et al., 
2009), which is an adapted strain of the J6/JFH-1 virus that possesses enhanced 
infectivity. It was kindly provided by H. Hotta, Division of Microbiology, Kobe 
University Graduate School of Medicine, Hyogo, Japan. The adapted virus was 
obtained by passaging the J6/JFH-1-infected cells 47 times and contains 10 
amino acid mutations (K78E, T396A, T416A, N534H, A712V, Y852H, W879R, 
F2281L, M2876L and T2925A) and a single nucleotide mutation in the 5’-UTR 
(U146A). 
 
2.16 Virus Titration 
Virus infectivity was measured by indirect immunofluorescence analysis as 
described (Deng et al., 2008). Briefly, culture supernatants containing HCV were 
serially diluted 10-fold in complete DMEM and used to infect 1.9 × 105 Huh7.5 
cells seeded on glass coverslips in a 24-well plate. The inoculum was incubated 
with cells for 5 h at 37°C and then replaced with fresh complete DMEM. At 24 h 
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post-infection, the cells were fixed with 4% paraformaldehyde for 15 min, 
permeabilized with 0.1% Triton X-100 for 15 min and blocked with PBS 
containing 1% bovine serum albumin (BSA; Sigma) for 30 min. The cells were 
then incubated with the serum of an HCV- infected patient (1:200) for 1 h and 
washed with PBS three times before incubating with AlexaFluor 488 goat anti- 
human IgG antibody (1:200; Sigma) for 1h. After three washes with PBS, the 
coverslips were mounted on glass slides using VECTASHIELD mounting medium 
with DAPI (Vector Labs, Burlingame, CA) and examined under a fluorescence 
microscope (BX60; Olympus, Center Valley, PA). All incubations and washes 
were performed at room temperature. The viral titre was determined by the 
average number of HCV- positive foci observed at the highest dilutions according 
to a previously described method (Zhong et al., 2005) and expressed as focus-
forming units (ffu) per millilitre of supernatant. 
 
2.17 HCV Infection 
Monolayers of Huh7.5 cells plated at a density of 6 × 105 cells/ml (6cm 
dish), 3 × 104 cells/ml (24-well plate), or 1 × 104 cells/ml (96-well plate), were 
infected with the virus suspended in DMEM (plus 10% FBS) at an m.o.i of 2. The 
virus was allowed to bind for 5 – 6 h at 37°C in a 5% CO2 incubator, after which 
the inoculum was removed and the cells replenished with fresh growth media and 




2.18 Isolation of Total Cellular RNA 
Huh7.5 cells in 24-well plates were infected with the J6/JFH1-P47 virus or 
treated with mock preparation and total RNA was isolated at 2, 4 and 6 days 
post-infection (d.p.i.). Following removal of culture medium, the cells were rinsed 
twice in PBS and RNA was extracted using an RNeasy Mini Kit with an on-
column DNase treatment step (Qiagen, Valencia, CA) according to the 
manufacturer’s protocol. The concentration and quality of RNA were determined 
using a NanoDrop spectrophotometer (Thermo Scientific, Rockford, IL). RNA 
samples with an OD260nm/OD280nm absorbance ratio between 1.8 and 2.0 were 
used. 
 
2.19 Reverse Transcription 
Total RNA was reverse transcribed into complementary DNA (cDNA) 
using the QuantiTect Reverse Transcription (RT) kit (Qiagen). Briefly, 1ug of RNA 
was incubated with the gDNA Wipeout Buffer for 2 min at 42°C to eliminate any 
contaminating genomic DNA. The RT master mix was prepared by mixing the 
Quantiscript Reverse Transcriptase, Quantiscript RT Buffer and RT Primer Mix 
containing an optimized blend of oligo-dT and random primers. Template RNA 
was added to the RT master mix and the RT reaction was performed at 42°C for 




For PCR array analysis, total RNA was reverse transcribed into cDNA using the 
RT2 First Strand Kit (SABiosciences, Frederick, MD) according to the 
manufacturer’s instructions. In brief, genomic DNA elimination buffer was added 
to 1ug of RNA in 10 μl reactions and incubated at 42°C for 5 min. An equal 
volume of the reverse transcription cocktail containing primers (random 
hexamers and oligo-dT), nucleotides and reverse transcriptase was added to 
each reaction and incubated at 42°C for 15 min. The enzyme was then 
immediately inactivated by heating at 95°C for 5 min. 
 
2.20 Viral RNA Quantification 
To measure intracellular HCV RNA replication levels, cDNA was subjected 
to quantitative real-time PCR analysis using the SYBR Green-based detection 
system. The cDNA was diluted 10X in water and added in triplicates to individual 
wells of a MicroAmp optical 96-well reaction plate (Applied Biosystems) 
containing the RT2 SYBR Green/ROX quantitative PCR (qPCR) master mix 
(SABiosciences) and gene-specific primers. One primer set amplifies a region in 
NS5A of the HCV genome while another probes the expression levels of human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as an 






5’-AGA CGT ATT GAG GTC CAT GC-3’ (sense)  
5’-CCG CAG CGA CGG TGC TGA TAG-3’ (antisense) 
 
GAPDH primers 
5’-CAT GAG AAG TAT GAC AAC AGC CT-3’ (sense)  
5’-AGT CCT TCC ACG ATA CCA AAG T-3’ (antisense) 
 
The plate was subjected to a two-step cycling program on an ABI 7900HT 
Fast Real-Time PCR System (Applied Biosystems). HCV and GAPDH transcript 
levels were determined relative to standard curves derived from serial dilutions of 
plasmids containing either the HCV J6/JFH-1 cDNA or the human GAPDH gene. 
 
2.21 Gene Expression Profiling using PCR arrays 
Template cDNA was mixed with RT2 SYBR Green/ROX qPCR master mix 
(SABiosciences) and 25 μl of this mixture was added to each well of the 96-well 
PCR array containing specific primer sets. The Human Apoptosis RT2 Profiler 
PCR Array (SABiosciences) examines 84 genes involved in the apoptotic 
pathway. These genes include members of the caspase, Bcl-2, IAP, TRAF, 
CARD, CIDE, death domain, death effector domain, and TNF receptor and ligand 
families, as well as genes involved in the p53 and DNA damage pathways. The 
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array also contains primer sets for five housekeeping genes and three RNA and 
PCR quality controls (Appendix 1). 
The PCR cycling program was performed using an ABI 7500 Fast Real-
Time PCR System (Applied Biosystems). Expression profiles of HCV- infected 
and mock-treated cells at the different time points were obtained from three 
independent experiments. The threshold cycle (Ct) values of each gene were 
used to calculate the fold changes in gene expression using the RT2 Profiler 
PCR Array Data Analysis software 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
 
2.22 Quantitative Real-time PCR 
Gene expression changes observed with the PCR arrays were confirmed 
by quantitative real-time PCR using TaqMan chemistry. Probes and primers 
specific to the host genes that were identified by the PCR arrays to be up-
regulated or down-regulated in response to HCV infection were obtained from 
Applied Biosystems (Inventorized gene expression assay primer-probe sets, see 
appendix 3 for catalogue numbers). GAPDH was selected as the reference gene 
for normalization. Each reaction was performed in triplicates and no template 
controls were included for each primer/probe set. Amplification was monitored on 
an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). The 
difference in Ct values (ΔCt) between the gene of interest and GAPDH control 
was used to calculate the fold changes in gene expression (2-ΔΔCt) between HCV-
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infected and mock-infected Huh7.5 cells. Results were pooled from at least three 
independent experiments. 
 
2.23 Statistical Analysis 
Statistical tests were mostly performed using Microsoft Excel and the RT2 
Profiler PCR Array Data Analysis software in the case of PCR array data. All 
experiments were repeated at least three times. Unless otherwise stated, the 
mean data for three independent experiments is presented with the standard 
error of the mean. For the rest of the studies, statistical analysis was performed 
using the Student’s t-test, with p < 0.05 considered significant. The relevant tests 
and level of significance are noted in the figure legends. For immunoblots, the 
ImageJ open-source gel analysis software (Rasband) was used for the 












THE P7 PROTEIN OF THE HEPATITIS C VIRUS INDUCES CELL DEATH 
DIFFERENTLY FROM THE INFLUENZA A VIRUS VIROPORIN M2 
 
3.1. The Regulation of Apoptosis by HCV Nonstructural Proteins 
The host cells’ response to a viral infection includes both immune 
activation and programmed cell death or apoptosis (Lei et al., 2009). Cell death 
regulation is therefore an important determinant in the survival of most viruses. 
For this reason, many viruses encode proteins that interfere with cell death 
signaling pathways, skewing it in their favour (Chen et al., 2006).  
A number of studies have indicated that HCV as well as the various HCV 
encoded proteins are involved in cell death modulation, although, there are 
conflicting data on the pro-apoptotic and pro-survival characterization (reviewed 
in (Aweya and Tan, 2011; Fischer et al., 2007)). Moreover, it is believed that the 
HCV proteins are among the most important factors that contribute to HCV 
mediated pathogenesis (Chu et al., 2011; Li et al., 2010). Therefore, we set about 
to characterize all the HCV-encoded nonstructural proteins so as to identify any 
potential modulators of apoptosis. For this we performed an initial screening 
using the three most common HCV genotypes in South East Asia (i.e., genotypes 
1b, 2a, and 3a).  Each gene was first cloned into a mammalian expression vector 
and overexpressed in Huh7.5 cells followed by caspase-3/7 activity 
measurements. Protein expression was verified by western blotting analysis. 
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Find in Figure 3.1 below the HCV nonstructural proteins that showed caspase-3/7 
activation and their protein expression by western blot analysis. A summary of 
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Figure 3.1. Caspase-3/7 activation and western blot analysis of HCV p7, NS2, 
NS4B and NS5A of genotypes 1b, 2a and 3a overexpressed in Huh7.5 cells. (A - 
D) CaspACE fluorometric assay system from Promega Corporation (Madison, 
WI) was used to measure the activation of caspase-3 in Huh7.5 cells that were 
transfected with the following plasmids (A) empty vector (Flag-vector), p7 of 
genotype 1b (p7 1b), 2a (p7 2a), and 3a (p7 3a),  (B) empty vector (Flag-vector), 
NS2 of genotype 1b (NS2 1b), 2a (NS2 2a), and 3a (NS2 3a), (C) empty vector 
(Flag-vector), NS4B of genotype 1b (NS4B 1b), 2a (NS4B 2a), and 3a (NS4B 
3a), (D) empty vector (Flag-vector), NS5A of genotype 1b (NS5A 1b), 2a (NS5A 
2a), and 3a (NS5A 3a). All experiments were performed in triplicate, and the 
average values with standard deviations are plotted. Western blot analysis was 
performed to determine the expression levels of the flag-tagged proteins in the 
different samples used and is shown below each plot in. The level of endogenous 
actin was used as a loading control of the total cell lysates used (bottom panel).   
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Table 3.1. Protein Expression and Caspase-3/7 activity of HCV NS Proteins  







1b Yes +++ Pro-apoptotic 
(only one paper) 2a Yes ++ 
3a Yes * 
NS2 
1b No ++  
Anti-apoptotic 2a Yes +++ 
3a No ++ 
NS3 
1b No +++ Pro-apoptotic 
and Anti-
apoptotic 
2a No ++ 
3a No ++ 
NS4A 
1b No *  
Pro-apoptotic 2a No * 
3a No * 
NS4B 
1b Yes ++ No report on 
apoptotic 
properties 
2a Yes +++ 
3a No +++ 
NS5A 
1b Yes +++ Pro-apoptotic 
and Anti-
apoptotic 
2a No +++ 
3a No +++ 
NS5B 
1b No +  
Pro-apoptotic 2a No + 
3a No + 
Level of protein expression by western blot: +++ (high), ++ (medium), + (low);  
*Expressed only when cells are treated with the proteasome inhibitor MG-132 
 
Of all the HCV proteins screened (Table 3.1), only one protein, p7, gave 
good and consistent data for all the three genotypes studied (Figure 3.1A). 
Moreover, there is currently limited information on the involvement of p7 protein 
in cell death modulation, except one study that reported on genotype 1b (Madan 
et al., 2008). Furthermore, there is increase interest among HCV researchers in 
the study of p7 protein as a potential antiviral target in HCV therapy due to its 
putative ion channel function (Griffin et al., 2003; Pavlovic et al., 2003) as well as 
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its apparent similarity to the M2 ion channel protein of influenza A virus (Griffin et 
al., 2008; Meshkat et al., 2009). We therefore proceeded to further characterize 
the p7 protein and to understand how it relates to the M2 protein in terms of their 
ion channel function and regulation of cell death. 
To begin with, when plasmids expressing the flag-tagged p7 proteins were 
overexpressed in Huh7.5 cells, we observed that all three p7 genotypes (1b, 2a 
and 3a) induced significantly high levels of apoptosis as determined by the 
activation of caspase-3/7, which is a hallmark of apoptosis (Figure 3.2A, top). 
Interestingly, the p7 protein of genotype 3a (p7-3a), which could not be detected 
by western blot analysis (Figure 3.2A, bottom), had very high caspase-3/7 
activity, which seems to suggest that there is probable link between its stability 
and its apoptosis activity, since proteasome inhibition protected against its 
degradation (Figure 3.2B). A recent paper has reported that p7 is an unstable 
protein which is degraded via the proteasome-dependent pathway and in a cell 
type-dependent manner(Haqshenas, 2013), but our results only found p7 of 
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Figure 3.2. Overexpression of HCV genotypes 1b, 2a and 3a p7 induces 
apoptosis in Huh7.5 cells. (A) Apo-One fluorometric assay system from Promega 
Corporation (Madison, WI) was used to measure the activation of caspase-3/7, 
which is a hallmark of apoptosis, in Huh7.5 cells that were transfected with empty 
vector, p7 of genotype 1b (p7-1b), p7 of genotype 2a (p7-2a), and p7 of genotype 
3a (p7-3a). All experiments were performed in triplicate, and the average values 
with standard deviations are plotted. (B) Western blot analysis was performed to 
determine the expression levels of the flag-tagged proteins in the different 
samples used in (A). (C) The expression of p7-3a was detected by western blot 
when cells were treated with a proteasome inhibitor (MG-132). The level of 
endogenous actin was used as a loading control of total cell lysates used 
(bottom). Data shown are representative of three independent experiments. P-
values were calculated using the student’s T-test with statistical significance 




The data on p7-3a was quite intriguing, so we decided to further probe into 
how the stability of the protein could possibly influence the apoptotic activity. To 
do this, we overexpressed the p7 proteins in Huh7.5 cells followed by treatment 
with a pan-caspase inhibitor, since our apoptosis assay measures caspase 
activation. Interestingly, we observed that (Figure 3.3A) p7-induced apoptosis 
was inhibited by the pan-caspase inhibitor (zVAD-fmk) but not an irrelevant 
peptide (zFA-fmk). But most importantly, the p7-3a protein, which is labile, was 
protected against degradation by the pan-caspase inhibition but not the irrelevant 
peptide (Figure 3.3B). This observation seems to confirm our initial thinking, that 



















Figure 3.3. HCV genotype 3a p7 protein’s stability is linked to its apoptosis 
activity (A) Apo-One fluorometric assay system from Promega Corporation 
(Madison, WI) was used to measure the activation of caspase-3/7 in Huh7.5 cells 
that were transfected with empty vector, p7 of genotype 1b, 2a or 3a. The p7 
expressing cells were treated with an irrelevant peptide, zFA-fmk (columns 2, 4 
and 6) or a pan-caspase inhibitor, zVAD-fmk (columns 3, 5 and 7). All 
experiments were performed in triplicate, and the average values with standard 
deviations are plotted. (B) Western blot analysis was performed to determine the 
expression of the flag-tagged proteins in the different samples used in (A)(top) 
and the levels of endogenous actin used as a loading control of total cell lysates 
used (bottom). *P<0.01 compared to Flag-vector. Data shown are representative 
of three independent experiments. P-values were calculated using the student’s 
T-test with statistical significance between the zFA-fmk treated and the zVAD-fmk 
treated samples marked by asterisk (*p<0.05 and **p<0.01). 
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Given this interesting preliminary data on p7 and the modulation of 
apoptosis, we sought to carryout detail and further characterization of this 
protein. But to be able to perform a meaningful study in the context of the entire 
viral genome and in an infection model, we can only use the genotype 2a HCV or 
the JFH1 strain, which is the only strain that can replicate efficiently in permissive 
cells (Wakita et al., 2005). Thus, the rest of our work was done using the 
genotype 2a p7 protein.  
 
3.2 Role of HCV p7 Protein in Cell death Modulation 
The precise role of p7 in the HCV lifecycle has been hard to define, but, 
like other viroporins, it is believed to be targeted to the mitochondrial membranes 
where it modulates apoptosis by altering the mitochondrial membrane 
permeability. However, there is currently limited information on the apoptotic 
activity of p7 except that reported by Madan and colleagues (Madan et al., 2008) 
who demonstrated that the p7 protein of genotype 1b HCV induces caspase-
dependent apoptosis via the mitochondria in baby hamster kidney cells. This 
study therefore sought to examine how p7 protein of the JFH1 strain modulates 
cell-death and how similar it is to the M2 ion channel protein of influenza A virus, 




3.2.1 HCV p7 Protein Induces Significant level of Apoptosis in Huh7.5 
Cells 
To examine the apoptosis activity of the genotype 2a HCV p7 protein in 
comparison with other known apoptosis inducers such as Bax, Huh7.5 cells, 
which are highly permissive for HCV replication, were transiently transfected with 
a cDNA expression plasmid containing the genotype 2a (JFH-1 strain) p7.  The 
Huh7.5 cells were also transfected with genotype 1b (S1) HCV p7 plasmid, the 
empty vector or an expression plasmid containing the Bax gene, which is a well-
known apoptosis inducer that acts via the mitochondria.  About 24 h post-
transfection, the cells were harvested, lysed and the cell lysate was used for 
western blot analysis and measurement of the activation of caspase-3/7, which is 
a hallmark of apoptosis. As shown in Figure 3.4A, cells overexpressing genotype 
1b p7 (p7-1b), genotype 2a p7 (p7-2a), or Bax have significantly higher level of 
caspase-3/7 activity than the vector control cells. Similarly, the cleavage of 
endogenous poly (ADP-ribose) polymerase (PARP), a substrate of activated 
caspase-3/7, was clearly observed in cells overexpressing p7-1b, p7-2a and Bax 
but there was less cleavage in cells transfected with the empty vector (Figure 
3.4B, middle). Western blot analysis showed the expression of flag-tagged 
protein (Figure 3.4B, top) and endogenous actin (Figure 3.4B, bottom). As stated 
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Figure 3.4. Overexpression of HCV genotype 1b (S1) and genotype 2a p7 in 
Huh7.5 cells induces apoptosis similar to Bax.  (A) Apo-One fluorometric assay 
system from Promega Corporation (Madison, WI) was used to measure the 
activation of caspase-3/7, which is a hallmark of apoptosis, in Huh7.5 cells that 
were transfected with empty vector, p7 of genotype 1b (p7-1b), p7 of genotype 
2a (p7-2a) and Bax. All experiments were performed in triplicate, and the 
average values with standard deviations are plotted. (B) Western blot analysis 
was performed to determine the expression levels of the flag-tagged proteins in 
the different samples used in (A) (top), the cleavage of endogenous PARP 
(middle), and the levels of endogenous actin as a loading control of total cell 
lysates used (bottom). Data shown are representative of three independent 
experiments. P-values were calculated using the student’s T-test with statistical 




3.2.2 HCV p7-induced Apoptosis is Caspase-dependent and is via both the 
Intrinsic and Extrinsic pathways 
To determine if p7-induced apoptosis is caspase-dependent and to 
elucidate which of the caspase-dependent apoptosis pathways is involved, 
Huh7.5 cells were transiently transfected with the p7 plasmid, followed by 
treatment with cell permeable pan-caspase inhibitor (zVAD-fmk) or an irrelevant 
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peptide (zFA-fmk) 6 h post-transfection. The level of apoptosis induced, as 
measured by caspase-3/7 activity, was observed to be significantly inhibited by 
the pan-caspase inhibitor but not the irrelevant peptide, suggesting the 
involvement of a caspase-dependent pathway in p7-induced apoptosis (Figure 
3.5A). Consistently, there was only a low level of cleaved PARP, as detected by 
western blot analysis, in the p7-overexpressing cells treated with zVAD-fmk 
treated cells (Figure 3.5B, middle).  However, a high level of cleaved PARP was 
observed in the p7-overexpressing cells that were treated with zFA-fmk (Figure 
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Figure 3.5. HCV p7 induces apoptosis via caspase-dependent pathways.  (A) 
Apo-One fluorometric assay system from Promega Corporation (Madison, WI) 
was used to measure the activation of caspase-3/7 in Huh7.5 cells that were 
transfected with empty vector or flag-tagged p7. The cells were treated with an 
irrelevant peptide, zFA-fmk (columns 1 and 2) or a pan-caspase inhibitor, zVAD-
fmk (columns 3 and 4). All experiments were performed in triplicate, and the 
average values with standard deviations are plotted. (B) Western blot analysis 
was performed to determine the expression levels of the flag-tagged proteins in 
the different samples used in (A) (top), the cleavage of endogenous PARP 
(middle), and the levels of endogenous actin as a loading control of total cell 
lysates used (bottom). Percentage cleaved-PARP values are shown below the 
blots. Data shown are representative of three independent experiments. P-values 
were calculated using the student’s T-test with statistical significance between 
the zFA-fmk treated p7 and the zVAD-fmk p7 samples marked by asterisks 
(*p<0.05).  
 
To further confirm the involvement of caspases in p7-induced apoptosis, 
the terminal uridine nick 3′ end-labeling (TUNEL) assay was performed. As 
shown in Figure 3.6, cells overexpressing p7 and treated with the irrelevant 
peptide (zFA-fmk) had more TUNEL-positive cells than those treated with the 




Figure 3.6. Detection of HCV p7 induced apoptotic cell by TUNEL assay. The 
DeadEnd™ Fluorometric TUNEL System from Promega Corporation (Madison, 
WI) was used to measure the activation of caspase-3/7 in Huh7.5 cells that were 
transiently transfected with empty vector or flag-tagged p7. The cells were 
treated with an irrelevant peptide (zFA-fmk) or caspase-3, caspase-8 and 
caspase-9 inhibitors (zDEVD-fmk, zIETD-fmk and zLEHD-fmk). At 24 h post 
transfection, the cells were fixed and permeabilized, and TUNEL assay was 
performed. Data shown are representative of three independent experiments. 
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Once we were able to establish that p7 induces apoptosis via caspase-
dependent pathway, the next step was to determine which of the caspase-
dependent pathways was involved. To do this, cell permeable non-toxic peptide 
caspase inhibitors that bind irreversibly to activated caspases and which have a 
short half-life (Ekert et al., 1999; Garcia-Calvo et al., 1998) and specific for 
different caspases, namely caspase-3 (zDEVD-fmk), caspase-8 (zIETD-fmk), 
and caspase-9 (zLEHD-fmk), were added to the cells 6 h post-transfection. As 
shown in Figure 3.7A, the level of p7-induced apoptosis after about 24 h post-
transfection, as reflected by the caspase-3/7 activity in the cell lysate, was 
significantly inhibited by all three caspase inhibitors, but not by the irrelevant 
peptide (zFA-fmk).  However, high levels of cleaved PARP were still observed in 
cells treated with the caspase inhibitors despite the low caspase-3/7 activity 
(Figure 3.7B, middle). This could possibly be due to the cleavage of PARP by 
caspase-independent PARP cleavage events (Yang et al., 2004) and other 
caspases in the absence of caspase-3 or caspase-7 activation. Indeed, it has 
been reported that PARP can be cleaved by protease-like molecules and several 
caspases (Fernandes-Alnemri et al., 1995; Germain et al., 1999; Lippke et al., 
1996; Malireddi et al., 2010; Muzio et al., 1996; Orth et al., 1996; Tewari et al., 
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Figure 3.7. HCV p7 induced apoptosis is via both the intrinsic and extrinsic 
apoptosis pathways.  (A) Apo-One fluorometric assay system from Promega 
Corporation (Madison, WI) was used to measure the activation of caspase-3/7 in 
Huh7.5 cells that were transiently transfected with empty vector or flag-tagged 
p7. The cells were treated with an irrelevant peptide (zFA-fmk) or caspase-3, 
caspase-8, and caspase-9 inhibitors (zDEVD-fmk, zIETD-fmk, and zLEHD-fmk). 
All experiments were performed in triplicate, and the average values with 
standard deviations are plotted. (B) Western blot analysis was performed to 
determine the expression levels of the flag-tagged proteins in the different 
samples used in (A) (top), the cleavage of endogenous PARP (middle), and the 
levels of endogenous actin as a loading control of total cell lysates used (bottom). 
Data shown are representative of three independent experiments. P-values were 
calculated using the student’s T-test with statistical significance between the zFA-
fmk treated p7 and the zDEVD-fmk, zIETD-fmk and zLEHD-fmk p7 samples 
marked by asterisks (**p<0.01).  
 
Similarly, when p7 was overexpressed in Huh7.5 cells followed by 
treatment with zFA-fmk, zDEVD-fmk, zIETD-fmk and zLEHD-fmk, the number of 
TUNEL-positive cells was not much different between cells treated with the 
irrelevant peptide (zFA-fmk) and the three caspase inhibitors (Figure 3.6, lower 
panel). We are therefore tempted to speculate that, probably because PARP 
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cleavage and DNA fragmentation are late apoptosis events (Collins et al., 1997; 
Duriez and Shah, 1997), they could not be completely blocked by the cell 
permeable caspase inhibitors, which have short half-life. However, early 
apoptotic events such as caspase-3/7 activation can be completely blocked by 
these inhibitors.  Hence, our results showed that p7-induced apoptosis is indeed 
caspase-dependent and involves activation of both caspase-8 and -9 which are 
initiator caspases of the death receptor (extrinsic) and mitochondria-mediated 
(intrinsic) pathways respectively, and found upstream of caspase-3/7, the 
executioner caspases.  
 
3.2.3 HCV p7-induced Apoptosis does not depend on its Ion Channel 
Activity 
The HCV p7 protein possesses ion channel activity and is thus classified 
in the family of viral ion channel proteins known as viroporins (Griffin et al., 2003; 
Pavlovic et al., 2003). Moreover, histidine 17 (H17), located within the amino-
terminal transmembrane domain of p7, has been implicated in p7’s ion channel 
function, and has also been shown to share functional similarity with histidine 37 
(H37) of the influenza A virus M2 ion channel protein (StGelais et al., 2009). 
However, the p7 of genotype 2a has an additional histidine 31 (H31), which is 
found in only a few other genotypes and thought to partly influence the gating 
function of p7 (Brohm et al., 2009; Montserret et al., 2010).  Thus, in order to 
express p7 lacking ion channel activity and to eliminate the probable influence of 
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H31, both H17 and H31 were substituted with alanine (A) to generate a double 
substitution mutant p7H17AH31A, and the mutations confirmed by sequencing. 
The membrane permeability of the mutants was then assessed using a modified 
form of the membrane permeabilization assay as described by Liao and 
colleagues (Liao et al., 2006). Briefly, cells seeded onto 6 cm dishes were 
transfected with plasmids expressing wild-type p7 or the mutants, followed by 
treatment of the cells with different concentrations of hygromycin B for 30 min at 
6 h post-transfection. The cells were harvested 24 h post-transfection, lysed and 
the clarified cell lysate containing the proteins were immunoprecipitated with anti-
Flag beads (Sigma) overnight at 4 °C. Following 3X washing with RIPA buffer, 
the samples were then analyzed by 15% SDS-PAGE. We observed that the 
overexpression of p7 resulted in the permeabilization of the cell membrane, as 
the translation of p7 protein was clearly inhibited in the presence of Hygromycin 
B (Figure 3.8, left panel). In contrast, the overexpression of p7H17AH31A had no 
effect on membrane permeability, as the addition of Hygromycin B could not 
permeate the cell membrane to inhibit the translation of p7H17AH31A (Figure 







Figure 3.8. Modification of membrane permeability by p7 protein. 293FT cells 
expressing wild-type p7 protein or the mutant (p7H17A31A) were treated with 0, 
1, and 2 mM of hygromycin B for 30 min at 6 h post-transfection (lanes 1, 2, and 
3). Cell lysates were prepared and the expression of the flag-tagged proteins was 
detected by immunoprecipitation with anti-Flag antibody under mild washing 
conditions. Proteins were separated by SDS-PAGE and visualized by 
autoradiography. The percentages of p7 and p7H17AH31A proteins detected in 
the presence of hygromycin B were determined by densitometry and indicated at 
the bottom. Data shown are representative of three independent experiments. 
 
When the level of apoptosis of cells overexpressing p7 and the double 
mutant was subsequently measured, it was observed that both the wild-type p7 
protein and the p7H17AH31A mutant induced significantly higher caspase-3/7 
activity than the vector (Figure 3.9A). It therefore appears that p7-induced 
apoptosis is independent of its ion channel activity.  In addition, the cleavage of 
endogenous PARP, a substrate of activated caspase-3/7, was clearly observed 
in Huh7.5 cells overexpressing either the wild-type p7 protein or the 
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Figure 3.9. p7 induced apoptosis is independent of its ion channel activity. (A) 
Apo-One fluorometric assay system from Promega Corporation was used to 
measure the activation of caspase-3/7 in Huh7.5 cells 24 hours post-transfection 
with flag-vector, wild-type p7, p7H17AH31A substitution mutant and the known 
apoptosis inducer, Bax.  (B) Western blot analysis was performed to determine 
the expression levels of the different flag-tagged proteins (top) and the cleavage 
of endogenous PARP, which is a substrate of activated caspase-3, from 116 to 
83 kDa (middle). Equal sample loading was verified by the detection of 
endogenous actin (bottom). Data shown are representative of three independent 
experiments. P-values were calculated using the student’s T-test with statistical 




3.2.4 Mutation of the Conserved Dibasic Amino Acids in the Cytoplasmic 
Domain of p7 Protein Affects its Apoptosis Activity 
Apart from the histidine residues in p7, there are two highly conserved 
basic amino acids (K/R33 and R35) in the cytoplasmic domain of p7 protein.  
When these dibasic residues in p7 are substituted by alanine (A) or glutamine 
(Q), the ion channel activity of p7 is lost and the production of infectious particles 
is reduced (Griffin et al., 2004; Steinmann et al., 2007a).  To determine if these 
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amino acid residues are essential for the apoptotic activity of p7 protein, 
substitution mutants were generated in the background of genotype 2a HCV p7 
protein and the mutations were confirmed by sequencing. Using the membrane 
permeabilization assay, we also demonstrated that these mutants lacked ion 
channel activity, as previously reported (Griffin et al., 2004). However, compared 
to the wild-type p7 protein, overexpression of the mutants had a lower level of 
caspase-3/7 activity (Figure 3.10A). Both single and double substitution mutants 
were highly expressed than the wild-type p7 protein, indicating that the lack of 
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Figure 3.10. p7 induced apoptosis is dependent on the cellular topology of p7 
protein. (A) Apo-One fluorometric assay system from Promega Corporation was 
used to measure the activation of caspase-3/7 in Huh7.5 cells 24 hours post-
transfection with flag-vector, wild-type p7, substitution mutants (containing either 
R to A or changes) and the known apoptosis inducer, Bax. (B) Western blot 
analysis was performed to determine the expression levels of the different flag-
tagged proteins (top) and the cleavage of endogenous PARP, which is a 
substrate of activated caspase-3, from 116 to 83 kDa (middle). Equal sample 
loading was verified by the detection of endogenous actin (bottom). Data shown 
are representative of three independent experiments. P-values were calculated 
using the student’s T-test with statistical significance between the mutant 
samples and wild-type p7 marked by asterisks (*p<0.05).  
 
As it has been reported that these residues (R33 and R35) are important 
in maintaining the topology of p7 (Steinmann et al., 2007a), the mutants could not 
induce much apoptosis as the wild-type p7 probably because the mutation might 
have distorted the folding and/or the overall structure of the protein, thus resulting 
in their wrong orientation in the host membranes.  
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3.2.5 HCV p7 Protein does not Induce Autophagic Cell Death but can 
Interact with Beclin-1 
The M2 protein of influenza A virus appears to be structurally and 
biochemically similar to p7. So from the above characterization, it thus seems 
that, p7, like M2, can induce caspase-dependent apoptosis, which is independent 
of the ion channel activity. It has also previously been shown that M2 protein is 
able to block autophagosome fusion with lysosomes and thus result in cell death 
(Gannage et al., 2009). Thus, to explore if p7 protein behaves in the same 
manner as M2, in terms of blocking autophagosome fusion with lysosome, we 
examined the induction of autophagy by these two proteins. The detection of the 
induction of autophagy is based on the conversion of microtubule-associated 
protein 1 (MAP1) light chain (LC3) from its free cytosolic form (LC3-I) to a 
membrane-bound or phosphatidylethanolamine-conjugated form (LC3-II), a 
hallmark of autophagy (Kabeya et al., 2000). Thus, the accumulation of LC3-II 
and its location to autophagosome (punctate dot formation) are commonly used 
as markers of autophagy (Bampton et al., 2005; Mizushima, 2004). Under 
autophagic conditions due to external or internal stressors, immunoblotting of 
LC3 usually detects two bands, i.e., cytosolic LC3-I (migrating at ~18 kDa) and 
autophagosome associated LC3-II (migrating at ~16 kDa)(Tanida et al., 2008). 
For this assay, Huh7.5 cells were transfected with plasmids for expressing p7 
and M2 and their effects on the conversion of LC3-I to LC3-II was analyzed by 
western blot. However, M2 failed to block macroautophagy probably due to the 
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low transfection efficiency in Huh7.5 cells (data not shown). Hence, the 
experiment was repeated using the highly transfectable 293FT cells (Invitrogen). 
The results showed that both p7 and M2 induce apoptosis in 293FT cells when 
overexpressed (Figure 3.11A and B), which is consistent with p7 induction of 
apoptosis in Huh7.5 cells (see above) and M2 in BHK cells (Madan et al., 2008). 
Interestingly, the levels of activated caspase-3/7 as well as cleaved PARP were 
much higher in the cells over-expressing p7 compared to those over-expressing 
M2. In lane 2, the major band for M2 is ~ 20 kDa, which is the expected 
molecular weight, but there are also some higher molecular weight bands.  These 
are likely to be oligomers of M2 which are resistant to boiling, 20 mM 
dithiothreitol, and 1% SDS (which are found in the Laemmli SDS loading buffer) 
as we have previously observed the same phenomenon with another 











(A)          (B) 
     
 
Figure 3.11. p7 induces a higher level of apoptosis than M2 of influenza A virus. 
(A) Apo-One fluorometric assay system from Promega Corporation was used to 
measure the activation of caspase-3/7 in 293FT cells 24 hours post-transfection 
with flag-vector, flag-p7, flag-M2 and the known apoptosis inducer, Bax.  (B) 
Western blot analysis was performed to determine the expression levels of the 
different flag-tagged proteins (top) and the cleavage of endogenous PARP, which 
is a substrate of activated caspase-3/7 (middle). Equal sample loading was 
verified by the detection of endogenous actin (bottom).  The multiple bands (#) in 
lane 2 are oligomers of M2. Data shown are representative of three independent 
experiments. P-values were calculated using the student’s T-test with statistical 
significance between the samples and empty vector marked by asterisks 
(**p<0.01).  
 
Just like in the previous study by Gannage et al (Gannage et al., 2009), 
we observed that the level of LC3-II in M2 overexpressing cells was much higher 
than cells transfected with the empty vector (Figure 3.12A (middle), lanes 2 and 
4). After performing four independent experiments and using densitometry to 
quantify the intensities of LC3-I and II, the conversion to LC3-II (i.e. LC3-II/LC3-
I+LC3-II) was found to be significantly higher (63%) in the cells overexpressing 
M2 as compared to the cells transfected with the empty vector (49%).  In 
contrast, the level of LC3-II (the autophagic marker) in p7 overexpressing cells 
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(41%) was not significantly different from the cells transfected with the empty 
vector (Figure 3.12B).  Untransfected cells untreated and treated with ammonium 
chloride, which is an inhibitor of autophagosome formation, served as negative 
and positive controls respectively. As the percentage of conversion to LC-II in the 
M2 overexpressing cells (63%) was statistically significant as in the case of the 
ammonium chloride-treated cells (87%), the assay was deemed sensitive enough 
to detect autophagic cell death. The expression of flag-tagged protein was 
detected by Western blot analysis (Figure 3.12A, top) and the level of 
endogenous actin (Figure 3.12A, bottom) was used as the loading control of the 














(A)      (B) 
 
 
Figure 3.12. p7 does not induce accumulation of autophagosomes. (A) 
Measurement of the conversion of LC3-I to LC3-II was used as an autophagic 
marker. 293FT cells, mock transfected, or transiently transfected with flag vector, 
flag p7, flag-M2 and untransfected cells untreated or treated with ammonium 
chloride were analyzed by Western blot analysis using anti-LC3 antibody 
(middle). Similarly, the expression levels of the different flag-tagged proteins 
were determined (top). Equal sample loading was verified by the detection of 
endogenous actin (bottom). The percentage conversion of LC3-I to LC3-II (i.e. 
LC3-II/LC3-I+LC3-II) is calculated after densitometry was used to quantify the 
intensities of LC3-I and II in the autoradiographs. Percentage LC3-II values are 
shown below the blots. (B) The mean LC3-II values quantified for four 
independent experiments were computed after densitometry and are plotted with 
standard deviations (error bars). Data shown are representative of three 
independent experiments. P-values were calculated using the student’s T-test 
with statistical significance between the samples and empty vector marked by 
asterisks (*p<0.05, **p<0.01 and no significant difference (ns)).  
 
In addition to LC3-II as an autophagosome marker, we also analyzed the 
accumulation of GFP-LC3 puncta (Bampton et al., 2005; Mizushima, 2009). To 
do this, Huh7.5 cells were transiently transfected with GFP-LC3 and M2 or p7 
expression plasmids. Twenty-four hours post transfection; we observed that only 
cells overexpressing M2 and GFP-LC3 showed an increased accumulation of 
LC3 puncta by immunofluorescence microscopy analysis (Figure 3.13). 
! "!111!"!
     
 
Figure 3.13. Effect of M2 and p7 proteins on the accumulation of GFP-LC3 
puncta.   Immunofluorescence analysis was performed on 293FT cells 
transfected with FLAG-tagged GFP-LC3 and expression plasmids encoding 
either FLAG-tagged M2 or p7. Twenty-four hours after transfection, cells 
expressing GFP-LC3 (green) and p7 or M2 (red) were analyzed by fluorescence 
microscopy. Merged images are shown below. Data shown are representative of 
three independent experiments. 
 
To further examine the difference in the ability of p7 and M2 to induce 
autophagic cell death, co-immunoprecipitation experiment was next performed to 
determine if they can interact with Beclin-1, which is a key component of the 
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molecular machinery of macroautophagy (reviewed in (Kang et al., 2011)) and 
also constitutes a major target for manipulation of autophagy by viruses (Dai et 
al., 2012; Munz, 2011). As shown in the top panel of Figure 3.14, both flag-M2 
and flag-p7, but not by an irrelevant protein, glutathione S-transferase (GST), 
bound to the endogenous Beclin-1 protein.  The expression levels of the flag-
tagged proteins in the cell lysates were similar (Figure 3.14, middle) and 
endogenous Beclin-1 expression was not affected by the expression of the flag-
tagged proteins (Figure 3.14, bottom). Hence, it appears that the binding of p7 to 




Figure 3.14. Interaction of M2 and p7 proteins with endogenous Beclin-1.  Co-
immunoprecipitation of M2 and p7 proteins with endogenous Beclin-1. 293FT 
cells were transfected with flag-vector, flag-GST (negative control), flag-M2 and 
flag-p7. The cells were harvested at about 24 h post-transfection, lysed, and 
subjected to IP with anti-Beclin-1 antibody and protein A agarose beads. The 
amount of flag-tagged proteins that co-immunoprecipitated (IP) with Beclin-1 was 
determined by Western blot analysis (WB) with an anti-flag antibody (top). The 
amounts of flag-tagged proteins and endogenous Beclin-1 in the lysates before 
IP were determined by subjecting aliquots of the lysates to Western blot analysis 
(middle and bottom). The protein marked with an asterisk represents the heavy 




Currently, apoptosis or caspase-dependent cell death is the most well 
characterized cell death pathway, although there is increasing evidence that 
other non-apoptotic or caspase-independent cell death pathways are involved in 
programmed cell death (Hetz et al., 2005). Autophagic cell death and 
programmed necrosis (necroptosis) are cell death mechanisms which are also 
important in viral infections and are thought to be exploited by viruses for their 
survival (Edinger and Thompson, 2004; Park et al., 2012). There is also some 
crosstalk or interrelationship between the different cell death mechanisms, which 
is exploited by some viruses for their survival in the host, as, reported for 
influenza A virus which determines the death of its host by inducing apoptosis 
and blocking autophagy (Gannage et al., 2009). With some recent studies 
suggesting that HCV induces caspase-independent cell death such as autophagy 
(reviewed in (Dreux and Chisari, 2011)), it is possible that HCV, like Dengue, 
Polio, influenza virus A and Coxsackievirus B3 infection, which upon 
autophagosome formation enhances viral replication and increase viral 
yield(Dreux and Chisari, 2010; Lin et al., 2010), might also be exploiting the 
interrelationship between apoptosis and non-apoptotic cell death for its survival in 
the host. Incidentally, the protein of interest in this study, p7 protein, happens to 
share some functional relationship with influenza A virus M2 protein (Mihm et al., 
2006), so it is tempting to speculate that p7 and M2 might play similar roles in cell 
death modulation. 
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In order to identify the viral factors that might be involved in the regulation 
of apoptosis in HCV infection, we went about to characterize the HCV 
nonstructural proteins in terms of apoptosis induction using our system, since 
there are conflicting attributes of pro-apoptotic and pro-survival properties to the 
various HCV proteins in the literature (see reviews by (Aweya and Tan, 2011; 
Fischer et al., 2007)). In common with these previous reports, we observed that 
most of the HCV proteins, except p7, gave conflicting and inconsistent data on 
their reported apoptosis properties coupled with the fact that they could not be 
expressed in hepatoma cells (Table 3.1). For this reason, the p7 protein was 
picked and characterized in detail.   
As reviewed in chapter one, the apoptotic activity of p7 of all the different 
HCV genotypes has not been reported except that of genotype 1b (Madan et al., 
2008). We however observed in this study that, all the three HCV p7 genotypes 
induced significant level of apoptosis, with p7-3a inducing the highest (Figure 
3.2). This is quite interesting because p7-3a is a labile protein, and therefore 
could not be detected by western blot, unless treated with a proteasome inhibitor. 
But with the same labile protein exhibiting very high apoptosis activity, seems to 
suggest that, p7-3a’s ability to induce very high level of apoptosis is somehow 
related to its stability, as treatment with a pan-caspase inhibitor also prevented its 
degradation (Figure 3.2). Although our results only demonstrated HCV genotype 
3a p7 to be an unstable protein, a recent study has reported that, p7 protein of 
both genotype 2a (JFH1 strain) and genotype 1b (HCV-A strain) were unstable 
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proteins that were degraded via the proteasome-dependent pathway 
(Haqshenas, 2013). This is at variance with our results, a possible reason being 
due to the different experimental systems (i.e., different expression vectors, 
transfection media, etc.) used in the two studies.  
In order to be able to study the functional significance of p7 protein’s 
apoptotic activity in the context of the entire viral genome and using the HCVcc 
system, this study focused on characterizing the cell death pathways activated by 
the p7 protein of the JFH-1 strain. Since the genotype 2a JFH1 strain is the only 
one that can replicate efficiently in permissive cells, such as Huh7.5 cells, without 
adaptive mutations.  To the best of our knowledge, this is the first time that the p7 
protein of genotype 2a has been shown to induce apoptosis to a similar level as 
that of genotype 1b p7 (Figure 3.2). As for genotype 1b p7, the results are similar 
to the observation by Madan et al (Madan et al., 2008) except that Huh7.5 cells 
were used in this study while BHK cells were used in the previous study. Further 
characterization of the apoptosis induced by the p7 protein of genotype 2a 
reveals that p7-induced apoptosis was efficiently blocked by a pan-caspase 
inhibitor as well as inhibitors specific for caspases 3, 8, or 9 (Figure 3.5, 3.6 and 
3.7).  In mammalian cells, apoptosis can be induced via two major pathways; the 
death receptor pathway (extrinsic pathway), triggered by the binding of FasL to 
Fas (CD95), with caspase-8, as the initiator caspase; and the mitochondria-
mediated pathway (intrinsic pathway), induced by the mitochondria in response 
to DNA damage, oxidative stress and viral proteins, with caspase-9 as the 
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initiator caspase (Kumar, 2007). Thus, our results confirm that p7-induced 
apoptosis is indeed caspase-dependent and involves both the intrinsic and 
extrinsic apoptosis pathways.  
Given that some previous studies have reported that ions channels play a 
key role in the regulation of cell physiology and in the induction of apoptotic cell 
death (Burg et al., 2006; Lang et al., 2003; Szabo et al., 2004), it was important 
to also determine whether this property of p7 has a link with its apoptotic activity. 
Although, details and the exact function of most ion channels in apoptosis 
mediation are currently unknown, it is believed that some viruses employ the 
control of ion channel homeostasis to promote viral persistence (Mankouri et al., 
2009). A recent study has demonstrated a relationship between ion channel 
activity and apoptosis by showing that the caspase-dependent apoptosis induced 
by the SARS-coronavirus 3a protein (which possesses ion channel activity) is 
abolished when its ion channel activity is blocked (Chan et al., 2009). In the case 
of p7, substitution of the two histidine residues (H17 and H31), which have been 
implicated in the gating function of p7 (Brohm et al., 2009; Montserret et al., 
2010), with alanine, did not reduce its apoptotic activity greatly (Figure 3.9), 
although the resultant double mutant had completely lost its ion channel activity 
(Figure 3.8).  It thus suggests that the caspase-dependent apoptosis induced by 
p7 protein is independent of its ion channel function, which is in common with 
what was previously reported for M2 protein of influenza A virus.  Nevertheless, 
p7 has to be properly folded and maintain the correct topology in the cell 
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membranes in order to induce apoptosis as single or double substitution of the 
dibasic amino acid residues R33 and R35, to glutamine (Q) in the background of 
genotype 2a HCV p7 protein significantly reduced the level of apoptosis induced 
by p7 (Figure 3.10) and to function as an ion channel.  This observation is in line 
with a previous report that mutating the dibasic motif of p7 can substantially 
impact the polyprotein processing and thus distort the topology of p7 protein 
(Steinmann et al., 2007a). 
Recent studies (reviewed in (Eisenberg-Lerner et al., 2009; Gordy and He, 
2012; Zhou et al., 2011)) have shown that there seems to exist a connection 
between pathways that regulate autophagy and apoptosis, with a number of 
molecules including Bcl-2 family proteins, Beclin-1, caspase-8, caspase-9, 
phosphoinositide-3-kinase class I, and ceramide implicated in the control of both 
apoptosis and autophagy. Apart from apoptotic or caspase-dependent cell death, 
HCV is reported to induce non-apoptotic cell death such as autophagy (reviewed 
in (Dreux and Chisari, 2011)). In one such report, when the autophagy machinery 
of HCV-infected hepatocytes was interrupted, it resulted in the induction of 
apoptosis (Shrivastava et al., 2011). Thus, it is believed that HCV exploits the 
autophagy pathway for its propagation and survival in the host, although the 
biological significance of this in the lifecycle of HCV is still unclear (Taguwa et al., 
2011). Similarly, the pro-apoptotic M2 ion channel protein of influenza A virus is 
reported to cause accumulation of autophagosomes by blocking their fusion with 
lysosomes which thus leads to apoptosis of the infected cells (Gannage et al., 
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2009). Since both p7 and M2 are viroporins and are known to induce caspase-
dependent cell death, several experiments were therefore conducted to 
determine if the p7 protein behaves like M2 protein of influenza A virus. Our 
results showed that unlike M2, the overexpression of p7 did not significantly 
increase the conversion of LCI to LCII (Figure 3.12) or the accumulation of GFP-
LC3 puncta (Figure 3.13) suggesting that probably p7 was not involved in 
autophagosome maturation despite the fact that both flag-tagged M2 and p7 
could interact with endogenous Beclin-1 in co-immunoprecipitation experiment 
(Figure 3.14). Since a number of viral proteins including M2 have been reported 
to interact with Beclin-1 and thus interfere with the class III PI3K (UVRAG-Beclin-
1-hVps34) complex’s function in autophagosome maturation (Dai et al., 2012; He 
and Levine, 2010; Munz, 2011), it is therefore tempting to speculate that probably 
M2 and p7 bind to different domains in the class III PI3K complex, with only M2 
able to interact with and inhibit autophagosome maturation (Gannage et al., 
2010).  
Taken together, these results indicate that HCV p7 protein induces 
caspase-dependent apoptosis which is independent of its ion channel activity. 
Although p7 and M2 share some functional properties in terms of ion channel and 
pro-apoptotic activity, they seem to differ in their abilities to induce autophagic 
cell death. It would therefore be very interesting to further identify the residues or 
motifs that are responsible for the apoptosis activity of p7. The use of the HCVcc 
system to generate mutant virus containing mutation(s) that abolishes p7’s pro-
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apoptotic activity would be useful in establishing the functional significance of the 
apoptotic activity of p7 during HCV infection. In addition, identification of these 
residues will allow the study of the interaction between HCV p7 and other viral 






































IDENTIFICATION OF CELLULAR APOPTOSIS-RELATED GENES 




HCV and HCV-encoded proteins are known to modulate the host cell 
death, invariably by targeting cellular factors. In chapter three, the contribution of 
the HCV nonstructural proteins to cell death was examined. After the screen, the 
HCV p7 protein was chosen for further detailed study, as it was the only protein 
that gave conclusive data coupled with the fact that there is dearth of information 
on its role in cell death modulation in HCV infection. Since in cell death 
modulation there is a concerted involvement of both viral and host factors, it is 
important to identify the host factor(s) that might be involved in this process, 
which is the subject of this chapter. 
 
4.2 HCV Infection Induces Cytopathic Effects or Apoptosis  
The hepatitis C virus (HCV) is generally known to be a non-cytopathic 
virus, however, using the JFH-1 infection system, our laboratory and others have 
recently shown that HCV can have direct cytopathic effects (CPE) and induce cell 
death in the form of apoptosis in hepatocytes (Deng et al., 2008; Mateu et al., 
2008; Mohd-Ismail et al., 2009; Walters et al., 2009; Zhu et al., 2007). In fact, 
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some accumulating evidence suggests that apoptosis of hepatocytes, which is 
clinically recognized as liver inflammation and fibrosis, plays a significant role in 
the pathogenesis of HCV infection (Calabrese et al., 2000; El-Domyati et al., 
2012; Fischer et al., 2007; Mankouri et al., 2009; Otsuka et al., 2002; Piazzolla et 
al., 2012). However, the mechanisms underlying this complex apoptotic pathway 
in HCV infection are currently not well understood. We therefore set about to 
identify and characterize the host factors that might be involved in HCV-induced 
apoptosis. To do this, we employed the technique of PCR array to profile a panel 
of host apoptosis-related genes that may be differentially expressed upon acute 
HCV infection. For this, a tissue culture-adapted HCV strain, J6/JFH-1-P47, 
which was previously shown to exert a stronger CPE than the parental J6/JFH-1 
virus (Deng et al., 2008) was used to infect Huh7.5 cells, and the effects on 
cellular apoptotic pathways were examined using PCR array.  
To first identify suitable conditions for the array experiment, the degree of 
apoptosis induced by J6/JFH-1-P47 infection of Huh7.5 was examined over 
different time points. Parallel infections were also performed in order to analyze 
the viral replication, infectious virus production, and the level of protein 
expression. Readings were taken at 2, 4, and 6 days post-infection (d.p.i.). 
As shown in Figure 4.1A, there was a significant inhibition on cell 
proliferation of the HCV-infected cells as compared to mock-infected cells, 
indicating that the virus had induced some CPE. To determine if the HCV-
induced CPE was in the form of apoptotic cell death, the activation of caspase-
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3/7, which is a hallmark of apoptosis, was determined in HCV-infected and mock-
infected Huh7.5 cells. As shown in Figure 4.1B, caspase-3/7 activity was 
observed to be significantly higher in HCV-infected cells than in the mock-
infected cells on 4 and 6 d.p.i, which suggests that the CPE was mediated largely 
through apoptosis. When the level of endogenous PARP, a substrate of activated 
caspase-3/7, was detected, there was higher level of cleaved PARP in the HCV-
infected than mock-infected cells at 2 and 4 d.p.i.  However, at 6 d.p.i, both 
infected and mock cells have high levels of cleaved PARP.  This could probably 
be due to the fact that the mock-infected cells were growing faster than the HCV-
infected cells, hence, the high density and crowding of cells that had 
accumulated at this late time point may have caused the induction of apoptosis; 
which is similar to an observation previously made by Krahling and colleagues in 
293/ACE2 cells infected with SARS-CoV or non-infected (Krahling et al., 2009). 
When the replication of the virus was determined, in terms of the amount of viral 
RNA in the HCV-infected samples, a significant steady increase in the level of 
HCV RNA was observed from day 2 to day 6 p.i (Figure 4.1C). To ascertain 
whether or not the infection was sustained, the level of HCV core protein was 
analyzed, and as shown in Figure 4.1D (top), we observed a similar level of core 
in the infected samples at all time points post-infection, which suggests that the 
infection was sustained. The level of endogenous actin served as a loading 
control (Figure 4.1D, bottom). 
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(A)      (B) 
  
(C)       (D) 
 
Figure 4.1: HCV infection induces apoptosis in Huh7.5 cells. (A and B) Huh7.5 
cells infected with HCV J6/JFH1-P47 or mock-infected were analyzed at 2, 4, and 
6 d.p.i to determine the cell viability/proliferation followed by the determination of 
caspase-3/7 activation in a multiplexed assay. The cell viability/proliferation 
readings of the HCV-infected samples were normalized to the readings of the 
mock-treated samples, which were arbitrarily expressed as 100%. Data from 
three independent experiments are shown with error bars representing the 
standard deviation. P-values were calculated using the student’s T-test with 
statistical significance shown by asterisks, *p<0.05 and **p<0.01. (C) Huh7.5 
cells infected with HCV J6/JFH1-P47 or mock-infected were harvested at 2, 4, 
and 6 d.p.i, and analyzed for HCV replication using quantitative real-time PCR 
analysis and normalized to endogenous GAPDH. Data from three independent 
experiments are shown with error bars representing the standard deviation. P-
values were calculated using the student’s T-test with statistical significance 
shown by asterisks, **p<0.01. (D) Huh7.5 cells were infected with HCV J6/JFH1-
P47 or mock-infected were harvested at 2, 4, and 6 d.p.i, followed by SDS-PAGE 
and western blot analysis. The level of endogenous actin was used as a loading 




4.3 The Expression of Apoptosis-related Genes in HCV-infected Huh7.5 
Cells 
Next, we used the PCR array platform to examine the effects of HCV 
infection on the differential expression of host apoptosis-related genes. This array 
allows the analysis of genes including the TNF ligands and their receptors; 
members of the Bcl-2, caspase, IAP, TRAF, CARD, death domain, death effector 
domain, CIDE families, as well as genes involved in the p53 and ATM pathways. 
Four independent experiments representing four biological replicates were 
performed, since each gene is only represented by one well in the 96-well array. 
Eighteen (18) genes were excluded from the analysis (see Appendix 2 for list of 
excluded genes) for having two or more peaks in their melting curves; a sign of 
non-specific binding of the primers or the presence of other variants of the gene 
in our sample. Data for the remaining 66 genes was analyzed using the EXCEL-
based RT2 Profiler PCR Array Data Analysis software (SABiosciences, Frederick, 
MD), which is based on the delta-delta Ct method with normalization of the raw 
data to GAPDH as described in the manufacturer’s manual. Differential gene 
expression with p<0.05 was considered statistically significant. In line with similar 
gene expression studies (Blackham et al., 2010; Walters et al., 2006; Walters et 
al., 2009), a cut-off point of at least 2-fold change in expression was used. As 




Table 4.1. Apoptosis-related genes differentially expressed by J6/JFH1-P47 




Day 2 p.i. Day 4 p.i. Day 6 p.i. 
Folda p-value Folda p-value Folda p-value 
BCLAF1  1.11 0.8554 1.37 0.5853 3.39 0.0323 
BIK  1.98 0.2526 2.49 0.0732 5.06 0.0200 
BIRC6  1.50 0.6656 1.30 0.3477 2.35 0.0163 
BNIP3  -1.30 0.1491 -2.10 0.0163 -3.86 0.0015 
BNIP3L  1.61 0.1054 -2.27 0.0451 -2.61 0.0046 
CIDEB  1.08 0.8313 -1.63 0.2696 -7.27 0.0007 
FAS  1.78 0.0304 2.13 0.0756 6.36 0.0144 
GADD45A  4.94 0.0007 3.00 0.0020 1.97 0.0518 
HRK  26.02 0.0100 20.04 0.0002 45.46 0.0083 
TNFRSF21  1.38 0.5586 2.15 0.0760 2.14 0.0072 
TNFRSF25  -1.24 0.5330 -1.42 0.2309 -2.43 0.0236 
TNFRSF9  30.84 0.1120 10.43 0.0844 14.72 0.0014 
TNFSF10  -2.32 0.0376 -2.59 0.0048 -3.76 0.0011 
TP53  1.15 0.6153 1.49 0.3156 2.32 0.0345 
TP53BP2  2.22 0.0263 2.25 0.0239 2.17 0.0532 
a Data represent mean fold change (≥2-fold) of four independent experiments. 
Significant p-values, compared to mock (p<0.05) are shown in bold. Red denotes 
≥3-fold upregulation and Blue denotes ≥3-fold downregulation. 
 
We observed that, a large proportion of the differentially expressed genes 
were on 6 d.p.i as compared to 2 d.p.i and 4 d.p.i (Figure 4.2), suggesting that 
there was some form of a temporal regulation of the host cells’ apoptosis 




Figure 4.2. Percentage of differentially expressed apoptosis-related genes in 
HCV-infected Huh7.5 cells. The percentage of significantly (with at least p<0.05) 
expressed apoptosis-related genes per each time point was calculated from the 
66 genes analyzed. Gray bars represent genes with fold change ≥2 and white 
bars represent genes with fold change ≥3. 
 
4.4 Validation of PCR array Results using Quantitative Real-time PCR 
and Western blot Analysis 
In order to validate the genes that were differentially expressed and 
identified in the PCR array screen, genes with a consistent and significant fold 
change of at least 3-fold at the same time point post-infection in all four 
independent experiments were selected. Nine (9) genes met this criterion, with 6 
up-regulated (red text in Table 4.1) and 3 down-regulated (blue text in Table 4.1). 
The expression of these 9 genes was then checked using quantitative real-time 
PCR (qPCR), based on the TaqMan chemistries, and with predesigned 
inventorized primer-probe pairs (see primer-probes and their catalogue numbers 
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in appendix 3). The qPCR measurements were carried out in triplicates, and 
cycle threshold (Ct) values in each observation were normalized to the 
housekeeping gene (GAPDH). The relative differential expression between mock-
infected and HCV-infected samples was calculated using the delta-delta Ct value 
method.  The fold changes from the qPCR experiments were then compared with 
their corresponding PCR array data. Finally, to verify whether the changes 
observed at the RNA level were concomitant with the protein expression, western 
blot analysis was carried out.  
 
4.4.1 Validation of the Expression of the Down-regulated Genes 
For the 3 down-regulated genes, BNIP3, CIDEB, and TNFSF10 (also 
known as TRAIL), the changes in mRNA expression were observed to be similar 
in the 2 independent assays (Figure 4.3 A to C), suggesting that HCV infection 
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Figure 4.3. Real-time qPCR and western blot validation of the PCR array data, 
performed for 3 genes down-regulated by HCV. Total RNA from HCV J6/JFH-1-
P47-infected or mock-infected Huh7.5 cells harvested at 2, 4, and 6 d.p.i was 
used to assess mRNA levels by TaqMan qPCR using specific primers to (A) 
BNIP3, (B) CIDEB, (C) TNFSF10, and normalized to endogenous GAPDH. The 
TaqMan qPCR data (gray bars) shown represent the mean ± standard deviation 
of triplicate wells for four independent experiments. Fold-changes calculated for 
the PCR array data, which relied on single wells, hence, standard deviations are 
not displayed, are also indicated (white bars). P-values were calculated using the 
student’s T-test with statistical significance between mock and infected marked 
by asterisks (*p<0.05 and **p<0.01). (D) Western blots were probed with human 
anti-BNIP3 (top), anti-CIDEB (second from top), anti-TRAIL or TNFSF10 (third 
from top), anti-HCV core (second from bottom), and anti-Actin (bottom); which 
was used as a loading control of the total cell lysate used. The western blots 
shown represent one of three independent experiments. 
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For the western blot analysis (Figure 4.3D), we observed that although 
there was corresponding changes in the expression for all three proteins, we 
noticed that, generally, the level of proteins for the mock-infected samples 
(Figure 4.3D, top 3 blots, lanes 1, 3, and 5) were progressively increased along 
the time points, while that of the infected samples (lanes 2, 4, and 6) were 
decreased in a similar manner. This observation seems to suggest that HCV 
might be blocking the expression of these proteins or other steps in the 
translation machinery, hence, the progressive decrease in protein expression in 
the infected samples. The converse is observed in mock-infected samples. The 
level of HCV core, an indication of infection, was similar for all 3 infected time 
points (Figure 4.3D, second from bottom).  
 
4.4.2 Validation of the Expression of the Up-regulated Genes 
The mRNA expression of the 3 up-regulated genes, BIK, GADD45A, and 
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Figure 4.4. Real-time qPCR and western blot validation of the PCR array data, 
performed for 3 genes up-regulated by HCV. Total RNA from HCV J6/JFH-1-P47-
infected or mock-infected Huh7.5 cells harvested at 2, 4, and 6 d.p.i were used to 
assess mRNA levels by TaqMan qPCR using specific primers to (A) BIK, (B) 
GADD45A, (C) HRK, and normalized to endogenous GAPDH. The TaqMan 
qPCR data (gray bars) shown represent the mean ± standard deviation of 
triplicate wells for four independent experiments. Fold-changes calculated for the 
PCR array data, which relied on single wells, hence, standard deviations are not 
displayed, are also indicated (white bars). P-values were calculated using the 
student’s T-test with statistical significance between mock and infected marked 
by asterisks (*p<0.05 and **p<0.01). (D) Western blots were probed with human 
anti-BIK (top), anti-GADD45A (second from top), anti-HRK (third from top), anti-
HCV core (second from bottom), and anti-Actin (bottom); which was used as a 
measure of the loading control of the total cell lysate used. The western blots 
shown represent one of three independent experiments. 
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The western blot analysis generally revealed a corresponding change in 
protein expression for BIK, GADD45A and HRK (Figure 4.4D).  However, not all 
three proteins’ expression displayed significant difference between mock and 
infected samples over all time points. For BIK, there was no significant increase 
in protein expression on 2 d.p.i, but the protein level increased dramatically on 4 
and 6 d.p.i (Figure 4.4D, top), similar to the mRNA expression (Figure 4.4A). On 
the other hand, we consistently observed that the protein level of GADD45A was 
unchanged over all time points, except a small increase on 2 d.p.i (Figure 4.4D, 
second from top). Similarly, the level of HRK protein expression did not change 
over the three time points, although we observed a slight increase on day 6 p.i 
(Figure 4.4D, third from top). The level of HCV core, an indication of infection, 
was similar for all 3 infected time points (Figure 4.4D, second from bottom).  
For the rest of the up-regulated genes, i.e., BCLAF1, FAS and TNFRSF9, 
we could not detect the endogenous proteins using commercially available 
antibodies. Nevertheless, the mRNA expression of these up-regulated genes was 
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Figure 4.5. Real-time qPCR validation of the PCR array data, performed for 3 
genes up-regulated by HCV. Total RNA from HCV J6/JFH-1-P47-infected or 
mock-infected Huh7.5 cells harvested at 2, 4, and 6 d.p.i was used to assess 
mRNA levels by TaqMan qPCR using specific primers to (A) BCLAF1, (B) FAS, 
(C) TNFRSF9, and normalized to endogenous GAPDH. The TaqMan qPCR data 
(gray bars) shown represent the mean ± standard deviation of triplicate wells for 
four independent experiments. Fold-changes calculated for the PCR array data, 
which relied on single wells, hence, has no standard deviations displayed, are 
also indicated (white bars). P-values were calculated using the student’s T-test 
with statistical significance between mock and infected marked by asterisks 
(*p<0.05 and **p<0.01).  
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4.5 Network Interaction between the Differentially Expressed Genes and 
the Role of the Other Non-validated Genes in HCV infection. 
Given that a plethora of molecular and cellular events are linked with HCV 
infection (Banerjee et al., 2010; Buhler and Bartenschlager, 2012; Ke and Chen, 
2012), it is right to speculate that, probably a large number of host apoptosis-
related genes would be involved in HCV-induced apoptosis. However, in this 
screen of 84 apoptosis-related genes, only 15 genes were differentially 
expressed with fold changes of at least 2; a cutoff used by previous studies 
(Blackham et al., 2010; Walters et al., 2006; Walters et al., 2009). Out of this 
number, 9 genes were validated. The other 6 genes with at least 2-fold change 
that were not validated may also be important in HCV infection and thus 
contribute to apoptosis modulation. Similarly, given that genes do not work alone, 
but in intricate network of interactions, it will be good to determine the interaction 
between all the differentially expressed genes following HCV infection. This will 
help us interpret the data in the context of biological processes, pathways, and 
networks. It will also give us a global perspective on the data in relationship to 
HCV infection. The network interactions between the gene sets were therefore 






Figure 4.6. Gene network diagram of the 15 differentially expressed host 
apoptosis-related genes differentially expressed in HCV-infected Huh7.5 cells. 
The Ingenuity IPA pathway programme was used to analyze the interactions 
between the genes that were differentially expressed by HCV infection with at 
least 2-fold change. Differentially up-regulated genes in this study are highlighted 
in red text while down-regulated genes are shown in blue text. Lines represent 
interaction. Neighboring genes in the network are shown in black text. 
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As shown in Figure 4.6, the network interaction map shows a complex but 
interesting relationship between the genes and their neighbours. However, we 
observe that all the network interactions appear to converge around three genes, 
namely, TP53, BIRC6, and UBC. Incidentally, BIRC6 and UBC (Ubiquitin C) are 
implicated in the ubiquitin–proteasome pathway, which is reported to regulate 
almost all cellular activities, including cell cycle progression, DNA replication and 
repair, transcription, protein quality control, immune/cellular response to stress, 
and apoptosis (Ciechanover, 1998; Ciechanover and Schwartz, 1998; Liu et al., 
2007; Pietenpol and Stewart, 2002). A number of viruses are known to 
manipulate the ubiquitin-proteasome pathway in order to modulate the cell cycle, 
inhibit apoptosis, evade the immune system, activate cell signaling and to enable 
persistent infection (Randow and Lehner, 2009), it is therefore believed that HCV 
might also manipulate this system so as to favor its propagation and contribute to 
viral pathogenesis (Shoji, 2012). BIRC6 was also the only anti-apoptotic protein 
identified in the PCR array screen. As a member of the human IAPs (inhibitors of 
apoptosis proteins), BIRC6 is capable of binding to and inhibiting active 
caspases, including caspases-3, 6, 7, and 9 (Bartke et al., 2004). Similarly, 
through its UBC domain, BIRC6 facilitates proteasomal degradation of pro-
apoptotic proteins such as caspase-9 (Hao et al., 2004), SMAC/DIABOLO (Hao 
et al., 2004; Qiu and Goldberg, 2005), and HTRA2/OMI (Bartke et al., 2004; 
Sekine et al., 2005). Apart from its anti-apoptotic function, BIRC6 is also a critical 
regulator of cytokinesis and therefore plays an important role in cell proliferation 
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(Pohl and Jentsch, 2008). Therefore, the elevated expression of BIRC6 observed 
in this study is likely to promote resistance of the host cell to apoptotic triggers. 
On the other hand, TP53 (encodes for p53 protein) responds to diverse 
cellular stresses so as to regulate the expression of target genes, thereby 
inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in 
metabolism (Pietenpol and Stewart, 2002). A number of viral infections have 
been shown to activate the p53 pathway, which leads to cell cycle arrest and 
apoptosis of the infected cells (Lazo and Santos, 2011; Turpin et al., 2005). For 
HCV, it had been reported that, p53 signaling was significantly affected during 
HCV infection, which is believed to provide the important link between oxidative 
stress/DNA damage, cell cycle arrest, and apoptosis (Rasmussen et al., 2012). It 
is therefore not surprising that some of the genes differentially expressed 
following HCV infection, as observed in this study and by others, are involved in 
cell cycle arrest and DNA damage/oxidative stress response. Similarly, apoptosis 
associated with cell cycle arrest is thought to be mediated through the 
mitochondria and p53 pathway (Bates and Vousden, 1996). It is therefore 
conceivable that perturbation of these pathways would have an important role in 
HCV-induced cell death. After all, it had previously been suggested that changes 
in the p53 signaling pathway play a key role in the perturbation of cell cycle and 
induction of apoptosis during HCV infection(Walters et al., 2009).  Up-regulation 
of TP53 in response to viral infections is said to be part of the host cell defenses, 
such that an increased p53-dependent apoptosis can reduce viral replication 
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(Takaoka et al., 2003). Apart from TP53, we observed an up-regulation of 
TP53BP2, also a p53 family member, which is a p53-binding gene that is able to 
bind p53 (Iwabuchi et al., 1994), Bcl-2 (Naumovski and Cleary, 1996), and the 
p65 subunit of NF-κB (Yang et al., 1999). TP53BP2 is believed to be a potent 
modulator of cell growth and survival because it has been shown to inhibit cell 
growth, impede cell cycle progression at G2/M, and induce apoptosis 
(Naumovski and Cleary, 1996; Yang et al., 1999). Therefore, the concerted up-
regulation of these two genes in our screen seems to suggest a very important 
role of the p53 pathway in HCV-induced cell death. 
One other gene that was not validated was BNIP3L (BNIP3-like), a 
homologue of BNIP3. BNIP3L was observed to be significantly down-regulated, 
although with fold changes less than 3. Since BNIP3 and BNIP3L interact 
physically (Figure 4.6) and have similar cellular functions including roles in cell 
death and autophagy (Zhang and Ney, 2009), it is understandable why there was 
a concerted inhibition of these two genes following HCV infection. It thus 
suggests that the functions of these genes may be important in HCV infection. 
The last set of genes that were differentially expressed following HCV 
infection, yet were not validated are TNFRSF21 and TNFRSF25, which are two 
other death receptors that belong to the TNF superfamily. Since several 
members of the TNF super family including TNFSF10 play important roles in 
clearing virus by inducing apoptosis and/or necrosis of infected cells via binding 
to death receptors such as FAS, TNFRSF21 and TNFRSF25 (Guicciardi and 
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Gores, 2009; Van Herreweghe et al., 2010), it is therefore not surprising that we 
observed a significant up-regulation of FAS as well as TNRRSF21 and the down-
regulation of TNFRSF25, albeit with 2-fold change. 
Taken together, it is therefore interesting to find that, using pathway 
interaction analysis, it is possible to further probe the functional implications and 




The tissue culture adapted HCV J6/JFH-1-P47 virus, which was previously 
shown to exert a stronger CPE than the parental JFH-1 virus and the J6/JFH-1 
chimera (Deng et al., 2008), has also been shown to have an increased ability to 
induce apoptosis which correlates with increase in viral replication and virion 
production (Bungyoku et al., 2009; Mateu et al., 2008). The current study was 
therefore performed on the basis of these useful features of the J6/JFH-1-P47 
model, coupled with the fact that it provides a convenient tool for characterizing 
direct CPE of HCV in cultured cells without the complications of immune-
mediated responses. Thus, using the J6/JFH-1-P47 virus, we demonstrated that 
indeed acute in vitro infection with this virus has the potential to induce CPE as 
shown by an increase in apoptosis, measured by caspase-3/7 activity (Figure 
4.1B). We also demonstrated that proliferation of the HCV-infected cells were 
significantly slower than the mock-infected cells (Figure 4.1A), which is 
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consistent with previous reports (Deng et al., 2008; Kannan et al., 2011; Timpe et 
al., 2008). However, although there was a significant reduction in cell 
proliferation, this did not impact significantly on viral replication, as we observed a 
steady increase in HCV RNA over the course of the infection (Figure 4.1C). The 
slow proliferation of the HCV-infected cells is in line with the belief that, a 
reduction in the viability of HCV-infected cells might be due to a reduced cellular 
proliferation, or a block in cell cycle progression, which is accompanied by 
differential expression of cell death genes and higher levels of apoptotic markers 
(Kannan et al., 2011; Marshall et al., 2005; Walters et al., 2009). Similarly, we 
found that the appearance of the highest CPE or apoptosis (Figure 4.1B) as well 
as the highest viral replication (Figure 4.1C) and the highest expression of the 
apoptosis-related genes (Figure 4.2) all coincided on 6 d.p.i. This suggests that 
intrahepatic HCV RNA levels play a role in hepatocyte cell death, an observation 
also previously made by Walters and colleagues (Walters et al., 2009).  
When HCV J6/JFH-1-P47-infected Huh7.5 cells were analyzed for host 
apoptosis-related genes using PCR array, 15 genes with ≥2-fold change (see 
relationship in Figure 4.6) were differentially expressed (Table 4.1). Nine genes 
with ≥3-fold change were chosen for validation by TaqMan qPCR, of which 3 
down-regulated and 3 up-regulated were further validated by western blot 
analysis (Figure 4.3 and Figure 4.4 respectively). However, 3 other up-regulated 
genes could not be validated by western blot analysis because of the lack of 
suitable antibodies (Figure 4.5). 
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4.6.1 Down-regulated Genes Validated by Western blot 
Infection of Huh7.5 cells with J6/JFH-1-P47 resulted in the suppression of 
the expression of BNIP3, CIDEB, and TNFSF10 at both the transcriptional and 
translational levels, which were demonstrated by two independent PCR-based 
assays as well as by western blot analysis (Figure 4.3).  
The mRNA expression of BNIP3 (Bcl-2/adenovirus E1B 19 kDa-interacting 
protein 3) was previously shown in a DNA microarray screen of Murine 
coronavirus mouse hepatitis virus (MHV) infected murine astrocytes cell line to 
be significantly decreased (Cai et al., 2003), which was postulated to promote 
viral persistence by inhibiting host antiviral apoptotic response. Thus, it is 
conceivable to also speculate that, the decrease in the expression of BNIP3 
observed in our study following HCV infection, especially occurring at the later 
stages during the infection, might be a viral strategy adapted so as to inhibit the 
antiviral apoptotic response of the host. In addition, it had previously been shown 
that the expression of HCV proteins activates hypoxia-inducible factor 1 (HIF-1) 
(Ripoli et al., 2010), which affects the expression of BNIP3 under hypoxic 
conditions (Bruick, 2000; Guo et al., 2001b; Sowter et al., 2001). Furthermore, 
the observed down-regulation of BNIP3L (a homolog of BNIP3) in the PCR array 
screen goes to buttress the fact that the concerted down-regulation of BNIP3 and 
BNIP3L might play a significant role in HCV-induced cell death. As a multi-
functional BH3-only protein, BNIP3 is implicated in a number of cell death 
pathways in addition to apoptosis. BNIP3 has been implicated in necrosis (Vande 
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Velde et al., 2000) and is reported to be a potent inducer of autophagy, which is 
believed to confer protection against cell death or contribute to autophagic cell 
death (Azad et al., 2008; Daido et al., 2004; Hamacher-Brady et al., 2007; 
Kanzawa et al., 2005). Recent studies have also shown BNIP3 to be a mediator 
of TNF-induced caspase-independent necroptosis (Kim et al., 2011b). It might 
therefore be difficult to conclude per these results whether its down-regulation is 
beneficial or detrimental to the host cell. 
CIDEB, a liver-specific pro-apoptotic protein, and a member of the novel 
cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector (CIDE) gene 
family, has been reported to induce cell death in a caspase-dependent manner 
by mediating cytochrome c release from mitochondria (Chen et al., 2000; Inohara 
et al., 1998). It had previously been shown that the HCV NS2 protein can inhibit 
CIDEB-induced apoptosis, which is believed to be one of HCV’s strategies used 
to subvert host cell defense (Erdtmann et al., 2003). A similar PCR array screen 
of Enterovirus 71 (EV71) infection had shown an interruption in the expression of 
CIDEB among other pro-apoptotic genes during the early stage of the infection. 
This observation according to the authors was due to the activation of caspase-3, 
which subsequently cleaved substrates such as CIDEB and thus triggered 
chromosomal DNA fragmentation (Shi et al., 2012). Although our data showed a 
down-regulation of CIDEB expression following HCV infection, it was only 
significant at the later stages (6 d.p.i) of the infection (Figure 4.3), which also 
coincided with the point we observed the highest caspase-3/7 activation (Figure 
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4.1). Therefore the down-regulation of pro-apoptotic CIDEB as observed in this 
study could also be one of the viral strategies adapted so as to subvert the 
antiviral apoptotic activity of the host cell. 
TNFSF10 (TRAIL) is a cytokine that belongs to the tumor necrosis factor 
(TNF) ligand family, and is known to induce apoptosis in cancer cells and cells 
infected with a variety of viruses (Babu et al., 2009; Janssen et al., 2003; Kotelkin 
et al., 2003; Lan et al., 2008; Liang et al., 2007; Walczak et al., 1999). Unlike 
BNIP3 and CIDEB, the role of TNFSF10 in HCV infection has been reported. It 
had previously been reported that sensitization of hepatocytes to TRAIL-induced 
apoptosis by HCV infection represents a novel antiviral host defense mechanism 
that may have important implications for the pathogenesis of HCV infection and 
may contribute to the elimination of virus-infected hepatocytes (Lan et al., 2008). 
Similarly, it had been demonstrated that the overexpression of HCV Core 
resulted in the down-regulation of TNFSF10/TRAIL among other genes (Nguyen 
et al., 2006). This observation is in agreement with our results (Figure 4.3). It 
therefore seems to suggest that the suppression of TNFSF10 expression by HCV 
may be a strategy adapted by the virus so as to minimize apoptosis of the 
infected cells and to maintain HCV persistence.  
Collectively, the progressive suppression of pro-apoptotic BNIP3, CIDEB, 
and TNFSF10 in addition to BNIP3L and TNFRSF25, by HCV infection, seems to 
suggest a concerted anti-apoptotic strategy employed by HCV to prevent 
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clearance by the host. This might also be the reason why we observed a 
corresponding progressive increase in the expression of anti-apoptotic BIRC6.  
 
4.6.2 Up-regulated Genes Validated by Western blot 
Among the up-regulated genes differentially expressed following infection 
of Huh7.5 cells with HCV J6/JFH-1-P47, it was only the expression of BIK, 
GADD45A, and HRK that was demonstrated at both the mRNA and protein levels 
(Figure 4.4). But even with that, it was only the expression of BIK protein that 
changed correspondingly for mock-infected and HCV-infected cells at the various 
time points. It is partly for this reason couple with the fact that the involvement of 
BIK in HCV infection has not been extensively studied, that we decided to 
perform a detailed study of the contributions of BIK to HCV-induced cell death; 
which is the subject of the next chapter.  
As a multifunctional gene, GADD45A has been implicated in regulatory 
roles in various cellular processes, including maintenance of genomic stability, 
cell proliferation, DNA repair, cell cycle control, and apoptosis (Hollander and 
Fornace, 2002; Rosemary Siafakas and Richardson, 2009; Tong et al., 2005). 
The overexpression of GADD45A has also been shown to induce cell death via 
the mitochondrial pathway by activating caspase-9 (Tong et al., 2005) and to lead 
to growth suppression in numerous cells through the activation of the G2 
checkpoint (Mullan et al., 2001), while deletion or repression of GADD45A is 
reported to lead to uncontrolled cell proliferation (Rosemary Siafakas and 
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Richardson, 2009; Zhan et al., 1994). A recent study has shown that the HCV 
NS5A down-regulated GADD45A expression at the transcriptional and 
translational levels and subsequently triggered cellular proliferation (Cheng et al., 
2013). Similarly, the expression of GADD45A in HCC patients has been shown to 
be down-regulated (Gramantieri et al., 2005). However, analysis of cell cycle 
arrest-related gene expression in both HCV-infected hepatoma cells and chronic 
HCV infection revealed that, GADD45A is one of several up-regulated genes 
(Sarfraz et al., 2009; Walters et al., 2009), which is in agreement with our 
observation. Therefore, the observed up-regulation of GADD45A in this study, 
especially at the initial time points (Figure 4.4), might have contributed to the 
delay in cell proliferation and caspase-3/7 activation (Figure 4.1). Which means 
that, once a chronic infection becomes established, HCV is able to utilize various 
strategies (such as NS5A to down-regulate cell-cycle control genes) to inhibit 
cellular apoptosis and promote cell proliferation, which is beneficial for viral 
survival (Cheng et al., 2013). All these therefore highlight the importance of 
GADD45A in HCV infection. Further studies might be required to further delineate 
the specific role of GADD45A in HCV-induced cell death. 
HRK (harakiri, BCL2 interacting protein) is a member of the pro-apoptotic 
BH3-only protein family, reported to selectively interact with the pro-survival 
proteins, Bcl-2 and Bcl-xL, and to regulate Bax-dependent apoptosis (Harris and 
Johnson, 2001; Inohara et al., 1997). It is transcriptionally regulated in various 
cell types (Imaizumi et al., 1999; Sanz et al., 2000), and is induced within an hour 
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after administration of cell death stimuli (Harris and Johnson, 2001). This could 
probably be one of the reasons why we observed a dramatic increase (~20-fold) 
in the mRNA level of HRK at day 2 p.i (Figure 4.4). In common with our 
observation, an increase in HRK expression was observed in the same genome-
wide transcriptional profiling study that showed an up-regulation of BIK and 
GADD45A in the early acute phase of HCV infection (Walters et al., 2009). A 
recent study of apoptotic gene expression profiling of HepG2 cells infected with 
dengue virus, another member of the Flaviviridae virus family, also showed a 
dramatic increase in HRK expression as well (Morchang et al., 2011). A strong 
up-regulation of HRK expression was also observed in Huh7 cells infected with 
CCHFV (Crimean–Congo hemorrhagic fever virus), a negative-strand RNA virus, 
which was attributed to the ability of the virus to induce apoptosis (Rodrigues et 
al., 2012). It therefore suggests that, an enhanced HRK expression may be 
another contributing factor to HCV-induced apoptosis. From the foregoing, it is 
therefore right to speculate that in acute HCV infection, there is a concerted up-
regulation of BIK, GADD45A, and HRK by the virus so as to induce cell death, an 
observation also previously made by Walters and colleagues (Walters et al., 
2009). 
 
4.6.3 Up-regulated Genes not Validated by Western blot 
The up-regulation of BCLAF1, FAS, and TNFRSF9 expression following 
J6/JFH-1-P47 infection of Huh7.5 cells, was observed in the PCR array screen 
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and validated by TaqMan qPCR (Figure 4.5). However, we could not detect the 
corresponding changes in protein expression, due to lack of suitable commercial 
antibodies. Nevertheless, the concerted up-regulation of all these genes following 
HCV infection, implicates their roles in HCV-induced cell death.  
Although, its role in HCV-induced cell death has not been reported, the 
nuclear protein BCLAF1 (BCL2-associated transcription factor 1) with no well-
defined molecular functions, has been implicated in a wide range of functions 
including apoptosis, transcriptional regulation, RNA processing, and the export of 
mRNA from the nucleus (Kasof et al., 1999; Renert et al., 2009; Sarras et al., 
2010). BCLAF1 is believed to promote cell death by interacting with and 
repressing the transcription of Bcl-2, thereby influencing the regulation of 
apoptosis. Similarly, when localized to the nuclear envelope, it is also able to 
induce apoptosis, an event that may occur as a result of DNA damage. It has 
recently been reported that, in human cytomegalovirus (HCMV) infection, 
BCLAF1 undergoes proteasomal degradation by the action of some viral proteins 
immediately following infection, and by virus-encoded microRNA at later stages 
of the infection, thereby down-regulating a cellular antiviral protein (Lee et al., 
2012). The up-regulation of BCLAF1 by HCV infection therefore suggests an 
antiviral mechanism adapted by the host cells. 
The up-regulation of FAS expression following HCV infection is 
uncommon, as a number of previous studies have reported an up-regulation of 
FAS in liver cells of chronic hepatitis C patients (Hiramatsu et al., 1994; Okazaki 
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et al., 1996), which was shown to correlate with severity of liver inflammation and 
with ongoing HCV infection (Akazawa and Gores, 2007; Calabrese et al., 2000; 
El Bassiouny et al., 2008; Hammam et al., 2012; Nasir et al., 2000; Zhang et al., 
2006). It is believed that the Fas/FasL system is the pathway most commonly 
used by immunocytes to kill virally infected cells (Yoneyama et al., 2002). This 
system plays an important role in liver cell injury by HCV infection (Feig et al., 
2007) and is thought of as a major mechanism for HCV-induced hepatocyte 
apoptosis (Dmitrieva et al., 2003; Jarmay et al., 2002). However, inhibition or 
dysregulation of the Fas/FasL system has been observed in hepatocellular 
carcinoma (HCC), possibly as a mechanism to evade the host immune response 
(Bortolami et al., 2008). It has been suggested that, HCV might regulate FAS 
expression differently during early and late stages of infection. The observed up-
regulation of FAS in this study therefore goes to buttress its importance in HCV 
infection. Further studies may have to be performed to examine the specific role 
of FAS in HCV-induced cell death using the HCVcc system. 
TNFRSF9 (CD137/4-1BB/ILA) encodes a surface glycoprotein that 
belongs to the tumor-necrosis factor receptor (TNFR) superfamily and was 
originally identified as an inducible costimulatory molecule on activated T‐cells 
(Schwarz et al., 1996). Binding of CD137 to its ligand (CD137L) leads to 
increased T-cell proliferation, cytokine production, functional maturation, and 
prolonged CD8 T-cell survival (Melero et al., 2008). In a similar PCR array screen 
of apoptosis genes, an increase in CD137 expression was observed among other 
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death ligand and receptor genes in Dengue virus capsid protein (DENV C)-
expressing HepG2 cells. It was also shown in that study that, the CD137-
mediated apoptotic activity in HepG2 cells expressing DENV C increased 
significantly following treatment with anti-CD137 antibody (Nagila et al., 2011). 
Although there is dearth of information on the role of TNFRSF9 expression in 
HCV infection, a recent study of global gene expression patterns of CD8+ T cells 
in HIV/HCV-co-infected and the HIV- or HCV-mono-infected treatment-naïve 
individuals, using microarray and qRT-PCR reported that, TNFRSF9 among other 
genes was involved in cell proliferation and death, with the expression of 
TNFRSF9 significantly elevated in the infected groups as compared to the 
uninfected healthy group (Zhao et al., 2012a). The observed up-regulation of 
TNFRSF9 expression by HCV infection as demonstrated by our PCR array and 
TaqMan qPCR results, therefore highlight the importance of TNFRSF9 in HCV, 
hence, warrant further investigation. 
 
4.6.4 Summary and Future Studies 
In summary, using the cell culture-adapted HCV J6/JFH-1-P47 virus and 
PCR array, we have identified a couple of host apoptosis-related genes that were 
differentially expressed in response to acute HCV infection, suggesting their role 
in HCV-associated apoptosis. All the differentially expressed genes have been 
implicated in either the intrinsic (BCLAF1, BIK, BNIP3, CIDEB, GADD45A, and 
HRK) or extrinsic (FAS, TNFRSF9, and TNFSF10) apoptosis pathways, 
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suggesting that HCV-induced apoptosis is induced via these two pathways. The 
observed slight delay in the onset of HCV-induced apoptosis, might suggest a 
mechanism for providing the virus with sufficient time to multiply. However, at the 
later stages during the infection, we observed a dramatic increase in apoptosis 
induction as well as the expression of several pro-apoptotic genes, suggesting a 
proviral state, which will allow the release of progeny virions. Nonetheless, the 
few down-regulated pro-apoptotic genes may represent a compensatory 
mechanism adapted by the host cell to overcome the stress brought about by the 
infection and to resist apoptosis induced by the virus.   
For the down-regulated genes, the protein expression as determined by 
western blots seems to suggest that, HCV infection is suppressing the normal 
increase in the levels of these proteins with growth. It may also suggest that the 
effects we have observed is not due to HCV infection per se but rather the 
inhibition of growth by HCV, which is manifested as a progressive decrease in 
protein expression in the infected as against an increase in the mock. Further 
studies in the form of overexpressing these genes and then determining the 
effect it may have on HCV infection are therefore required. On the other hand, for 
the up-regulated genes, the use of RNAi to deplete the expression of these 
genes may be required in future studies so as to further delineate the exact role 
that these genes may play in HCV infection. Similarly, since proteins, and not 
mRNA, are the major effectors of cellular function, the corresponding changes in 
protein level for all the differentially expressed genes would have to be confirmed 
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before the contribution of these genes to HCV-induced apoptosis can be 
determined.  
Taken together, these results strongly suggest that HCV infection induces 
cytopathic effects or apoptosis, through a reduction in the viability of the infected 
cells by reducing cellular proliferation and/or blocking cell cycle progression, 
which subsequently affects the expression of cell death-associated genes and 
other apoptotic markers. Apart from apoptosis, there is also the possible 
involvement of other cell death pathways such as autophagy, and 
necrosis/necroptosis, in HCV-induced cell death due to the concerted 






























In chapter four, 3 apoptosis-related host genes were found to be up-
regulated and 3 were found to be down-regulated on both mRNA and protein 
levels. In order to examine the contribution of the up-regulated genes on HCV 
replication, standard RNA interference methodology could be used.  Out of the 3 
up-regulated genes, only BIK was observed to be up-regulated at 3 different 
time-points post-infection, hence, we have chosen BIK for detailed study in this 
chapter. 
The BH3-only proteins of the Bcl-2 family to which BIK belong, consists of 
a growing number of members including Bad, Bid, Noxa, Puma, BIK (NBK), Bim 
(Bod), HRK (DP5), Blk, Bmf, BNIP3 (nix), BNIP3L, p193, and Bcl-G (Pommier et 
al., 2004). These proteins are known to bind strongly to the pro-survival members 
of the Bcl-2 family through their BH3 domains thereby antagonizing their pro-
survival function (Chen et al., 2005). The activity of the BH3-only proteins can 
also be regulated by transcriptional expression as well as by post-translational 
modifications (Huang and Strasser, 2000; Puthalakath and Strasser, 2002). In 
addition to their canonical role in apoptosis, several BH3-only members also 
regulate diverse cellular functions in cell-cycle regulation, DNA repair, and 
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metabolism (Hetz and Glimcher, 2008; Pommier et al., 2004). A number of BH3-
only proteins including BAD, EGL-1, and BIK as well as BH3 mimetics are also 
reported to induce autophagy and autophagic cell death, possibly by releasing 
the BH3-only autophagic effector Beclin-1 from complexes with Bcl-2 and Bcl-xL 
(Feng et al., 2007; Maiuri et al., 2007; Oberstein et al., 2007; Pattingre et al., 
2005; Pommier et al., 2004; Rashmi et al., 2008). 
BIK (Bcl-2 interacting killer, also know as BP4, NBK, or BIP1) is the 
founding member of the BH3-only pro-apoptotic proteins of the Bcl-2 family (Boyd 
et al., 1995). It is predominantly localized in the ER where it activates the 
mitochondrial apoptotic pathway by inducing Ca2+ release from the ER and the 
remodeling of the mitochondrial cristae that releases cytochrome c and activates 
caspase-9 (Chinnadurai et al., 2008; Germain et al., 2002). However, 
functionally, BIK is said not to be a direct initiator of apoptosis, but acts upstream 
of the pro-survival Bcl-2-family members (Letai et al., 2002). It is reported that 
BIK exhibits its death-promoting activities by binding directly to Bcl-2 or Bcl-XL 
through its BH3 domain, and inactivates their anti-apoptotic functions. Therefore, 
an increase in BIK levels lowers the cellular apoptotic threshold by blocking the 
anti-apoptotic function of Bcl-2 family proteins (Shimazu et al., 2007). Similarly, it 
is suggested that BIK might also activate the downstream effectors Bak or Bax 
directly to cause apoptosis (Mathai et al., 2005). BIK protein is induced in 
response to a variety of cell stress stimuli, including genotoxic agents (Mathai et 
al., 2005; Paquet et al., 2004; Real et al., 2006), oncogenic stress (Mathai et al., 
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2002), hypoxia (Koong et al., 2000), as well as viral infections and cytokines 
(Chinnadurai et al., 2008).  Like other BH3-only proteins, the cellular levels of BIK 
are controlled by both posttranslational and transcriptional mechanisms (Hur et 
al., 2006; Marshansky et al., 2001). 
 
5.2 Small interfering RNA (siRNA) Mediated Knockdown of BIK and its 
Effect(s) on HCV Infection 
To explore the functional significance of BIK's up-regulation in HCV 
infected cells, we set about to examine the effect(s) of BIK depletion using siRNA 
on host (i.e., cell viability/proliferation and apoptotic cell death) and viral factors 
(i.e., replication and release of infectious particles into the culture supernatant) in 
response to HCV infection. 
For an efficient, complete and long-term knockdown of BIK expression, 
preliminary experiments were performed so as to determine the optimal siRNA 
concentration required and how long it would take to obtain a complete 
knockdown. Huh7.5 cells transfected with different concentrations (10nM, 20nM, 
and 40nM) of siRNA targeted against human BIK (hereafter siBIK) or with a non-
targeting control siRNA (hereafter siCtrl) were harvested at 2 and 4 days post-
transfection (d.p.t) and analyzed by western blot analysis using anti-human BIK 
antibodies to assess efficiency of knockdown. As shown in Figure 5.1A, 20nM of 
the siBIK was able to completely knockdown the expression of BIK on day 2 
post-transfection, whereas a lower (10nM) or higher (40nM) concentration of the 
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siRNA, and a longer period of siRNA treatment could not completely deplete BIK 
expression (Figure 5.1B). An optimal siBIK concentration of 20nM was therefore 
taken to be that required to achieve an efficient and complete knockdown of BIK 





Figure 5.1. siRNA-mediated depletion of BIK expression in Huh7.5 cells. Huh7.5 
cells were transfected with the indicated amounts of siBIK or siCtrl. On day 2 (A) 
and day 4 (B) post-transfection, cells were harvested and the level of BIK protein 
expression was determined by western blot analysis using anti-human BIK 
antibodies, with endogenous actin as control. The western blots shown are a 
representative of three independent experiments. 
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Next, the length of time that the knockdown could be sustained was 
examined, since in the preceding chapter (chapter 4), the HCV infection studies 
were performed over 6 days, the same time course that will be used in this study. 
For this, Huh7.5 cells were transfected with 20nM of siBIK or siCtrl, and cells 
were harvested and analyzed at 2, 4, 6, and 8 d.p.t. As shown in Figure 5.2A, the 
level of BIK knockdown was sustained up to day 8 post-transfection, although 





















Figure 5.2. Sustained siRNA-mediated knockdown of BIK expression in Huh7.5 
cells and effects on cell proliferation. (A) Huh7.5 cells transfected with 20nM 
siBIK or siCtrl were harvested and analyzed by western blot on 2, 4, 6, and 8 
d.p.t using anti-human BIK antibodies, with the level of endogenous actin as 
control. The western blots shown are a representative of three independent 
experiments. (B) Huh7.5 cells transfected with 20nM siBIK or siCtrl were 
analyzed for cell proliferation/viability at 2, 4, 6 and 8 d.p.t. The percentage of cell 
viability on day 2 post-transfection was arbitrary set at 100% and the 
percentages of the other samples relative to day 2 were then determined. Data 
from three independent experiments are shown with error bars representing the 
standard deviation. 
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As BIK is a pro-apoptotic protein, we next assessed if the absence of BIK 
could affect the viability of the cells. For this, cell viability assay was performed at 
the indicated time points on Huh7.5 cells transfected with siBIK or siCtrl. As 
shown in Figure 5.2B, siRNA-mediated depletion of BIK expression in Huh7.5 
cells did not adversely affect cell viability as both siBIK-treated and siCtrl-treated 
cells were observed to proliferate at the same rate on all the days post 
transfection. These results thus indicate that sustained knockdown of 
endogenous BIK expression in Huh7.5 cells is attainable with 20nM of the siRNA 
up to day 8 post-transfection and with no adverse effects on the viability or 
proliferation of the cells.  
 
5.2.1 Effect of BIK Depletion on HCV-induced Apoptosis and on Cell 
Proliferation 
To examine BIK depletion on the cells’ response to apoptosis stimulus 
from HCV infection and its effect on the viability of the cells, siBIK or siCtrl-
treated Huh7.5 cells were infected with HCV J6/JFH-1-P47 and harvested at 2,4, 
and 6 d.p.i for analysis. As shown in Figure 5.3A (top), the western blots revealed 
successful knockdown of BIK as well as a sustained infection, indicated by the 
HCV core protein (Figure 5.3A, middle). Interestingly, it was observed that BIK 
depletion did not significantly affect the proliferation of Huh7.5 cells infected with 
HCV, as both siBIK-infected and siCtrl-infected cells had similar cell viability and 
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their proliferation was progressively inhibited to the same extend by HCV when 


























Figure 5.3. Apoptosis and proliferation of BIK depleted Huh7.5 cells infected with 
HCV J6/JFH1-P47 virus. (A) HCV-infected siBIK or siCtrl transfected Huh7.5 
cells were analyzed by western blot at 0, 2, 4, and 6 d.p.i using anti-human BIK 
and anti-HCV core antibodies, with the level of endogenous actin as control. The 
western blots shown are representative of three independent experiments. (B) 
HCV-infected siBIK or siCtrl transfected Huh7.5 cells were analyzed for cell 
viability/proliferation at 0, 2, 4, and 6 d.p.i. Readings were normalized to mock-
infected samples, which were arbitrary set at 100%. Data from three independent 
experiments are shown with error bars representing the standard deviation. P-
values were calculated using the student’s T-test with statistical significance 
shown by asterisks (*p<0.05 and **p<0.01). (C) HCV-infected siBIK or siCtrl 
transfected Huh7.5 cells were analyzed for Caspase-3/7 activation at 0, 2, 4, and 
6 d.p.i. The readings were normalized to cell numbers as determined by the cell 
viability assay (above). Data from three independent experiments are shown with 
error bars representing the standard deviation. P-values were calculated using 
the student’s T-test with statistical significance shown by asterisks (*p<0.05). 
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Since BIK is a pro-apoptotic protein, it is expected that in the absence of 
BIK, Huh7.5 cells would be less susceptible to HCV induced apoptosis. Indeed, 
as shown in Figure 5.3C, a significant reduction (4 d.p.i and 6 d.p.i) was 
observed in the induction of apoptosis, measured in terms of caspase-3/7 
activity, by HCV infected siBIK-treated cells as compared to HCV infected siCtrl-
treated cells. This observation is in common with some previous studies that had 
shown that the absence or depletion of BIK affected the induction of apoptosis by 
various agents. For instance, Shimazu and colleagues reported a reduction in the 
level of activated caspase-3 in adenovirus infected BIK-deficient iBMK cells 
(immortalized baby mouse kidney cells) (Shimazu et al., 2007), while the 
inhibition of BIK expression siRNA was shown to greatly attenuate bortezomib-
induced cell death in head and neck squamous cell carcinomas (HNSCC) (Li et 
al., 2008). Similarly, siRNA-mediated suppression of BIK in ZR75-1 cells was 
demonstrated to inhibit apoptosis induced by the MG132 proteasome inhibitor 
(Hur et al., 2006). 
To substantiate the observed induction of apoptosis by HCV infection in 
the siBIK and siCtrl-treated Huh7.5 cells using an independent assay, the TUNEL 
(Terminal deoxynucleotidyl transferase dUTP nick end labeling) assay was 
performed. This assay measures nuclear DNA fragmentation, a late apoptotic 
event and an important biochemical hallmark of apoptosis (Gavrieli et al., 1992). 
Given that the results of our caspase-3/7 activation assay only demonstrated a 
significant induction of apoptosis by HCV infection on 4 d.p.i and 6 d.p.i (Figure 
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5.3), the TUNEL assay was limited to only these two days. As shown in Figure 
5.4A, there were more TUNEL positive cells in the HCV-infected siCtrl-treated 
cells than in HCV-infected siBIK-treated cells. Nevertheless, the fewer number of 
TUNEL positive cells observed in the infected siBIK-treated cells on both 4 d.p.i 
and 6 d.p.i was not as a consequence of a fewer number of cells being infected, 
as almost all cells at the time of the assay were shown to be expressing HCV 
antigens in both siCtrl and siBIK infected cells (Figure 5.4B). Therefore, this data 
further corroborates the observation that, BIK-depleted Huh7.5 cells were less 




















Figure 5.4. Analysis of HCV-induced apoptosis in BIK depleted or control siRNA 
treated Huh7.5 cells by TUNEL assay. (A) HCV-infected siBIK or siCtrl 
transfected Huh7.5 cells were analyzed for nuclear DNA fragmentation as a 
measure of apoptosis at 4 and 6 d.p.i. Nuclei were counterstained with DAPI 
(Blue). Data shown are representative of three independent experiments. (B) 
HCV-infected siBIK or siCtrl transfected Huh7.5 cells were analyzed at 4 and 6 
d.p.i for HCV antigens using an HCV-infected patient’s serum. Nuclei were 
counterstained with DAPI (Blue). Data shown are representative of three 
independent experiments. 
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5.2.2 Effect (s) of siRNA-mediated BIK Depletion on HCV Replication and 
Viral Release. 
Next, the effect of BIK knockdown on HCV replication and viral release 
were examined by qPCR and immunofluorescence-based focus-forming assay. 
Interestingly, when the data for the viral replication was analyzed, we observed 
that there was a significant decrease in the level of HCV RNA replication in the 
infected siBIK-treated cells as compared to infected siCtrl-treated cells (Figure 
5.5A), especially on 4 and 6 d.p.i, suggesting that BIK expression in the host cell 




















Figure 5.5. HCV replication and release of infectious viral particles into culture 
supernatant. (A) HCV-infected siBIK or siCtrl transfected Huh7.5 cells were 
harvested at 2, 4, and 6 d.p.i, and analyzed for HCV replication using quantitative 
real-time PCR analysis and normalized to endogenous GAPDH. Data from three 
independent experiments are shown with error bars representing the standard 
deviation. P-values were calculated using the student’s T-test with statistical 
significance shown by asterisks (**p<0.01). (B) Culture supernatant of HCV 
infected siBIK or siCtrl-treated Huh7.5 cells collected at 2, 4, and 6 d.p.i was 
used to re-infect naïve Huh7.5 cells. The virus infectivity/release was determined 
at 24 hours post-infection using an HCV-infected patient’s serum. Data from 
three independent experiments are shown with error bars representing the 
standard deviation. P-values were calculated using the student’s T-test with 




Since depletion of BIK expression in Huh7.5 cells led to a significant 
decrease in HCV RNA replication, further experiments were performed so as to 
determine whether or not the decrease in viral replication would have any 
adverse effects on the release and infectivity of viral particles released into the 
culture supernatant. Indeed, as shown in Figure 5.5B, the number of infectious 
HCV particles released into the culture supernatant by infected siBIK-treated was 
significantly lower on 4 and 6 d.p.i than that released by infected siCtrl-treated 
cells. However, the effect of BIK depletion on viral release was not that drastic, 
as compared to the viral RNA replication (Figure 5.5A), as less than 1 log 
decrease was observed. A probable explanation for this discrepancy is the 
sensitivity and specificity of the two assay methods, as it had been noted by 
others, the amount of viral RNA (quantified by qPCR) does not always correlate 
with the number of cell free viral particles in the supernatant (quantified by 
counting foci under the microscope) (Park et al., 2013). This might be the reason 
why less than 1 log difference in viral production was observed, although the 
difference is statistically significant. Taken together, these results suggests that 
siRNA-mediated depletion of BIK expression in Huh7.5 cells affects HCV RNA 
replication and the release of infectious viral particles into the culture 






The expression of BIK is believed to play a critical role in apoptosis 
induction, and has been shown to trigger apoptosis in a variety of cells (Daniel et 
al., 1999; Germain et al., 2002; Han et al., 1996; Oppermann et al., 2005; Tong 
et al., 2001). BIK expression has also been reported to be elevated by some viral 
infections (Chinnadurai et al., 2008; Subramanian et al., 2007), including HCV 
infection (Walters et al., 2009). In the previous chapter, BIK was found to be up-
regulated on both transcriptional and translational levels by acute HCV J6/JFH-1-
P47 infection of Huh7.5 cells. To follow up, RNAi experiments were conducted to 
decipher the role of BIK in HCV infection. Our findings demonstrate that loss of 
BIK in Huh7.5 cells did not adversely affect cell viability of BIK-depleted 
uninfected (Figure 5.2B) and HCV-infected (Figure 5.3B) cells relative to non-
depleted BIK control cells. It showed that siRNA-mediated knockdown of BIK 
induced some level of anti-apoptotic effects in HCV-infected cells (Figure 5.3C 
and Figure 5.4A), which affected the replication of HCV (Figure 5.5A), but 
resulted in a slight but significant reduction in the release of infectious viral 
particles (Figure 5.5B).  
In examining the effect(s) of BIK suppression on the host cell following 
HCV infection, it was first demonstrated using siRNA-mediated knockdown that, 
both siBIK-treated and siCtrl-treated cells proliferated at the same rate, 
suggesting that, the absence of BIK did not affect the proliferation of Huh7.5 cells 
(Figure 5.2). Similarly, upon infecting the cells with HCV J6/JFH-1-P47, no 
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significant difference was observed in the cell viability between siBIK-treated and 
siCtrl-treated cells, as the proliferation of both infected cells were inhibited to the 
same extent by HCV (Figure 5.3). A similar observation was made by Urban and 
colleagues where they reported that, MEFs (Mouse embryonic fibroblasts) 
deficient in a number of BH3-only proteins including Bim, BIK, Bmf, BAD, Puma, 
Noxa or a combination of Bim and BAD (Bim/BAD DKO) died in response to SFV 
(Semliki Forest virus) (also an RNA virus) infection in a similar manner as wild-
type MEFs (Urban et al., 2008). However, for Adenovirus (Ad), it was reported 
that depletion of BIK enhanced the viability of cells infected with wild-type or 
mutant Ad 5 (Subramanian et al., 2007). A possible explanation for this 
discrepancy may be due to fact that the authors attributed their observation to 
probably modest levels of basal BIK in the cell. 
When the impact of BIK depletion on the host cell’s response to apoptosis 
stimulus from HCV infection was next examined, we observed that the level of 
apoptosis induced in the form of caspase-3/7 activation and DNA fragmentation 
(TUNEL positive cells) was significantly higher in the HCV-infected non-targeting 
control siRNA (siCtrl) treated cells than in HCV-infected BIK depleted (siBIK) 
cells (Figures 5.3 and 5.4). This is not surprising because ideally as a pro-
apoptotic protein, cells should be less susceptible to apoptosis stimulus in the 
absence of BIK. Consistently, a number of studies have shown that siRNA-
mediated BIK-depleted cells were resistant to apoptosis induced by a variety of 
agents (Fu et al., 2007; Hur et al., 2006; Li et al., 2008; Mebratu et al., 2008; 
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Viedma-Rodriguez et al., 2013). Similarly, the ablation or depletion of a number 
of pro-apoptotic Bcl-2 family members such as Noxa (Wensveen et al., 2013), 
Bop (Zhang et al., 2012), PUMA (Wang et al., 2006), BNIP3 (Diwan et al., 2007), 
BAD (Tran et al., 2013), and HRK (Chang et al., 2013) have also been shown to 
confer significant protection against apoptosis, hence, suggesting their 
significance in apoptosis. In terms of viral induced apoptosis and BIK expression, 
our observation is in common with a few previous studies. For instance, 
Subramanian and colleagues reported that, A549 cells (Human lung 
adenocarcinoma epithelial cell line) depleted of BIK by the use of siRNA reduced 
the level of Ad-induced apoptosis (Subramanian et al., 2007), while a reduction in 
the level of activated caspase-3 was reported in Ad-infected BIK-deficient iBMK 
cells (immortalized baby mouse kidney cells) (Shimazu et al., 2007).  
A comparison of the cell viability and apoptosis assay results however 
gives us quite an intriguing contrast. While the loss of pro-apoptotic BIK protected 
against HCV-induced apoptosis as would be expected, there was no significant 
effect on the cell viability of the infected cells. A couple of reasons could account 
for this unusual dichotomy. Firstly, it has been demonstrated that there is a 
diversion of cells to autophagic cell death when there is deficiency or block in 
apoptosis (Rashmi et al., 2008). Thus, it is probable that the decrease in 
apoptosis in the HCV infected BIK-depleted cells is compensated by an increase 
in autophagic or other forms of cell death. Secondly, HCV infection is reported to 
perturb and induce cell cycle arrest (Kannan et al., 2011; Walters et al., 2009), 
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with a resultant inhibition on cell proliferation. If this effect is the dominant factor 
in determining the viability of the HCV infected cells, then a decrease in 
apoptosis in the BIK-depleted cells may not have a major effect on cell viability. 
Future experiments can be designed to address these hypotheses. 
Viral replication is generally affected by the ability of the virus to 
counteract pro-apoptotic signals induced by host cells, since premature cell death 
of infected cells would prevent the production of progeny virions. It is therefore 
expected that in the absence of pro-apoptotic BIK, viral replication will be 
enhanced. Ironically, examination of HCV replication in siBIK-treated and siCtrl-
treated cells revealed a significant reduction in viral replication at 4 and 6 d.p.i in 
BIK depleted cells as compared to replication in control siRNA-treated cells 
(Figure 5.5). Although consistent with the HCV replication, we were surprised to 
observe that the release of infectious viral particles into the culture supernatant 
was only slightly reduced (less than 1 log) but significant at 4 and 6 d.p.i in the 
BIK depleted cells relative to control siRNA-treated cells (Figure 5.5). Despite the 
fact that the effects of BIK depletion on HCV kinetics have not been reported, 
some previous studies involving the depletion of other pro-apoptotic BH3-only 
proteins, specifically, Bim and Bid, have reported an enhancement in virus 
replication and production in Bim and Bid depleted cells infected with Human 
Herpesvirus 8 (HHV-8) as compared to infected control cells (Choi and Nicholas, 
2008; Choi and Nicholas, 2010; Choi et al., 2012). A recent study has however 
reported that influenza virus-induced cell death is inhibited in Bad (a pro-
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apoptotic Bcl-2 family protein) knockdown cells and that virus replication is 
dramatically reduced (Tran et al., 2013). Relating these findings to BIK 
expression as observed in this study, it seems to suggest that BIK most likely 
alters the capacity of HCV to replicate in Huh7.5 cells but has minimal effect on 
the release of infectious viral particles into the culture supernatant. It can 
therefore be proposed that, inhibition of pro-apoptotic BIK diverts the cells to 
other forms of cell death, such as autophagy (which is exploited by a number of 
viruses for their replication), with resultant effect on viral replication, as BIK might 
associate and interact with the replication complex in the ER where it is localized. 
After all, RNA viruses are reported to associate with several unknown cellular 
factors in the replication complex (Sklan et al., 2007a), with HCV NS5A shown to 
specifically interact with the host cell protein TBC1D20 (a Rab1 GTPase-
activating protein), depletion of which severely impaired HCV replication and 
prevented the accumulation of viral RNA (Sklan et al., 2007b). Similarly, the 
interaction of HCV NS4B with Rab5 (also a Rab GTPase) was demonstrated to 
be crucial for HCV replication (Manna et al., 2010; Stone et al., 2007).  
While the findings here are interesting, further experiments are needed to 
confirm our observations. For instance, the apparent disparity between the 
amount of viral RNA and viral particles, brings to fore, the accuracy of the assay 
methods. While the sensitivity and specificity of the qPCR assay used for 
quantification of viral RNA is high, one major caveat in the conventional foci 
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prone due to the subjectivity of counting the foci under the microscope. As seen 
here, there was no correlation between the amount of viral RNA and the number 
of viral particles, an observation also made by Park and colleagues (Park et al., 
2013). It is partly for this reason that a number of alternative high throughput 
methods with high sensitivity and specificity are being designed on commercial 
basis and in-house. Some of these methods include, an ELISA assay (HCV Core 
Antigen ELISA Kit), which can be used to detect the quantity of the HCV core 
protein in the culture free supernatant; a new assay named 'Enzyme Linked Apto-
Sorbent Assay (ELASA) that quantifies infectious HCV particles using aptamers 
against HCV E2 (Park et al., 2013); the use of the infectious HCV reporter 
system expressing Renilla luciferase which allows infectivity to be assessed by 
measuring Renilla Luciferase activities using the Renilla Luciferase Assay 
System (Liu et al., 2011); the use of diagnostic kits such as the Kehua HCV RNA 
real-time RT-PCR detection kit (Shanghai Kehua Bio-Engineering Co. Ltd.) which 
can detect HCV RNA in culture supernatant, and quantification of HCV RNA 
levels in culture supernatants by real-time RT-PCR relative to a standard curve 
comprised of serial dilutions of plasmid containing the HCV JFH-1 cDNA (Xu et 
al., 2013). We hope to leverage on one of these methods in future so as to 
enable us to quantify the discrete difference between the viral quantities between 
BIK-depleted and control siRNA treated cells. 
In summary, the findings presented here revealed that Huh7.5 cells 
depleted of BIK are protected against HCV-induced apoptosis, but surprisingly 
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were not protected against the inhibitory effects of HCV infection, suggesting 
some probable compensation by other BH3-only proteins. The data further 
showed that BIK is essential for HCV RNA replication, while it seems to have little 
effect on viral production. It thus suggests that BIK is an important host factor 
that plays a vital role in the host cells’ response to HCV infection and somehow 
influences some aspects of the viral life cycle, especially viral replication. It is 
therefore conceivable to postulate that BIK may be interacting with the HCV 
replication complex in the ER to promote viral replication. This would however 
have to be substantiated in future experiments.  
Since the findings presented here are far from being exhaustive and have 
opened up new questions, further investigations would have to be performed. 
Future studies would include, overexpressing BIK and determining the effects on 
HCV infection, using a pool of siRNA to achieve higher knockdown efficiency of 
BIK and to eliminate off-target effects, and for a better comparison of the specific 
effects of BIK on host and viral factors during HCV infection, other BH3-only 













GENERAL DISCUSSION, CONCLUSION AND FUTURE DIRECTION 
The host cell provides the basic infrastructure and molecular machinery for 
the replication of viruses and for the production of progeny virions; hence, viruses 
tend to exploit these factors to their advantage. Thus, to establish persistent or 
chronic infection, HCV, like other viruses, is reported to manipulate a number of 
cellular signaling pathways as well as interact with a couple of cellular proteins so 
as to delay or prevent programmed cell death or apoptosis.  
As reviewed in chapter one, although non-cytopathic, HCV and HCV-
encoded proteins are reported to induce apoptosis in the HCV replicon and the 
HCVcc system (Deng et al., 2008; Deng et al., 2012; Mateu et al., 2008; Mohd-
Ismail et al., 2009) as well as in heterologous expressions of the individual 
proteins (reviewed in (Aweya and Tan, 2011; Fischer et al., 2007)). Similarly, 
chronic HCV infection has been shown to result in liver injury and long-term liver 
complications, while several lines of evidence have linked hepatocyte apoptosis 
with HCV-induced liver injury and other liver pathologies (Bantel et al., 2001; 
Bantel and Schulze-Osthoff, 2003; Canbay et al., 2004b; Delladetsima et al., 
2008; Lim et al., 2012; Mengshol et al., 2007). Furthermore, the use of the 
HCVcc system in some recent genome-wide transcriptional profiling of genes 
expressed following acute HCV infection have identified among others, the 
differential expression of host apoptosis-related genes (Blackham et al., 2010; 
Liu et al., 2010; Walters et al., 2009), which further highlights the importance of 
HCV infection in the modulation of key cellular pathways. However, the specific 
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viral and host factors that are involved in these pathways have not yet been 
identified.  
The research work presented in this thesis is therefore an attempt to gain a 
better insight into the molecular and functional significance of HCV-induced 
apoptosis and to identify the viral and host factors that are involved in the 
regulation of this cellular pathway. Employing both cell culture overexpression 
and the HCVcc system coupled with transcriptional profiling, the work focused on 
the identification and characterization of viral factors and apoptosis-related host 
factors, and how these factors regulate apoptosis. The results of our studies are 
summarized below: 
a. It was demonstrated that most of the HCV proteins, except p7, gave 
conflicting data on their apoptosis properties, when overexpressed in 
Huh7.5 cells. 
b. All the three HCV genotypes (1b, 2a, and 3a) of p7 protein studied 
induced significantly higher levels of apoptosis, with genotype 3a p7 
inducing the highest, although it is a labile protein, which could not be 
detected by western blot analysis unless treated with a proteasome 
inhibitor or with a pan-caspase inhibitor. Thus, the apoptosis ability of HCV 
genotype 3a p7 protein seems to be linked with its stability. 
c. Focusing on only the genotype 2a p7 protein, it was demonstrated that this 
HCV protein induced apoptosis, which was efficiently blocked by a pan-
caspase inhibitor as well as by inhibitors specific for caspase 3, 8, and 9. 
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This provides evidence that p7-induced apoptosis is caspase-dependent 
and is induced via both the intrinsic or mitochondrial and the extrinsic or 
receptor-mediated pathways. 
d. Site-directed mutagenesis of the two histidine residues (H17 and H31) of 
genotype 2a p7, which have been implicated in the gating function of p7, 
abrogated the ion channeling function of the mutant, but did not 
significantly reduce the apoptosis ability of p7, suggesting that p7’s 
apoptosis ability is independent of its ion channel function. 
e. The dibasic arginine amino acid residues, R33 and R35, located in the 
cytoplasmic domain of genotype 2a p7, are important in the folding and 
topology of p7, as single and double substitution to glutamine using site-
directed mutagenesis significantly reduced the level of apoptosis induced 
by p7 as well as its ability to function as an ion channel.  
f. Although functionally similar to the M2 protein of influenza A virus in terms 
of ion channel activity and induction of caspase-dependent apoptotic cell 
death, it was demonstrated that the overexpression of p7 protein did not 
significantly increase the conversion of LC3-I to LC3-II or the accumulation 
of GFP-LC3 puncta, suggesting that p7 was not involved in 
autophagosome maturation, despite the fact that both M2 and p7 did 
interact with endogenous Beclin-1 in co-immunoprecipitation experiments. 
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g. Using the HCVcc system, HCV of the J6/JFH-1-P47 strain was shown to 
efficiently induce apoptosis as well as significantly inhibit the proliferation 
of Huh7.5 cells during acute infection. 
h. Gene expression analysis using pathway-specific PCR array of host 
apoptosis-related genes revealed that, HCV J6/JFH-1-P47 infection of 
Huh7.5 cells induced the expression of 15 genes, of which 11 genes were 
up-regulated while 4 genes were down-regulated.  
i. Most of the differentially expressed apoptosis-related genes either 
belonged to the TNF superfamily or the Bcl-2 family, which are mediators 
of the intrinsic and extrinsic apoptotic pathways. This provides evidence to 
suggest that HCV J6/JFH-1-P47 induces apoptosis via these two 
pathways. 
j. The mRNA expression of 9 of the 15 differentially expressed genes was 
validated using real-time qPCR based on the TaqMan chemistry and 
employing different set of primers. There was agreement between the two 
data sets. 
k. The corresponding change in protein expression of 3 down-regulated 
(BNIP3, CIDEB, TNFRSF9) and 3 up-regulated (BIK, GADD45A and HRK) 
of the 9 validated genes was demonstrated by western blot analysis. 
However, the protein expression of 3 other up-regulated genes (BCLAF1, 
FAS and TNFRSF9) could not be determine by western blot due to the 
lack of suitable commercial antibodies. 
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l. Out of the 3 up-regulated genes (BIK, GADD45A, and HRK), it was only 
the expression of BIK at both the mRNA and protein levels that was 
observed to be up-regulated at 3 different time-points post-infection, 
hence, BIK was chosen for detailed characterization. 
m. When the expression of BIK in Huh7.5 cells was depleted using RNA 
interference followed by HCV J6/JFH-1-P47 infection, we demonstrated 
that there was no significant difference in the cell proliferation of HCV-
infected BIK-depleted and HCV-infected control siRNA treated cells as 
both were inhibited to the same extent relative to mock. 
n. It was however shown that, the level of apoptosis induced by the HCV 
J6/JFH-1-P47 infection was significantly lower in BIK-depleted cells than 
in control siRNA treated cells. 
o. In terms of effects of BIK-depletion on viral kinetics, we demonstrated 
using qPCR and indirect IFA that, HCV J6/JFH-1-P47 infection of BIK-
depleted Huh7.5 cells resulted in a significant decrease in the replication 
of the virus but had minimal but significant effect on the release of 
infectious viral particles. 
In the first part of this study, we sought to identify and characterize the viral 
factors that were involved in HCV-induced apoptosis. Here, we demonstrated 
using overexpression studies that, the three HCV genotypes (1b, 2a, and 3a) of 
the non-structural proteins, except p7, could not be properly expressed in Huh7.5 
cells, and even when they did, their ability to induce apoptosis, in terms of 
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caspase-3/7 activation, was inconclusive. Thus, focusing on the p7 protein of the 
genotype 2a or JFH-1 strain, we demonstrated that the p7 ion channel protein, 
like M2 ion channel protein of influenza A virus, is pro-apoptotic and induces 
caspase-dependent apoptosis via both the intrinsic and extrinsic pathways 
(Aweya et al., 2013). However, p7 unlike other ion channel proteins, which have 
been shown to display a link between their ion channel function and their ability 
to induce apoptosis, we demonstrated that the pro-apoptotic activity of p7 is 
independent of its ion channel function. Furthermore, comparison of p7 and M2 
protein in terms of their ability to induce autophagic cell death, revealed that, 
unlike M2 protein, p7 could not increase the conversion of LC3-I to LC3-II (the 
autophagic marker), nor could it increase the accumulation of GFP-LC3 puncta in 
cells, although, we did demonstrate that both M2 and p7 proteins interact with 
Beclin-1, suggesting that probably, both M2 and p7 proteins interacted with the 
class III PI3K complex differently, with only M2 being able to interfere with the 
complex and thus inhibit autophagosomes maturation. While these results 
present interesting and novel information on HCV p7 protein and cell death 
modulation, future studies are required to further identify residues or motifs that 
are responsible for the apoptosis activity of p7. Similarly, to establish the 
functional significance of the apoptosis activity of p7 in the context of the entire 
viral genome and in an infection, the HCVcc system will have to be used to 
generate mutant viruses containing the mutations that were shown to abolish the 
apoptotic activity of p7. The study of p7 protein in the context of the entire viral 
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genome will also allow for the study of the interaction between p7 and other viral 
and host factors in the induction of cell death during an infection. 
In the second part of the thesis, which was mainly focused on identifying and 
studying the host factors involved in HCV-induced apoptosis, we analyzed the 
expression of host apoptosis-related genes differentially expressed following 
acute infection with HCV J6/JFH-1-P47. In this screen, 15 genes were identified 
while 9 genes (implicated in both the intrinsic and extrinsic apoptosis pathways) 
were selected and further validated. Of the 9 validated genes, 3 (BNIP3, CIDEB, 
and TNFSF10) were down-regulated, and this was demonstrated to correlate at 
both the mRNA and protein expression levels, while 6 genes (BCLAF1, BIK, 
FAS, GADD45A, HRK, and TNFRSF9) were up-regulated, with only the 
expression of BIK, GADD45A, and HRK, demonstrated to correlate at both the 
mRNA and protein levels. The protein expression of the other 3 up-regulated 
genes could not be validated using western blot analysis due to lack of suitable 
antibodies. Although there was a correspondence between the mRNA and 
protein levels for BIK, GADD45A, and HRK, it was only the expression of BIK 
that displayed concordance between HCV-infected and mock-infected cells at all 
the time points post infection. Since genes implicated in both the intrinsic and 
extrinsic apoptosis pathways were observed to be differentially expressed 
following HCV infection, it implies that HCV J6/JFH-1-P47 induces apoptosis via 
these two pathways. Network analysis of all the differentially expressed genes 
revealed how the genes were related in a pathway setting. Though a new 
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approach in HCV research, network analysis permits a global overview of the 
intricate relationship between genes, how they are involved in disease 
pathogenesis as well as the potential of identifying novel regulators and 
therapeutic targets. Future studies are however needed to further determine the 
specific role(s) and the mechanism of action of these genes in the modulation of 
HCV-induced apoptosis. 
In the last part, we went on to study the functional significance of the 
differential expression of BIK (Bcl2-interacting killer), as it was the only up-
regulated gene that demonstrated good correspondence in both mRNA and 
protein expression at all time points post infection. Interestingly, we observed that 
the loss of BIK gene expression did not enhance the viability of cells by 
protecting them from the inhibitory effects of HCV, although it did offer some 
protection against apoptosis insults from HCV. Similarly, the loss of BIK 
expression significantly reduced the replication of HCV RNA, but had minimal yet 
significant effect on the release of infectious viral particles into the culture 
supernatant. These results provide evidence to suggest that BIK is an important 
host factor that plays a critical but partial role in the viral-host interaction during 
HCV infection. 
Hepatocytes apoptosis is an important aspect in the pathogenesis and 
disease progression in HCV infection, and therefore, it is an important area in 
HCV research. Moreover, as we strive to find a vaccine and better treatment 
options for HCV infection, information about the molecular mechanisms involved 
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in the complex interaction between the virus and host and how this is regulated 
can directly impact our current understanding of HCV infection and management.  
In addition, an understanding of this intricate viral-host interaction has the 
potential to yield new and exciting strategies for therapeutic intervention. For 
instance, a number of studies (Clarke et al., 2006; Griffin, 2010; Griffin et al., 
2003; Meredith et al., 2013; Pavlovic et al., 2003; Premkumar et al., 2004; 
StGelais et al., 2007) have shown that drugs such as amantadine, rimantadine, 
hexamethylene amiloride (HMA) and long-alkyl-chain iminosugar derivatives, that 
block HCV p7’s ion channel activity can as well inhibit efficient assembly and 
release of infectious virions. Since we demonstrated that that p7 has pro-
apoptotic activity that is independent of its ion channel activity (Aweya et al., 
2013), implies that, if there is any drug or small molecule that can block p7-
induced apoptosis, then this drug may have important therapeutic implications, 
as this can be explored for possible effect(s) on decreasing HCV pathogenesis.  
In summary, the ability of HCV p7 to induce caspase-dependent apoptosis via 
both the intrinsic (mitochondrial) and extrinsic (receptor-mediated) pathways 
could stem from the fact that, it is reported to be localized to the plasma 
membrane (Carrere-Kremer et al., 2002), mitochondria (Griffin et al., 2005; Griffin 
et al., 2004) and the ER (Carrere-Kremer et al., 2002; Griffin et al., 2005; 
Haqshenas et al., 2007; Vieyres et al., 2013). In these organelles, p7 protein can 
interact with members of the TNF receptor family in the plasma membrane or 
Bcl-2 family proteins in the mitochondria, thus leading to the induction of 
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apoptosis via these two pathways. Similarly, BIK is reported to be localized to the 
ER (Chinnadurai et al., 2008; Viedma-Rodriguez et al., 2013), so the siRNA 
knockdown of BIK might have distorted the microstructure of the ER, hence, 
affecting the HCV replication complex, and therefore resulting in a decrease in 
viral replication. However, the release of HCV particles was not affected to the 
same extent as the viral replication, since this step in the HCV lifecycle takes 
place outside the ER. Figure 6.1 is a simple diagrammatic summary of the 
findings in this study. 
 
Figure 6.1: Diagrammatic summary of a proposed model of apoptosis 
induction by HCV p7 protein and the effects of BIK on HCV RNA replication and 
viral release. Not drawn to scale. 
 
 
To conclude, we have characterized several viral and host factors that are 
involved in regulating apoptosis in HCV infection in vitro. Although not 
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exhaustive, the findings have provided new insights into the complex interaction 
between virus and host, and the interplay between different cell-death pathways.  
Future studies are however required to further identify which viral factors are 
responsible for the differential expression of the host apoptosis-related genes 
identified in the study. A detailed characterization of all the other genes identified 
is also needed so as to delineate their specific role(s) in HCV-induced cell death. 
Last but not least, the availability of newly established mouse models for studying 
HCV infection will open up new opportunities to examine the roles of viral-host 
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Caspase 1, apoptosis-related cysteine peptidase 
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Appendix 2: Apoptosis-related genes excluded from PCR array analysis 
Position Gene  Description 
A11 BCL2 B-cell CLL/lymphoma 2 
B11 BIRC3 Baculoviral IAP repeat-containing 3 
C02 BIRC8 Baculoviral IAP repeat-containing 8 
C11 CASP1 Caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
D01 CASP14 Caspase 14, apoptosis-related cysteine peptidase 
D08 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
D10 CD40 CD40 molecule, TNF receptor superfamily member 5 
D11 CD40LG CD40 ligand 
E01 CIDEA Cell death-inducing DFFA-like effector a 
E08 FASLG Fas ligand (TNF superfamily, member 6) 
E12 LTA Lymphotoxin alpha (TNF superfamily, member 1) 
F04 PYCARD PYD and CARD domain containing 
F06 TNF Tumor necrosis factor (TNF superfamily, member 2) 
G01 CD27 CD27 molecule 
G04 CD70 CD70 molecule 
G05 TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 
G08 TP73 Tumor protein p73 





















Appendix 3: Primer-probes for TaqMan® Gene Expression Assays 
 
Gene Catalog Number  
BCLAF1  Hs03004661_g1 
BIK  Hs00154189_m1 
BNIP3  Hs00969291_m1 
CIDEB  Hs00205339_m1 
FAS  Hs00236330_m1 
GADD45A  Hs00169255_m1 
HRK  Hs02621354_s1 
TNFSF10  Hs00921974_m1 
TNFRSF9 Hs00155512_m1 
Human GAPD (GAPDH) 4352934E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
